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Abstract 
 
T lymphocytes are critical components of the adaptive immune system that 
protects us against a variety of infections. However, during chronic infections 
such as with HIV, HCV and HBV as well as cancers, T cells become functionally 
impaired in order to limit immunopathology. This in turn allows these infections 
to persist or tumours to grow and spread. Scientific research over the last 
decades lead to the development of checkpoint inhibitors which can 
reinvigorate exhausted CD8+ T cells. This enables them to fight persisting 
infections and to eliminate even advanced tumours. Based on this success, 
checkpoint immunotherapy has revolutionized cancer treatment. With the 
identification of the memory-like TCF-1+ subset of exhausted CD8+ T cells that 
responds to checkpoint immunotherapy, predictions for clinical responses can 
be further improved. Yet, despite the enormous success and routine 
application, a deeper mechanistic understanding of checkpoint immunotherapy 
is required in order to help patients in whom this therapy failed. 
 
In this study, we elucidate critical cellular interaction partners of exhausted 
CD8+ T cells during anti-PD-L1 treatment. Using the murine chronic LCMV 
model, we found that DC with their key function in T cell activation are pivotal 
for a successful therapy demonstrated by the expansion of virus-specific CD8+ 
T cells and control of viral load. Notably, different DC subsets represent 
complementary roles in this context. The cross-presenting subset of XCR1+ DC 
are critical to maintain the population of memory-like TCF-1+ exhausted CD8+ T 
cells while the remaining DC promote proliferation of such. Data presented in 
this study indicate that a complex network of signalling molecules delivered by 
DC subsets is involved in this process. Performing detailed transcriptional 
analysis of memory-like TCF-1+ cells, we deciphered that this cell pool 
represents a heterogenous population and our results imply that the different 
subsets reside in different areas of secondary lymphoid organs. Investigation of 
the microanatomy of the CD8+ T cell – DC interaction revealed three distinct 
areas of the spleen where communication of the cellular subsets occurs.  
 Abstract 
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Taken together, we elucidated a complex interplay between exhausted CD8+ T 
cells and DC during chronic viral infection and anti-PD-L1 treatment. This 
communication impacts on the transcriptional and functional level of exhausted 
CD8+ T cells as well as on their localization in secondary lymphoid organs. 
Overall, our data identified critical cellular interaction partners and their specific 
anatomical localization that is essential for the successful reinvigoration of 
exhausted CD8+ T cells during checkpoint immunotherapy. 
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1. Introduction 
 
The immune system protects the body from many different pathogens, such as 
bacteria, viruses, fungi, protozoa and helminths and is an important defence 
system against cancer. To protect the host from disease, this highly complex 
network of cells, signalling and effector molecules communicates on many 
different levels. The underlying processes, called the immune response, need 
to be tightly regulated. 
Physical barriers such as skin and mucosa hinder pathogens from invading the 
body. For example, the skin protects the body from infection with features such 
as low pH, chemicals and a distinct microbial flora, that prevents pathogens 
from entering (Park and Lee 2017). 
In case this first line of defence does not prevent pathogens from entering, the 
innate immune system can quickly recognize these invaders as well as tissue 
injury. The innate arm can control the infection to a certain extent but 
importantly also activates the adaptive immune system. T and B cells of this 
arm detect foreign antigen in a highly specific manner. Upon proliferation, these 
antigen-specific cells gain effector functions and produce antibodies to clear the 
infection. In addition, memory T and B cells are generated and deliver long-term 
protection from reinfection with the same pathogen (Ahmed and Gray 1996). 
The innate and the adaptive immune system represent two highly intertwined 
systems, which can together fully overcome an infection. 
Nevertheless, some pathogens have developed strategies to evade these 
immune responses and are thus able to persist. A constant and highly activated 
immune response can severely harm the host and cause immunopathology. 
Therefore, regulatory elements are of great importance to ensure both: control 
of the infection and control of the immunological response.  
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1.1 The innate immune system 
 
The innate immune response is an overall term for the rapid reaction of certain 
cells, antimicrobial enzymes and peptides as well as the complement system to 
the invasion of pathogens. Cells of the innate immune system are leukocytes, 
such as NK cells, mast cells, eosinophils and basophils, as well as phagocytic 
cells such as macrophages, monocytes, neutrophils and dendritic cells. Some 
of these cells reside in different tissues whereas others circulate through the 
body and are recruited to the tissue upon an infection (Iwasaki and Medzhitov 
2010). In comparison to the adaptive immune response, the innate arm of the 
immune response is evolutionary older and exists in vertebrates as well as 
invertebrates and plants (Buchmann 2014).  
Recognition of foreign and potentially pathogenic material is performed in a 
non-antigen-specific manner. Immune cells are able to recognize conserved 
molecular patterns, which are absent in the host, and are only expressed by 
pathogens. Such motifs are for example part of the cell wall and membrane of 
bacteria like lipoteichoic acid of gram-positive and lipopolysaccharides (LPS) of 
gram-negative bacteria. Importantly, the immune system also recognizes 
material which is found outside of its usual compartments. For example, viruses 
can be recognized by their nucleic acids. If DNA or RNA is detected in the 
cytoplasm or endosomal compartments, signalling pathways of the innate 
immune response are initiated (Mogensen 2009). Apart from these so-called 
pathogen-associated molecular patterns (PAMPs) (Janeway 1989) there are 
also damage-associated molecular patterns (DAMPs). Also called alarmins, 
these endogenous molecules are released by stressed cells or cells which 
undergo necroptosis (Matzinger 1994). PAMPs and DAMPs are recognized by 
pattern recognition receptors (PRRs) (Akira, Takeda et al. 2001, Janeway and 
Medzhitov 2002). A plethora of different PRRs have been identified to be active 
in the context of infection and pathogen recognition. These receptors can be 
distinguished by their cellular localization. Toll-like receptors (TLRs) and C-type 
lectin receptors (CLRs) are expressed on the cell surface or in endosomal 
compartments (Zelensky and Gready 2005, Kaisho and Akira 2006). Retinoic 
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acid inducible gene I (RIG-I) -like receptors (RLRs) and nucleotide-binding 
oligomerization domain-containing (NOD) -like receptors (NLRs) sense foreign 
patterns in the cytosol (Takeuchi and Akira 2010). These innate sensing 
mechanisms are positioned at specific locations to optimally detect pathogens 
and distinguish the foreign material from the hosts own one by specific motifs 
and by their existence in an unusual location.  
Signal transmission of these receptors depends on certain adaptor proteins with 
enzymatic activity, which are often shared between different PRRs. For 
example, all TLRs but TLR3, signal via the myeloid differentiation primary 
response gene 88 (MyD88) (Takeda and Akira 2004). MyD88 signalling induces 
the activation of other adaptor proteins (IRAK, TRAF6) which can lead to the 
activation of important transcription factors like nuclear factor 'kappa-light-chain-
enhancer' of activated B-cells (NF-kB), activator protein 1 (AP-1) and interferon 
regulatory factor 3 and 7 (IRF3/7). Thereby, transcription of pro-inflammatory 
cytokines (e.g. IL-6, IL-1b, TNF, IL-12, IFN I) and co-stimulatory molecules is 
induced which are crucial for the control of infections (Theofilopoulos, Baccala 
et al. 2005, Kawai and Akira 2006). Cytoplasmic PRRs, like RIG-I and 
melanoma differentiation-associated protein 5 (MDA-5), both belonging to the 
RLR family and sensing viral nucleotides, also signal via adaptor proteins which 
induce the transcription of pro-inflammatory cytokines via NF-kB as well as 
IRF3 and IRF7 (Yoneyama, Kikuchi et al. 2004). This very rapid innate immune 
response can induce direct killing of pathogens and infected cells but 
importantly also enables the activation of the adaptive immune system. 
 
1.2 The T cell response as part of the adaptive immune system 
 
Invertebrates and plants solely rely on the protection by the innate immune 
response. However, in vertebrates a second arm of the immune system, the 
adaptive one, evolved. Hallmarks of the adaptive immune system are a highly 
specific recognition of pathogens and the ability to generate memory which 
protects from reinfection with the same pathogen. Full activation of the adaptive 
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immune system requires more time compared to the innate one. Nevertheless, 
this response is highly essential to combat infections. 
The adaptive immune response is divided into the humoral and the cellular arm 
consisting of B lymphocytes (B cells) and T lymphocytes (T cells), respectively. 
Both cell types arise from the common lymphoid progenitor (CLP). In this study, 
we focused on T cell responses during chronic viral infection and will therefore 
focus on this cellular element of the adaptive immune response. 
T cells do not recognize pathogens directly, but antigens which are processed 
and presented by antigen-presenting cells (APC). This recognition is enabled by 
the T cell receptors (TCR), which are genetically recombined receptors of 
different specificities (Garcia and Adams 2005). The cellular adaptive immune 
response is represented by CD4+ and CD8+ T cells, named after the expression 
of the co-receptors CD4 and CD8, which support TCR signalling. In comparison 
to B cells, CLPs which leave the bone marrow and enter the thymus via the 
blood, become T cell precursors (Pui, Allman et al. 1999, Wilson, MacDonald et 
al. 2001). These developing T cells do not yet express the co-receptors CD4 
and CD8 and are therefore termed double negative (DN). DN thymocytes 
undergo b chain rearrangement and start expressing CD4 and CD8 (double 
positive (DP)) (Aifantis, Feinberg et al. 1999). Rearrangement of the a chain loci 
further enables TCR diversity. To ensure that TCR signalling is functional, these 
double positive cells undergo positive selection in the cortex. Epithelial cells 
present self-antigen via MHCI and MHCII molecules and only cells with a high 
affinity and therefore functional TCR engagement will survive (Jameson, 
Hogquist et al. 1995, Kisielow and von Boehmer 1995). This is followed by 
negative selection in the medulla with mainly DC presenting self-antigen. In 
contrast to the first selection step, T cells that recognize peptide with high 
affinity at this stage will be eliminated. This is a critical step during T cell 
development to generate self-tolerant T cells, which only recognize foreign 
antigen. Surviving T cells become MHCI or MHCII restricted by downregulation 
of either of the two co-receptors CD4 and CD8, respectively (Starr, Jameson et 
al. 2003). These mature CD4+ and CD8+ T cells exit the thymus and circulate in 
the blood. 
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Naïve T cells circulate through the body and are able to enter and exit 
secondary lymphoid organs like lymph nodes, spleen and mucosa-associated 
lymphoid tissue (MALT). By doing so, these T cells are able to constantly scan 
the body for foreign antigen. For this recirculation, certain homing receptors that 
enable migration from the blood into lymphoid tissue are expressed (von 
Andrian and Mempel 2003). L-selectin (CD62L) is expressed by naïve T cells 
and binding to its ligands GlyCAM-1 and MadCAM-1 on high endothelial 
vessels (HEVs) mediates transient attachment and is described as a rolling 
process. For activation-dependent arrest of the T cells, CCR7-CCL19/21 
signalling is important. CCR7 is expressed on naïve T cells and CCL19 and 
CCL21 by endothelial cells. Signalling via this axis leads to the activation of 
leukocyte function-associated antigen 1 (LFA-1), an integrin which can in turn 
bind to intracellular adhesion molecule 1 (ICAM1) and ICAM2. This interaction 
finally enables transmigration of the cells into the lymphoid organ (von Andrian 
and Mempel 2003).  
In the T cell zone, cells are able to quickly migrate and scan for their cognate 
antigen. This migration is supported by fibroblastic reticular cells (FRC) that are 
directly associated with HEVs and form a stromal network which helps guiding 
cells to their destinations (Bajenoff, Egen et al. 2006). If no antigen is 
recognized, cells exit the lymphoid organ. Upon signalling, CCR7 is internalized. 
In addition, egress is supported by an increasing gradient of lipid messenger 
sphingosine-1-phosphate (S1P) towards the efferent lymph. Binding of S1P to 
sphingosine-1-phosphate receptor (S1PR1), promotes exit of T cells into the 
lymph to re-enter the circulation (Matloubian, Lo et al. 2004, Pham, Baluk et al. 
2010). 
 
In the secondary lymphoid tissues, antigen-presenting cells (APC) like 
macrophages and dendritic cells (DC) present antigen via major 
histocompatibility complex (MHC) molecules. There are two different classes of 
MHC molecules – MHC class I and II. MHC I molecules are present on every 
nucleated cell, while MHC II molecules are primarily expressed by specific cells 
with phagocytic activity like macrophages and DC. Typically, endogenous 
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antigen from intracellular pathogens is processed into peptide fragments and 
presented with MHC I complexes (Vyas, Van der Veen et al. 2008). In contrast, 
exogenous material is internalized, processed and presented via MHC II 
complexes (Swain 1983).  
T cells become activated once they recognize cognate antigen. CD4+ T cells 
recognize antigen presented in complex with MHC II molecules (Gay, Maddon 
et al. 1987). This interaction is stabilized by the co-receptor CD4. In contrast, 
CD8+ T cells become activated by TCR engagement with antigen presented by 
MHC I molecules. Again, the co-receptor (CD8) stabilizes this interaction 
(Rudolph, Stanfield et al. 2006). However, TCR engagement itself does not 
mount full activation of T cells. Without further signals, cells become anergic 
and subsequently die (Wells 2009).  
Three different signals are described to be critical for complete T cell activation 
(Lenschow, Walunas et al. 1996, van Stipdonk, Lemmens et al. 2001, 
Curtsinger and Mescher 2010). TCR engagement is referred to as signal 1. 
Signal 2 is provided by co-stimulatory signalling pathways like CD80/CD86-
CD28, CD40L-CD40 and ICOSL-ICOS (Greenwald, Freeman et al. 2005, Watts 
2005). The third signal, that T cells need to receive during activation, is 
delivered via cytokines like IL-12, IFN I and to some extend IFNg produced by 
APCs, innate lymphocytes and NK cells (Curtsinger, Lins et al. 2003, Curtsinger 
and Mescher 2010). In addition, IL-2 plays an important role for the proliferation 
and survival of activated T cells. Via autocrine production and the expression of 
the high affinity IL-2 receptor (IL2Ra, CD25), T cells boost their own response 
(Lanzavecchia and Sallusto 2001).  
Activated T cells proliferate and remain in the lymphoid tissue for several days 
due to the expression of CD69. This activation marker causes internalization of 
S1PR1 which hinders cells from egress from secondary-lymphoid tissues 
(Cebrian, Yague et al. 1988). After proliferation, T cells are able to egress by 
downregulation of CD69 and subsequent S1PR1 signalling (Shiow, Rosen et al. 
2006). 
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Depending on the infection, cytokines (signal 3) determine the differentiation of 
CD4+ T cells into different subsets – Th1, Th2, Th17, TFH, Treg cells. 
Differentiation into Type 1 helper cells (Th1) is induced by IFNg and IL-12 
(Grogan, Mohrs et al. 2001, Mullen, High et al. 2001). Th1 cells are able to 
activate infected macrophages via IFN-g to promote microbial killing of 
intracellular pathogens and therefore resemble most of the CD4+ T cells during 
viral infections (Schroder, Hertzog et al. 2004, Zhu and Paul 2008). On the 
other hand, IL-4 promotes differentiation of CD4+ T cells into Type 2 helper cells 
(Th2) (Grogan, Mohrs et al. 2001). Th2 responses enable the recruitment of 
eosinophils, basophils and mast cells to fight extracellular parasites. T helper 17 
cells (Th17) cells are activated by combined signalling of TGF-b and IL-6 (Park, 
Li et al. 2005). These cells release high amounts of IL-17, an important 
interleukin for the recruitment of neutrophils playing a role during infection with 
extracellular bacteria and helminths (Harrington, Hatton et al. 2005). IL-6 itself, 
without additional TGF-b signalling, rather promotes the differentiation into 
follicular helper T cells (TFH), which are able to migrate to B cell follicles to 
optimally activate B cells and thereby the humoral arm of adaptive immunity 
(Reinhardt, Liang et al. 2009). On the other hand, TGF-b signalling by itself 
rather induces the generation of regulatory T cells (Treg). These cells play an 
important role during infections and autoimmunity as they regulate the immune 
response on various levels by the production of anti-inflammatory cytokines like 
IL-10 and TGF-b (Zheng, Wang et al. 2004).  
CD4+ T cells have been shown to play an essential role for optimal priming of 
CD8+ T cells in various infection models. During HSV-1 infection, CD4+ T cells 
were essential for optimal priming of CD8+ T cells by DC (Greyer, Whitney et al. 
2016). During chronic LCMV infection, CD4+ T cells are crucial to control viral 
load as depletion of such prolongs viral persistence in various organs 
(Matloubian, Concepcion et al. 1994, Zajac, Blattman et al. 1998). Similar, 
during HCV infection, antigen-specific CD4+ T cells highly impact the CD8+ T 
cell response and disease outcome (Smyk-Pearson, Tester et al. 2008). 
However, CD4+ helper T cells are not able to directly interact with CD8+ T cells. 
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Our group could describe that a specific DC subset serves as a platform where 
helper signals get exchanged (Eickhoff, Brewitz et al. 2015). 
 
Activated CD8+ T cells become so-called cytotoxic T cells (CTL) and play a 
supreme role during viral infections (Haring, Badovinac et al. 2006). As 
mentioned above, three signals are essential for optimal priming (Butz and 
Bevan 1998, Curtsinger, Lins et al. 2003). Cytokines that impact and support 
CD8+ T cell activation are for example IFN I, IFN-g and IL-12 (Cousens, 
Peterson et al. 1999, Mescher, Curtsinger et al. 2006). IFN I cytokines are 
essential to mount a full CD8+ T cell response upon LCMV infection (Keppler, 
Rosenits et al. 2012). Additionally, also IFN-g boosts the expansion of 
CD8+ T cells during LCMV infection (Badovinac, Tvinnereim et al. 2000). During 
VSV infection, IL-12 and IFN I signalling are critical (Keppler, Rosenits et al. 
2012). Fully activated CD8+ T cells release granules containing cytotoxic 
effector molecules like perforin and granzymes. Perforin is a cytolytic protein 
which forms pores into the target cell plasma membrane. Loss of membrane 
potential in combination with the ability of granzymes to enter the cell induce 
apoptosis in targeted cells. Granzymes are serine proteases which through 
activation of caspases initiate DNA degradation (Trapani and Smyth 2002). 
Importantly, the CD8+ T cell pool displays a heterogeneous group of cells with 
some exhibiting stronger effector functions than others. The two main subsets 
are short-lived effector cells (SLECs) and memory-precursor effector cells 
(MPECs). Whereas most of the activated CD8+ T cells during the peak of an 
immune response are SLECs, which are limited in their capacity to proliferate, 
some MPECs develop into long-lived memory cells. The CD8+ T cell response 
to viral infections and the impact of certain cytokines will be discussed in more 
detail in chapter 1.4. 
Overall, the adaptive immune response enables specific and highly regulated 
elimination of various pathogens with life-long protection. Nevertheless, for its 
full activation, the adaptive immune response relies on an intact innate immune 
system and professional cells that enable communication between these two. 
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 1.3 Conventional dendritic cells 
 
Dendritic cells (DC) play a superior role for the immune system as they 
represent a crucial link between the innate and adaptive arm. These 
professional antigen-presenting cells (APC) are most effective at stimulating 
naïve T cells (Steinman and Witmer 1978, Inaba and Steinman 1984). 
Discovered by Steinman and Cohn in 1973, DC were named after the Greek 
word for tree (dendron) due to their morphological features (Steinman and Cohn 
1973).  
DC derive from common myeloid progenitors (CMPs) in the BM, which further 
differentiate into macrophage-dendritic cell progenitors (MDPs) that give rise to 
common dendritic cell progenitors (CDPs). From these CDPs, pre-conventional 
DC (pre-cDC) or pre-plasmacytoid DC (pre-pDC) arise (Naik, Sathe et al. 2007, 
Liu, Victora et al. 2009). These pre-DC exit the BM and circulate in the blood 
from where they can migrate into secondary- and non-lymphoid tissues and 
differentiate into cDC and pDC (Dalod, Chelbi et al. 2014).  
pDC are described to have a comparatively low potential to present antigen and 
rather act as important IFN I producers (Rodrigues, Alberti-Servera et al. 2018). 
In contrast, cDC are highly professional APCs. There are two distinct subgroups 
of cDC, migratory and tissue-resident DC, which can be further divided into 
cDC1 and cDC2. Notably, cDC1 have been shown to be critical for the 
activation of CD8+ T cells whereas cDC2 promote the activation of CD4+ T cells 
(Dudziak, Kamphorst et al. 2007). It is described that differentiation into either of 
the subsets takes place in the tissue. However, studies suggest that pre-cDC1 
and pre-cDC2 already exist in the BM (Schlitzer, Sivakamasundari et al. 2015). 
Certain cytokines impact the generation and development of DC (Schmid, 
Kingston et al. 2010). Fms-like tyrosine kinase 3 ligand (Flt3L), produced by 
stromal, endothelial and activated T cells, is essential for DC development 
during steady state (Karsunky, Merad et al. 2003, Waskow, Liu et al. 2008). 
Especially cDC1 depend on Flt3 signalling (Ginhoux, Liu et al. 2009). 
Additionally, certain transcription factors were shown to drive differentiation of 
pre-DC into the different subsets. Whereas Batf3, Nfil3, Id2, and Irf8 support 
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cDC1 generation (Hildner, Edelson et al. 2008, Jackson, Hu et al. 2011, 
Kashiwada, Pham et al. 2011, Sichien, Scott et al. 2016), Irf4- and Zeb2-
dependent pathways are able to control differentiation of cDC2 (Suzuki, Honma 
et al. 2004, Tamura, Tailor et al. 2005, Scott, Soen et al. 2016). DC have a 
short half-life of only 3-5 days and therefore need to be constantly replenished 
from the BM (Liu, Waskow et al. 2007). 
Migratory DC sample foreign antigen in the periphery and subsequently migrate 
in a CCR7-dependent manner to the T cell zones of the draining lymph node 
(LN), where they present the antigen to naïve T cells. These DC are not found 
in the spleen (Liu and Nussenzweig 2010). 
Resident DC are MHCII+ and CD11chi and can be distinguished by the 
expression of CD8 (cDC1) and CD11b (cDC2). Most of the CD8+ cDC1 
specifically express the chemokine receptor XCR1 (Dorner, Dorner et al. 2009, 
Bachem, Hartung et al. 2012). This chemokine receptor can bind its ligand 
XCL1, expressed by NK and activated CD8+ T cells, and enables migration of 
XCR1+ DC towards the source of XCL1. Our group revealed an essential role of 
the XCL1-XCR1 axis during acute viral infections (Brewitz, Eickhoff et al. 2017). 
However, the role of this signalling pathway during chronic infections remains 
unclear. Another feature of XCR1+ DC, as well as their migratory counterpart 
the CD103+ DC, is the ability of cross-presentation (Dudziak, Kamphorst et al. 
2007, Bedoui, Whitney et al. 2009). As mentioned above, antigen from 
intracellular pathogens is typically presented with MHC I complexes (Vyas, Van 
der Veen et al. 2008) whereas exogenous material is internalized, processed 
and presented via MHC II complexes (Swain 1983). However, XCR1+ DC are 
able to take up exogenous material and present it via MHC I to stimulate CD8+ 
T cells (Bevan 1976). Therefore, this unique feature plays an important role for 
CD8+ T cell responses during infection with intracellular pathogens such as 
viruses (Rock 2003, Joffre, Segura et al. 2012). Additionally, cytokine 
production by XCR1+ DC was shown to strongly affect the T cell response. For 
example, IL-12 produced by DC regulates the differentiation of T cells 
(Hochrein, Shortman et al. 2001). Furthermore, DC-derived IL-15 is essential for 
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optimal priming of CD8+ T cells during HSV-1 infection (Greyer, Whitney et al. 
2016). 
CD11b+ DC (cDC2), in contrast to XCR1+ DC, preferentially activate CD4+ T 
cells by presentation of antigen in complex with MHC II molecules (Dudziak, 
Kamphorst et al. 2007). These DC do not produce IL-12 but instead shape T 
cell responses by secretion of IL-6 and IL-23 (Persson, Uronen-Hansson et al. 
2013, Schlitzer, McGovern et al. 2013). 
DC not only present antigen to T cells (signal 1) and secrete cytokines that drive 
T cell responses (signal 3), but also deliver important co-stimulatory molecules 
(signal 2). Under inflammatory conditions, DC upregulate CD40, CD80 and 
CD86 (Guermonprez, Valladeau et al. 2002, Belz and Nutt 2012). CD80 and 
CD86, for example, are the ligands for CD28, which is expressed on T cells. 
CD28 signalling supports TCR signalling and thereby T cell activation 
(Shahinian, Pfeffer et al. 1993). 
The different DC subsets do not only deliver necessary signals, but are also 
optimally positioned in secondary lymphoid organs for rapid uptake of antigen 
and priming of T cells (Mildner and Jung 2014). In the spleen, XCR1+ DC are 
mainly located in the T cell zones of the white pulp as well as the marginal 
zone. Few of these DC reside in the red pulp (Pulendran, Lingappa et al. 1997, 
Steinman, Pack et al. 1997). In contrast, CD11b+ DC populate the bridging 
channels (Gatto, Wood et al. 2013). Therefore, position of DC subsets highly 
correlates with the T cell subsets they preferentially prime and exhibits another 
prerequisite for optimal activation of the adaptive immune response (Calabro, 
Liu et al. 2016). 
 
1.4 T cell responses to acute and chronic viral infections 
 
As described above, viral infection is rapidly detected by the innate immune 
response. PAMPs are recognized by PRRs expressed on various cell types. 
Cells of the innate immune system induce pro-inflammatory processes by 
cytokine and chemokine production and activate the adaptive arm of the 
immune response.  
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The T cell response during acute viral infections is initiated by a strong 
expansion phase to generate a cytotoxic CD8+ T cell response with which the 
infection can be cleared. This is followed by a rapid contraction of the cells to 
prevent an overrepresentation and dominance by CD8+ T cells specific for one 
pathogen (Badovinac and Harty 2006). Cells that survive will remain as memory 
CD8+ T cells which can quickly eliminate pathogens upon reinfection 
(Figure 1.1, left). 
 
 
 
Figure 1.1: CD8+ T cell responses to acute and chronic infections 
Upon an acute infection (left) naive CD8+ T cells expand and differentiate into 
memory precursor T cells (MPECS) and effector T cells (Teff). The infection can 
be controlled and cleared whereupon most of the effector T cells die during the 
contraction phase. Memory CD8+ T cells are able to survive and provide long-
term protection from reinfection with the same pathogen. In comparison to acute 
infections, which can be resolved, chronic infections are marked by the 
persistence of antigen (right). To prevent immunopathology, CD8+ T cells 
become exhausted (Tex) and have a very limited potential to control the 
infection. Therefore, antigen load stays high and a fully functional memory cell 
pool cannot be established (McLane, Abdel-Hakeem et al. 2019). 
 
 
In detail, APCs and especially DC prime and activate CD8+ T cells in secondary 
lymphoid organs by the presentation of antigen via MHC I complexes as well as 
by delivery of co-stimulatory signals and cytokines (van Stipdonk, Lemmens et 
al. 2001, Chopin, Allan et al. 2012). Following the activation by DC, antigen-
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specific CD8+ T cells proliferate in a so-called expansion phase and exit the 
lymphoid organs to fight the infection (Williams and Bevan 2007). Infected cells 
can be killed by cytotoxic T cells with the production and release of perforin and 
granzymes, which together cause apoptosis of target cells (Kaech and Cui 
2012).  
Activated CD8+ T cells display a heterogeneous group of cells with most of 
them being short-lived effector cells (SLECs), distinguished by the expression of 
killer cell lectin-like receptor subfamily G member 1 (KLRG1) (Robbins, Terrizzi 
et al. 2003). These cells are terminally differentiated as they cannot proliferate 
after secondary contact with antigen and will die by apoptosis after clearance of 
the infection during the contraction phase. Besides SLECs, also long-lived cells 
exist which will give rise to the memory cell compartment and are therefore 
termed memory precursor effector cells (MPECs). This population expresses 
high levels of survival receptors such as IL7Ra (CD127) (Joshi and Kaech 
2008). There are various models that explain how these different CD8+ T cell 
subsets emerge. Nevertheless, a complete understanding of this process is still 
missing. The CD8+ T cell response peaks around day 7 post infection. As the 
infection is cleared by this day, approximately 95 % of the effector CD8+ T cells 
(SLECs) will die (Badovinac and Harty 2006). In contrast, MPECs are able to 
survive. The generation of memory cells, which are maintained in an antigen-
independent manner, highly depends on certain transcription factors. For 
example, the interplay between EOMES and T-bet seems to influence this 
formation. T-bet expression favours the development of SLECs under pro-
inflammatory conditions whereas stronger EOMES expression during weaker 
inflammatory responses drives MPECs (Joshi, Cui et al. 2007, D'Cruz, 
Rubinstein et al. 2009, Kaech and Cui 2012). Additionally, Id2 supports the 
formation of memory cells (Cannarile, Lind et al. 2006). Cytokines have been 
shown to play a pivotal role for effector and memory development as well. In 
this context, IL-7 and IL-15 signalling is essential for complete development of a 
memory cell pool (Schluns and Lefrancois 2003, Ma, Koka et al. 2006, Boyman, 
Purton et al. 2007). In summary, the T cell response during acute viral infections 
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is initiated by a strong expansion phase which leads to clearance of the 
infection, followed by a contraction phase and memory formation. 
In contrast to an acute infection, chronic infections such as with HIV, HBV or 
HCV are not cleared by the immune system. These viruses evolved strategies 
to evade the immune response and the infection becomes chronic. With the 
continuous stimulation of the immune system caused by persisting antigen, the 
host is at high risk to be harmed by immunopathology rather than direct effects 
of the pathogen. An ongoing and excessive immune response needs to be 
prevented. Therefore, the immune system dampens itself with a highly complex 
and regulated network of inhibitors to a level where immunopathology is kept to 
a minimum (Cornberg, Kenney et al. 2013). However, in this attenuated state, 
the immune system is not able to clear the infection (Figure 1.1, right).  
In the past decades, numerous research labs focused on the T cell response 
during chronic viral infections and most of the current understanding was 
achieved with studies using the lymphocytic choriomeningitis virus clone 13 
(LCMV Cl13) infection model (Chapter 1.5). Initial CD8+ T cell responses were 
described to be comparable during chronic and acute infection (Wherry 2011). 
However, recent studies show that expression of the exhaustion-driving HMG-
box transcription factor (TOX) is significantly increased already at day four post 
infection with the chronic LCMV strain clone 13 (Khan, Giles et al. 2019). Other 
studies describe further differences at the transcriptional level of CD8+ T cells 
eight days post infection, when comparing acute and chronic viral infections 
(Scott-Browne, Lopez-Moyado et al. 2016, Man, Gabriel et al. 2017). Early 
studies with LCMV Cl13 revealed that CD8+ T cells enter a state of 
hyporesponsiveness, also called exhaustion (Zajac, Blattman et al. 1998) 
(Chapter 1.6). Associated with the expression of certain inhibitory receptors, T 
cell responses are downregulated and loss of effector functions appears in a 
progressive manner (Wherry 2011). Nevertheless, it remains unclear when 
exactly CD8+ T cells enter this phase of exhaustion. Effector cells during the 
early phase of chronic infection express activation markers such as CD69, 
comparable to effector cells during acute infection (Wherry, Ha et al. 2007). 
Some CD8+ T cells also keep in vivo killing activity, indicating that these cells 
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are not completely impaired (Fuller, Khanolkar et al. 2004, Agnellini, Wolint et 
al. 2007). However, the infection cannot be cleared and CD8+ T cells that 
largely lost their functional activity can be detected as well (Fuller and Zajac 
2003, Wherry, Blattman et al. 2003). During some chronic infections, extreme 
exhaustion ending in deletion of antigen-specific CD8+ T cells has also been 
reported (Battegay, Moskophidis et al. 1994, Fuller, Khanolkar et al. 2004). One 
of the hallmarks of the adaptive immune system is the formation of memory 
cells. During chronic infection, however, CD8+ T cells fail to differentiate into this 
cell type and the memory compartment is described to be absent (Wherry, 
Barber et al. 2004, Shin and Wherry 2007). Still, exhausted CD8+ T cells display 
a very heterogeneous population and recent studies have shown that two main 
subpopulations can be described. Terminally exhausted CD8+ T cells can be 
distinguished by the expression of Tim3, while memory-like exhausted CD8+ T 
cells express TCF-1. These memory-like cells harbor some features of memory 
cells as well as stem cells and possess the ability of self-renewal as well as 
differentiation into terminally exhausted cells (Im, Hashimoto et al. 2016). 
 
Overall, T cell responses during chronic infections differ substantially from 
responses during acute infections. T cells become exhausted, viral replication 
outcompetes control mechanisms and T cells fail to differentiate into memory 
cells (Figure 1.1). The underlying mechanisms of T cell exhaustion will be 
discussed in chapter 1.6. Nevertheless, there are many aspects of the immune 
response during chronic viral infection which remain elusive such as early 
factors which drive exhaustion of cells and the extent to which expansion and 
contraction of CD8+ T cells contribute to this. 
 
1.5 Infection model of lymphocytic choriomeningitis virus 
 
In 1933, the American virologist Charles Armstrong isolated and described the 
lymphocytic choriomeningitis virus (LCMV) during an encephalitis epidemic 
(Muckenfuss 1934). Although LCMV was subsequently revealed to not be the 
cause of this epidemic, Armstrong’s studies laid the foundation for many 
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immunological discoveries using LCMV as an infection model. Today, LCMV is 
one of the best-studied infection models in the fields of virology and 
immunology.  
LCMV belongs to the family of Arenaviridae and mainly infects rodents (Childs, 
Glass et al. 1992). This enveloped virus contains two segments of negative 
single-stranded RNA coding for three structural proteins, the nucleoprotein (NP) 
and the glycoproteins GP-1 and GP-2, as well as the viral polymerase (L) and a 
small zinc finger motif protein (Z) (Lee, Novella et al. 2000, Lee, Perez et al. 
2002). LCMV infects cells by binding to alpha-dystroglycan (aDG) and 
consequent receptor-mediated endocytosis (Cao, Henry et al. 1998, Buchmeier 
2007). aDG is a surface receptor of various cell types with a high expression in 
developing tissues and plays a role for the assembly of basement membranes 
by linking the extracellular matrix to the actin cytoskeleton (Ervasti and 
Campbell 1991, Durbeej, Henry et al. 1998, Winder 2001). Virions are 
internalized upon binding to the receptor into vesicles and acidification of these 
vesicles leads to the fusion of the viral and vesicle membranes, hence allowing 
viral replication in the cytosol (Borrow and Oldstone 1994, Quirin, Eschli et al. 
2008). Transmission of LCMV from mice to humans is rare and usually leads to 
asymptomatic and self-limiting infection (Emonet, Retornaz et al. 2007). 
However, in severe cases, aseptic meningitis and encephalitis have been 
reported (Barton and Hyndman 2000, Peters 2006). 
There are two main features of the murine LCMV infection model which make it 
well suitable to study the immune system. First, LCMV is a non-cytolytic virus. 
Therefore, pathogenesis is solely caused by the immune response and allows 
the investigation of the innate and adaptive system on many different levels. 
Second, different strains of LCMV lead to acute and chronic infections which 
can be directly compared as T cells specific for the same epitope can be 
studied. The broadly used strains Armstrong (Arm) and Clone 13 (Cl13) differ in 
only three amino acids which induce a change in the GP and L proteins 
resulting in higher affinity to the entry receptor aDG (Matloubian, Kolhekar et al. 
1993, Sullivan, Emonet et al. 2011). Therefore, infection with the Cl13 strain 
leads to a persistent infection with higher viral replication whereas an infection 
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with the Arm strain can be cleared by the immune system (Mims and 
Wainwright 1968, McChesney and Oldstone 1987). 
Immunological research using the LCMV infection model greatly improved the 
understanding of immune responses. Conceptual discoveries made with this 
model are for example the presentation of foreign antigen to T cells by MHC 
complexes (Zinkernagel and Doherty 1974, Doherty and Zinkernagel 1975). 
Furthermore, formation and maintenance of immunological memory as part of 
the adaptive immune response were described (Lau, Jamieson et al. 1994, 
Murali-Krishna, Lau et al. 1999). Also, the phenomenon of T cell exhaustion as 
a state of hyporesponsiveness was observed and described using the LCMV 
model and led to a better understanding of exhaustion in other chronic 
infections as well as cancer (Moskophidis, Lechner et al. 1993, Gallimore, 
Glithero et al. 1998, Zajac, Blattman et al. 1998). 
The innate immune response to LCMV infection is based on the recognition by 
endosomal and cytoplasmic PRRs. As LCMV infects cells through endocytosis, 
the endosomal TLR7 plays a crucial role for the initial recognition of the virus 
(Walsh, Teijaro et al. 2012). Additionally, signalling via RIG-I-like receptors 
(RLR), which detect viral RNA in the cytosol, is also critical to induce production 
of IFN I cytokines in response to LCMV infection (Clingan, Ostrow et al. 2012). 
Cytokines generated by the innate immune response effectively activate cells of 
the adaptive arm of the immune system. It has been shown that CD4+ T cells 
are not required for viral clearance during acute infection (Matloubian, 
Concepcion et al. 1994). In contrast, during chronic LCMV infection depletion of 
CD4+ T cells leads to increased viral load and further perpetuates viral 
persistence in serum and spleen (Matloubian, Concepcion et al. 1994, 
Blackburn, Shin et al. 2009). CD4+ T cell help during chronic infection was 
shown to support CD8+ T cell as well as B cell responses (Battegay, 
Moskophidis et al. 1994, Ciurea, Hunziker et al. 2001). Partly, CD4+ T cell 
interact with antigen-presenting cells and enable optimal co-stimulatory 
signalling via CD40-CD40L to induce cytotoxic T cell responses (Schoenberger, 
Toes et al. 1998). Additionally, CD4+ T cells support cytotoxic T cell function by 
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the production of IL-21 (Elsaesser, Sauer et al. 2009, Frohlich, Kisielow et al. 
2009, Yi, Du et al. 2009). 
Killing of infected cells is dependent on cytotoxic functions of CD8+ T cells. 
Depletion of these T cells during acute LCMV infection prevents clearance of 
the infection (Buchmeier, Welsh et al. 1980, Matloubian, Concepcion et al. 
1994). These findings are mirrored by studies with simian immunodeficiency 
virus (SIV). Depletion of CD8+ T cells during the course of infection leads to 
increased viral loads and persistence (Schmitz, Kuroda et al. 1999, Gaufin, 
Ribeiro et al. 2010). Overall, clearance of LCMV infection highly depends on the 
strain and route of infection. Perforin-mediated as well as IFNg-mediated 
cytotoxicity were shown to be pivotal for the control of acute LCMV infection 
(Kagi, Ledermann et al. 1994, Walsh, Matloubian et al. 1994, Nansen, Jensen 
et al. 1999, Ou, Zhou et al. 2001). However, during chronic infection perforin 
plays a two-sided role. It mediates control of the infection and at the same time 
regulates the expansion of antigen-specific CD4+ and CD8+ T cells in order to 
avoid an overt cytokine production (Matloubian, Suresh et al. 1999). 
The present study focuses on chronic infection with the LCMV Cl13 strain. 
Whereas the acute Arm strain mediates strong expansion of T cells, is cleared 
within eight days of infection and leads to the formation of memory cells that 
protect from reinfection with the same virus, Cl13 infection persists and causes 
T cell exhaustion (Ahmed, Salmi et al. 1984). LCMV Cl13 causes high viremia 
in blood, spleen and liver for up to three months and persists in kidney, brain 
and salivary glands (Wherry, Blattman et al. 2003). However, infection with this 
chronic LCMV strain prevents lethal immunopathology by partial paralysis of the 
immune response. Especially the phenomenon of T cell exhaustion described 
during chronic LCMV infection served as a model to understand immune 
responses during other chronic infection such as HIV and HCV as well as in the 
context of cancer. With this knowledge new therapies, targeting the reactivation 
of exhausted T cells, have been developed and revolutionized cancer 
treatment. 
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1.6 CD8+ T cell exhaustion during chronic infection and cancer 
 
The phenomenon of T cell exhaustion was first described by Gallimore et al. 
and Zajac et al. in 1998 by studying the cellular adaptive immune response 
during chronic LCMV infection (Gallimore, Glithero et al. 1998, Zajac, Blattman 
et al. 1998). As described in chapter 1.4, T cell exhaustion arises during chronic 
infections and cancer with persistent antigen and is characterized by a 
hyporesponsiveness of T cells. Exhaustion can be described as downregulation 
of immune responses, with the aim to prevent severe immunopathology and 
therefore presents a regulatory element that protects the host. At the same 
time, it prevents clearance of infection or eradication of tumour cells and 
thereby contributes to chronicity, which in turn further supports exhaustion. The 
exact underlying mechanisms which drive T cell exhaustion are still not fully 
understood, but immunological research of the last decades shed more light 
into the complexity of T cell responses and exhaustion, which also occurs 
during human chronic infections such as with HIV, HBV and HCV as well as 
during cancer (Virgin, Wherry et al. 2009). 
Exhausted CD8+ T cells are distinct from effector and memory CD8+ T cells, 
which arise during acute infections, on the transcriptional, epigenetic and 
metabolic level. The exhausted or dysfunctional state of T cells is described by 
a progressive loss of certain effector functions. The ability to produce IL-2 is one 
of the first functions which is lost during the development of CD8+ T cell 
exhaustion. This is followed by the loss of TNF production, cytotoxic functions 
and proliferative capacity. More severely exhausted CD8+ T cells also show 
defects in IFNg production (Wherry, Blattman et al. 2003, Fuller, Khanolkar et al. 
2004). In the final stage of exhaustion, CD8+ T cells can be physically deleted 
(Battegay, Moskophidis et al. 1994, Wherry, Blattman et al. 2003, Fuller, 
Khanolkar et al. 2004) (Figure 1.2). Interestingly, during chronic LCMV infection, 
CD8+ T cells specific for certain epitopes are more prone to this physical 
deletion than others. Gp33- and gp276-specific CD8+ T cells are dysfunctional 
but are preserved during the course of chronic infection (Moskophidis, Lechner 
et al. 1993, Wherry, Blattman et al. 2003, Fuller, Khanolkar et al. 2004). 
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However, why some exhausted cells are deleted whereas others can survive 
remains to be clarified. 
 
 
 
 
Figure 1.2: Progressive loss of effector functions during T cell exhaustion 
Naïve CD8+ T cells are activated by antigen presentation and co-stimulation 
and are able to differentiate into effector and memory precursor cells during 
acute infection. The viral infection can be cleared and highly functional memory 
cells are generated. These memory cells display a strong proliferative capacity 
and can rapidly produce cytokines and exert cytotoxic functions upon 
reinfection with the same pathogen. In contrast, during chronic infections 
antigen persists and the CD8+ T cells become exhausted. This exhaustion 
follows a hierarchical pattern, starting with the loss of IL-2 production, followed 
by TNF and finally IFNg production. Simultaneously, exhausted CD8+ T cells 
lose the ability to proliferate and perform cytotoxic functions. This dysfunctional 
phenotype is partly caused by a strong co-expression of various inhibitory 
receptors like PD-1, Lag-3 and 2B4. Furthermore, terminally exhausted CD8+ T 
cells are prone to undergo apoptosis. Adopted from (Wherry 2011). 
 
 
As described, exhausted CD8+ T cells lose many effector functions. 
Nevertheless, some effector functions are not completely abolished and the 
infection can be controlled to a certain extent. These findings are supported by 
studies where CD8+ T cells were depleted during the course of chronic 
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infection. For example, depletion of CD8+ T cells during infection with simian 
immunodeficiency virus (SIV) lead to an increase of viral load in untreated 
animals as well as animals under antiretroviral therapy (Jin, Bauer et al. 1999, 
Schmitz, Kuroda et al. 1999, Cartwright, Spicer et al. 2016). Furthermore, 
exhausted T cells have also been shown to be essential for the content of 
tumour growth and spread (Fridman, Pages et al. 2012, Li, van der Leun et al. 
2019).  
In addition, it is important to mention, that there are two different types of 
exhausted CD8+ T cells. Most of them display an effector, but terminally 
differentiated phenotype and can be identified by the expression of Tim3. A 
smaller subset of TCF-1+ exhausted CD8+ T cells displays a memory-like 
phenotype and plays a crucial function as this subset can not only undergo self-
renewal but also gives rise to the Tim3+ subset. A more detailed overview of the 
differences between memory-like exhausted and terminally exhausted CD8+ T 
cells as well as factors which influence the generation and maintenance of both 
will be discussed below. 
First, an important question that is still not fully answered is how and when T 
cell exhaustion develops post infection. Studies using the chronic LCMV model 
describe that the persistence of antigen drives exhaustion (Wherry, Blattman et 
al. 2003). This factor has very likely a strong impact as normal effector and 
memory cells similar to the ones generated during acute infections were 
detected when antigen was removed early during the course of a chronic 
infection (Angelosanto, Blackburn et al. 2012, Ahn, Youngblood et al. 2016). In 
contrast, when antigen was removed at a later time point, the CD8+ T cells 
retained their exhausted phenotype and generation of normal effector and 
memory cells was impeded (Utzschneider, Legat et al. 2013, Wieland, 
Kemming et al. 2017). Additionally, studies show that the severity of exhaustion 
correlates with antigen load (Wherry, Blattman et al. 2003, Blackburn, Shin et 
al. 2009). For example, the chronic LCMV strain Cl13 exhibits a stronger affinity 
to the entry receptor aDG than the acute LCMV strain Arm. This was shown to 
affect viral tropism, as it enables LCMV Cl13 to infect DC and replicate faster 
compared to LCMV Arm (Kunz, Sevilla et al. 2001). The high load of antigen 
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during chronic infections and as a consequence continuous TCR signalling 
could be the main driver of T cell exhaustion. Transcriptional changes which are 
connected to T cell exhaustion have been described already four days post 
infection with LCMV Cl13 (Khan, Giles et al. 2019). Therefore, factors like viral 
tropism and antigen presentation might introduce transcriptional programs 
triggering the start of exhaustion. Further on, antigen persistence and a 
complex network of intrinsic (expression of inhibitory receptors, transcriptional 
and epigenetic changes) and extrinsic factors (cytokines, lack of CD4+ T cell 
help and regulatory suppressor cells) sustains the exhausted phenotype later 
on during chronic infection (Wherry and Kurachi 2015). Again, all of these 
elements are upregulated to protect the host from an overwhelming immune 
response and immunopathology, but at the same time sustains chronicity of the 
infection (Speiser, Utzschneider et al. 2014). 
One of the hallmarks of T cell exhaustion is the expression of high levels of 
various inhibitory receptors such as PD-1, CTLA-4, Lag-3, 2B4, TIGIT and 
Tim-3 (Jones, Ndhlovu et al. 2008, Blackburn, Shin et al. 2009, Golden-Mason, 
Palmer et al. 2009, Jin, Anderson et al. 2010). Many of these inhibitory 
receptors are expressed during acute infections where they also display 
inhibitory functions (Blackburn, Shin et al. 2009, Cook and Whitmire 2016, Ahn, 
Araki et al. 2018). They play an important role for the regulation of T cell 
responses and prevent T cell hyperactivation as well as subsequent 
immunopathology and are therefore termed immune checkpoints. However, 
during acute infection, expression levels of these inhibitory receptors are lower 
and downregulated with the control of viral infection (Ahn, Araki et al. 2018). 
Additionally, sustained co-expression of various inhibitory receptors can only be 
detected during chronic infections (Blackburn, Shin et al. 2009). One of the 
most relevant inhibitory receptors during chronic infection is programmed cell 
death protein 1 (PD-1). Its signalling pathway and the possible blockade by 
checkpoint immunotherapy will be discussed in the chapters 1.7 and 1.8. 
Exhausted CD8+ T cells express up to seven inhibitory receptors simultaneously 
which share some overlapping as well as non-overlapping pathways of 
inhibition (Blackburn, Shin et al. 2009). Many inhibitory receptors, such as PD-1, 
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2B4 and TIGIT, express an immunoreceptor tyrosine-based inhibition motif 
(ITIM) in their cytoplasmic domain. This intracellular signalling leads to the 
recruitment of phosphatases which inhibit TCR and co-stimulatory signalling 
pathways (Hannier, Tournier et al. 1998, Hui, Cheung et al. 2017, McLane, 
Abdel-Hakeem et al. 2019). Lag3, in contrast, functions through a KIEELE motif 
and inhibits cell cycle progression (Workman, Dugger et al. 2002). Tim3 also 
executes its inhibitory function by non-ITIM intracellular motifs, which can 
interfere with intracellular TCR signalling (Anderson, Joller et al. 2016). CTLA-4 
binds the ligands of the co-stimulatory receptor CD28: CD80 and CD86. 
Therefore, it competes with CD28 and can decrease co-stimulatory signalling 
(Walker and Sansom 2011). Some of the precise mechanisms of inhibitory 
signalling pathways are still not fully understood, but the simultaneous 
expression of various checkpoint receptors dampens T cell activation on various 
levels and blockade of more than one inhibitory receptor mostly showed 
synergistic effects for checkpoint immunotherapy (Chapter 1.8). 
In addition to the upregulation of inhibitory receptors, T cell exhaustion is linked 
to specific transcriptional changes. Recent studies have revealed a key role for 
the transcription factor TOX in promoting CD8+ T cell exhaustion (Alfei, Kanev 
et al. 2019, Khan, Giles et al. 2019, Scott, Dundar et al. 2019, Seo, Chen et al. 
2019, Yao, Sun et al. 2019). Already four days post infection with a virus 
causing a chronic infection enhanced TOX expression was detected (Khan, 
Giles et al. 2019). In the absence of TOX, CD8+ T cells did not acquire an 
exhausted phenotype but rather differentiated into functional effector cells 
expressing KLRG1 (Alfei, Kanev et al. 2019). However, in this scenario, mice 
suffered from severe immunopathology. TOX induces the upregulation of 
inhibitory receptors and was shown to be crucial for the survival of the memory-
like TCF-1+ exhausted CD8+ T cell population (Alfei, Kanev et al. 2019). 
Additionally, it also impacts the differentiation of cells on the epigenetic level as 
it has been described to promote chromatin remodelling (Khan, Giles et al. 
2019). Therefore, TOX seems to play a key role in the formation of T cell 
exhaustion. Moreover, other transcription factors have been described to drive 
exhaustion. Already early post infection CD8+ T cells from chronically infected 
 Introduction 
24 
animals expressed higher levels of Irf-4, Batf and Nfat-1 (Man, Gabriel et al. 
2017). These transcription factors have been described to promote T cell 
exhaustion by upregulation of inhibitory receptors, they suppress T cell 
expansion and can also lead to metabolic reprogramming (Martinez, Pereira et 
al. 2015, Scott-Browne, Lopez-Moyado et al. 2016). 
Exhausted CD8+ T cells also display a unique phenotype regarding their 
epigenetic landscape. Epigenetic effects such as DNA methylation and histone 
modification have been described and studied in the context of acute and 
chronic infections by comparing effector and memory CD8+ T cells with 
exhausted CD8+ T cells. These studies revealed that there is a great number of 
differentially accessible chromatin regions in exhausted CD8+ T cells (Sen, 
Kaminski et al. 2016). One locus studied more intensively is the Pdcd1 locus 
which encodes for PD-1. During acute infection, this locus was shown to be 
demethylated during the effector phase, allowing transcription of the gene. 
Upon viral clearance and memory formation, the locus was remethylated, 
preventing Pdcd1 transcription (Bally, Austin et al. 2016). However, during 
chronic infection, the Pdcd1 locus was demethylated throughout the course of 
infection and even post checkpoint immunotherapy, when viral load was 
decreased (Pauken, Sammons et al. 2016). The constant demethylation of the 
Pdcd1 locus was also detected in CD8+ T cells during HIV infection 
(Youngblood, Oestreich et al. 2011). To which extent a full reinvigoration of 
exhausted CD8+ T cells can be maintained after immunotherapy therefore 
needs to be evaluated.  
 
All these T cell-intrinsic factors can induce and maintain exhaustion, but the 
cellular state is additionally highly influenced by extrinsic factors. As viral loads 
are high and persist during chronic infections, a plethora of cytokines, both pro-
inflammatory and anti-inflammatory, have been described to play a role for 
CD8+ T cell exhaustion. However, the expression of certain cytokine receptors 
and signalling pathways are again different to the ones seen in bona fide 
effector and memory CD8+ T cells (Wherry, Ha et al. 2007, Wherry and Kurachi 
2015). Some cytokines have been described to be critical for the maintenance 
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of functions exerted to a limited extent by exhausted CD8+ T cells. Among them 
are IL-2 and IL-21. IL-2 drives the expansion of CD8+ T cells during acute 
infections. Likewise, IL-2 signalling has been shown to be important for the 
physical maintenance of antigen-specific cells during chronic LCMV infection 
(Bachmann, Wolint et al. 2007). Similar to IL-2, IL-21 has also been described 
to sustain functionality of exhausted CD8+ T cells (Elsaesser, Sauer et al. 2009, 
Frohlich, Kisielow et al. 2009, Yi, Du et al. 2009). Importantly, the two receptors 
for IL-2 and IL-21 remain expressed on exhausted CD8+ T cells, albeit to a 
lesser extent than on CD8+ T cells during acute infections (Ingram, Yi et al. 
2011, Beltra, Bourbonnais et al. 2016).  
In contrast to these cytokines which support CD8+ T cell functions, other 
cytokines, like IL-10 and TGF-b, further drive exhaustion and inhibit effector 
functions. During chronic LCMV infection as well as during human chronic viral 
infections, IL-10 levels are increased and have been associated with 
suppressive capacities regarding T cell activation and proliferation (Brooks, 
Trifilo et al. 2006, Wilson and Brooks 2011, Wherry and Kurachi 2015). During 
chronic LCMV infection, CD4+ T cells were described to be a critical source of 
IL-10. This was put in context with the viral tropism of the chronic LCMV Cl13 
strain, which unlike the acute strain LCMV Arm is able to infect DC (Baca 
Jones, Filippi et al. 2014). Smith et al. showed that IL-10 signalling negatively 
impacts TCR signalling and thereby increased the threshold for CD8+ T cell 
activation (Smith, Boukhaled et al. 2018).  
Compared to cytokines which either oppress or support CD8+ T cell exhaustion, 
the IFN I cytokines IFNa and IFNb have a more complex role during chronic 
infections. Early during the infection, IFNa/b signalling plays a supportive role 
for effector CD8+ T cells and therefore enhances viral control as an important 
signal 3 cytokine (Teijaro, Ng et al. 2013, Wilson, Yamada et al. 2013). 
However, ongoing IFN I signalling can induce IL-10 as well as PD-L1 
expression and drive CD8+ T cell exhaustion (Ivashkiv and Donlin 2014). Such 
a dual role, where ongoing IFN I signalling has deleterious rather than beneficial 
effects, is described during chronic LCMV as well as SIV and HIV infection 
(Dagenais-Lussier, Loucif et al. 2017). Some of these cytokines have been 
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tested as therapeutic targets mostly in combination with checkpoint 
immunotherapy, which will be discussed in more detail in chapter 1.8.  
Besides soluble mediators, cellular interaction partners with their specific 
surface molecules are able to strongly impact CD8+ T cell responses and 
exhaustion during chronic infections. An important driver of CD8+ T cell 
exhaustion is missing help from CD4+ T cells. During acute infections, CD4+ T 
cells potently support CD8+ T cell responses by optimizing the interaction with 
DCs (Ridge, Di Rosa et al. 1998, Eickhoff, Brewitz et al. 2015). In this study, we 
mainly focus on CD8+ T cell exhaustion. Nevertheless, it must be mentioned 
that exhaustion is also described for CD4+ T cells (Oxenius, Zinkernagel et al. 
1998, Brooks, Teyton et al. 2005). Similar transcriptional changes caused by 
chronic infections have been detected for CD4+ and CD8+ T cells (Crawford, 
Angelosanto et al. 2014). Missing CD4+ T cell help in the context of chronic 
LCMV infection as well as during HIV infection and cancer leads to a higher 
viral burden and promotes CD8+ T cell exhaustion (Matloubian, Concepcion et 
al. 1994, Kalams, Buchbinder et al. 1999, Borst, Ahrends et al. 2018). 
Additionally, as described earlier, CD4+ T cells can impact the CD8+ T cell 
exhaustion by the production of cytokines such as IL-21 and IL-10. Moreover, 
CD4+ T cell help for B cells by TFH cells supports the generation of neutralizing 
and non-neutralizing antibodies, which in turn control viral titers and therefore 
influence persistence (Planz, Ehl et al. 1997, Richter and Oxenius 2013, 
Greczmiel, Krautler et al. 2017). In contrast to CD4+ T cells which support CD8+ 
T cell activation, also immunosuppressive regulatory CD4+ T cells (Treg cells) 
play a role during chronic infections. However, it remains unclear if Treg cells 
are able to directly drive T cell exhaustion or contribute to an 
immunosuppressive environment by the production of TGF-b and IL-10 (Veiga-
Parga, Sehrawat et al. 2013, Wherry and Kurachi 2015). Besides Treg cells, 
myeloid-derived suppressor cells (MDSC) expanded during chronic LCMV 
infection and the depletion of these innate immune cells improved the activation 
of CD8+ T cells. MDSC were also correlated with the progression of human 
HCV infection (Cai, Qin et al. 2013). 
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The plethora of different players of T cell exhaustion (inhibitory receptors, 
transcriptional and epigenetic regulation, soluble mediators and cellular 
interaction partner) reflects that CD8+ T cell exhaustion is regulated on 
numerous levels. This complex network of different factors which impact the 
state of exhausted CD8+ T cells is still not fully understood and certain elements 
may vary during different chronic infections and cancer.  
 
As mentioned above, all antigen-specific cells display an exhausted phenotype 
during chronic infections and generation of bona fide memory cells is lacking. 
However, this pool of exhausted CD8+ T cells is heterogeneous and 
immunological research of recent years lead to a better understanding of its 
subpopulations. Interestingly, a small group of exhausted CD8+ T cells shares 
features with memory cells. These cells are therefore termed memory-like 
exhausted CD8+ T cells. The second and bigger group of exhausted CD8+ T 
cells displays effector functions but at the same time is more exhausted. These 
cells have been described as terminally exhausted CD8+ T cells (He, Hou et al. 
2016, Im, Hashimoto et al. 2016, Leong, Chen et al. 2016, Utzschneider, 
Charmoy et al. 2016). One of the first studies describing different 
subpopulations of exhausted CD8+ T cells was published by Blackburn et al. in 
2008. By blocking the PD-1/PD-L1 signalling pathway during chronic LCMV 
infection, they showed that only a subset, the later termed memory-like cells, 
responded to therapy (Blackburn, Shin et al. 2008). Phenotypically, the subsets 
were distinguished by the expression of PD-1 and CD44. The subset, which 
responded to immune checkpoint therapy expressed lower levels of PD-1 and 
higher levels of CD44 and therefore displayed a less exhausted phenotype. 
Their terminally exhausted counterpart expressed higher levels of PD-1 and 
lower levels of CD44 (Blackburn, Shin et al. 2008). Since 2016, these two 
subsets have been described in more detail with transcriptional, epigenetic and 
phenotypic differences as well as differences in their localization throughout 
different organs. In detail, to date memory-like exhausted CD8+ T cells can be 
best distinguished from terminally exhausted CD8+ T cells by the expression of 
the transcription factor T cell factor 1 (TCF-1), whereas their counterpart 
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expresses the surface receptor T-cell immunoglobulin and mucin-domain 
containing-3 (TIM-3) (Im, Hashimoto et al. 2016, Wu, Ji et al. 2016). These two 
populations will be termed TCF-1+ and Tim3+ from now on. TCF-1 is also 
expressed by naïve and memory CD8+ T cells (Zhou, Yu et al. 2010). 
Exhausted TCF-1+ cells are able to perform self-renewal and additionally give 
rise to the Tim3+ subset (Figure 1.3), which expresses higher levels of effector 
molecules such as perforin and granzymes (Im, Hashimoto et al. 2016). This 
subset expresses lower levels of certain inhibitory receptors such as PD-1 and 
largely lack the expression of Tim3 and 2B4 (Im, Hashimoto et al. 2016). 
Another marker for this subset is the chemokine receptor CXCR5 (Im, 
Hashimoto et al. 2016). However, there TCF-1+ cells which are CXCR5-. 
Therefore, distinguishing these cells by TCF-1 might be more accurate.  
 
 
 
Figure 1.3: Exhausted CD8+ T cells during chronic viral infection 
Memory-like exhausted (TCF-1+) and terminally exhausted (Tim3+) CD8+ T cells 
develop during chronic LCMV infection. TCF-1+ cells express lower levels of 
PD-1 compared to Tim3+ cells and are able to respond to checkpoint 
immunotherapy. These memory-like cells are able to self-renew and give rise to 
the terminally exhausted subset of CD8+ T cells. Adopted from (Philip and 
Schietinger 2019). 
 
 
Certain transcriptional differences have been described to drive the 
differentiation into TCF-1+ or Tim3+ cells. The transcription factor B lymphocyte-
induced maturation protein-1 (Blimp-1) presents a strong regulator of the 
differentiation of exhausted CD8+ T cells as it downregulates TCF-1 expression 
(Shin, Blackburn et al. 2009, Leong, Chen et al. 2016). In contrast, the 
transcription factor Forkhead Box O1 (FOXO1) induces TCF-1 expression and 
Memory-like exhausted 
PD-1int 
responsive to checkpoint  
immunotherapy 
Terminally exhausted 
PD-1hi 
Tcf-1+ Tim3+ 
Exhausted CD8+ T cells 
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thereby promotes the memory-like subpopulation (Staron, Gray et al. 2014, 
Utzschneider, Delpoux et al. 2018). As the TCF-1+ population gives rise to the 
Tim3+ population which present important effector functions, mice deficient of 
FOXO1 were not able to control the infection to the extent that WT mice did 
(Staron, Gray et al. 2014, Utzschneider, Delpoux et al. 2018). Additionally, the 
transcriptional regulators Id2 and Id3 drive differentiation of exhausted CD8+ T 
cells. Important for the generation of memory cells, Id3 is also expressed by 
memory-like TCF-1+ cells. In contrast, Id2 is expressed by terminally exhausted 
Tim3+ cells (Im, Hashimoto et al. 2016, Leong, Chen et al. 2016). Interestingly, 
the transcription factors have been described to impact the expression of 
CXCR5 (Leong, Chen et al. 2016). To date, there are only few studies 
investigating the impact of the localization of the generation and maintenance of 
the two subsets. In contrast to Tim3+ cells, TCF-1+ cells have been detected 
only in lymphoid tissues. In the spleen, they mainly reside in the T cell zone (Im, 
Hashimoto et al. 2016). These cells also express the co-stimulatory receptor 
CD28, which was shown to be essential for the reinvigoration by checkpoint 
immunotherapy (Kamphorst, Wieland et al. 2017). Importantly, the 
subpopulation of TCF-1+ and CXCR5+ memory-like exhausted CD8+ T cells 
have also been described in various tumour models and also there displays the 
population of exhausted CD8+ T cells which are able to respond to immune 
checkpoint inhibition (Siddiqui, Schaeuble et al. 2019).  
In summary, CD8+ T cells undergo several states of exhaustion during chronic 
infections and cancer. This process is initiated to protect the host from immune-
related pathology and regulated on various levels by intrinsic and extrinsic 
factors. However, a subset of exhausted CD8+ T cells maintains certain 
functions similar to bona fide memory CD8+ T cells and can be targeted by 
checkpoint immunotherapy to reinvigorate CD8+ T cell responses and decrease 
viral or tumour burden. 
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1.6.1 The PD-1 signalling pathway 
 
Programmed cell death 1 (PD-1) is one of the most studied inhibitory receptors 
which drives T cell exhaustion during chronic infection and cancer. In addition, 
targeting this signalling pathway with monoclonal antibodies, revolutionized 
cancer treatment. PD-1 is a transmembrane protein which belongs to the CD28 
family of regulatory receptors (Schildberg, Klein et al. 2016). The extracellular 
part comprises a IgV domain and the cytoplasmic regions harbour ITIM and 
ITSM motifs, which are important phosphorylation sites during signalling 
(Arasanz, Gato-Canas et al. 2017). The ligands of PD-1 are PD-L1 and PD-L2 
(Zhang, Schwartz et al. 2004). PD-L1 is expressed on various immune and non-
immune cells and can be upregulated on infected cells as well as tumour cells. 
Here, several cytokines such as IFN I, IFNg, TNFa and IL-10 have been 
reported to induce upregulation of PD-L1 (Eppihimer, Gunn et al. 2002). In 
contrast, PD-L2 expression has been described for DC, macrophages and 
germinal center B cells (Schildberg, Klein et al. 2016). There are also soluble 
forms of PD-L1 and PD-L2, however, their contribution to T cell exhaustion 
remains incompletely understood. In this study, we focus on PD-1 expression 
on CD8+ T cells. However, it can also be expressed by CD4+ T cells, NK cells, B 
cells, macrophages and DC (Nishimura, Agata et al. 1996, Petrovas, Casazza 
et al. 2006, Chang, Kim et al. 2008, Liu, Yu et al. 2009).  
CD8+ T cells upregulate PD-1 upon activation by TCR stimulation within 24 h 
and various cytokines, such as IFN I, IL-2, IL-7, IL-15 and IL-21, can further 
promote the expression (Kinter, Godbout et al. 2008, Terawaki, Chikuma et al. 
2011, Schildberg, Klein et al. 2016). In contrast to the transient expression on 
activated effector CD8+ T cells during acute infection, PD-1 expression 
becomes permanent during chronic infections and cancer. Due to persistence 
of high loads of antigen, PD-1 levels stay upregulated (Blattman, Wherry et al. 
2009). Upon binding of its ligands PD-L1 or PD-L2, tyrosine residues of ITIM 
and ITSM motifs of the intracellular tail of PD-1 become phosphorylated 
(Freeman, Long et al. 2000, Schildberg, Klein et al. 2016). This results in the 
recruitment of the phosphatases SHP1 and SHP2 (Yokosuka, Takamatsu et al. 
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2012). These phosphatases are able to dephosphorylate various adaptor 
proteins of the intracellular domains of the TCR as well as the co-stimulatory 
receptor CD28 (Sheppard, Fitz et al. 2004, Hui, Cheung et al. 2017). ZAP70 
and PI3K belong to the signalling cascade of TCR and CD28 receptors and are 
targets of SHP1 and SHP2. Thereby, T cell expansion and various functions are 
inhibited (Figure 1.4). 
 
 
 
Figure 1.4: PD-1 signalling 
Upon binding of its ligands PD-L1 or PD-L2, the intracellular ITIM and ITSM 
motifs of PD-1 are phosphorylated and recruit the phosphatases SHP-1 and 
SHP-2. Dephosphorylation of TCR and CD28 adaptor proteins ZAP70 and PI3K 
inhibits downstream signalling and results in a decrease of proliferation, 
cytokine production and cytotoxicity of the cells (Lee, Ahn et al. 2015). 
 
 
Although PD-1 strongly impacts T cell exhaustion and has been shown to play a 
crucial role during various chronic infections and cancer, exhaustion does also 
develop in the absence of PD-1 (Odorizzi, Pauken et al. 2015). Ultimately, PD-
1-/- CD8+ T cells display a more exhausted phenotype than WT cells (Frebel, 
- 
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Nindl et al. 2012, Odorizzi, Pauken et al. 2015). As mentioned earlier, strong 
TCR signalling drives exhaustion and the expression of various inhibitory 
receptors. As PD-1 signalling decreases activation of CD8+ T cells, it also 
prevents ongoing strong TCR signalling.  
Importantly, the state of T cell exhaustion is at least to some extent reversible 
and targeting PD-1 signalling showed great success during chronic infections 
and cancer. By the administration of monoclonal antibodies that either block 
PD-1 or PD-L1, signalling can be abrogated and the inhibitory function of this 
checkpoint receptor suppressed. 
 
1.6.2 Checkpoint Immunotherapy: PD-1 and PD-L1 blockade  
 
Through the detailed examination of CD8+ T cell responses during chronic 
infection and cancer and the connection between functional paralysis and the 
expression of inhibitory receptors, new treatment strategies for the 
reinvigoration of exhausted CD8+ T cells could be developed. The great 
success of checkpoint immunotherapy was awarded with the 2018 Nobel Prize 
in Physiology or Medicine to James P. Allison and Tasuku Honjo "for their 
discovery of cancer therapy by inhibition of negative immune regulation" 
(NobelPrize.org 2019). 
In 2006, Barber et al. showed that inhibition of the PD-1/PD-L1 signalling 
pathway with monoclonal antibodies can reinvigorate exhausted CD8+ T cells 
and decrease viral load in the chronic LCMV model (Barber, Wherry et al. 
2006). This reinvigoration included expansion of CD8+ T cells as well as 
increased frequencies of IFNg- and TNFa-producing CD8+ T cells, reflecting 
regained effector functions (Barber, Wherry et al. 2006). Yet, the reactivation of 
exhausted CD8+ T cells was dependent on CD28 signalling, revealing an 
essential role for co-stimulatory signalling pathways in the context of checkpoint 
immunotherapy (Hui, Cheung et al. 2017, Kamphorst, Wieland et al. 2017). The 
necessity of CD28 signalling strongly points towards a critical role for specific 
cellular interaction partners that deliver these co-stimulatory ligands. However, 
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very little is known about the complex network of immune and non-immune cells 
which contribute to checkpoint immunotherapy. 
To date, several immune checkpoint inhibitors blocking PD-1 and CTLA-4 
signalling are used for cancer treatment (Rotte 2019). With these therapies 
melanoma, non-small cell lung carcinoma, urothelial carcinoma and other 
tumour entities can be successfully treated (Rotte 2019). Nevertheless, immune 
checkpoint inhibitors are not suitable for all types of cancer and chronic 
infections and in many patients severe side effects have been reported. 
As described in chapter 1.6, a broad range of soluble and cellular components 
influence T cell exhaustion. All these different elements are possible 
therapeutical targets and a plethora of combinatorial treatment approaches are 
currently investigated in animal models as well as clinical trials. 
Approaches either target inhibitory elements, such as inhibitory receptors and 
regulatory soluble and cellular mediators, as well as factors which maintain T 
cell functions during exhaustion such as co-stimulatory receptors and cytokines. 
For example, combined blockade of several inhibitory receptors has been 
shown to provoke synergistic effects. Anti-PD-1 together with anti-CTLA-4 
treatment showed improved outcome over monotherapy for the treatment of 
melanoma (Larkin, Hodi et al. 2015). In contrast to treatment of certain cancers, 
CTLA-4 blockade during chronic infections such as LCMV, SIV and HIV was not 
sufficient to reinvigorate exhausted CD8+ T cells and decrease viral load 
(Barber, Wherry et al. 2006, Kaufmann and Walker 2009). However, in 
combination with anti-PD1 treatment it showed synergistic effects, yet also 
increased side-effects (Kaufmann, Kavanagh et al. 2007). Similarly, co-
treatment of anti-PD-1 with anti-Lag3 or anti-Tim3 lead to improved control of 
chronic viral infections and tumour burden (Blackburn, Shin et al. 2009, Jin, 
Anderson et al. 2010, Kassu, Marcus et al. 2010, Sakuishi, Apetoh et al. 2010). 
Next to inhibitory receptors, immune regulatory cells, such as Treg cells, 
enhance T cell exhaustion as depletion of such increased the number of 
antigen-specific CD8+ T cells during chronic LCMV infection. Viral titers could 
be decreased significantly by the combination of Treg cell depletion and 
blockade of the PD-1 pathway (Penaloza-MacMaster, Kamphorst et al. 2014). 
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Notably, Treg cells can affect T cell exhaustion by the production of 
immunosuppressive cytokines such as IL-10 but also by the consumption of IL-
2, which is a key cytokine important for survival and activation of CD8+ T cells. 
Both cytokines have been investigated as therapeutical targets. Blockade of the 
inhibitory cytokine IL-10 by the administration of neutralizing antibodies early 
during chronic LCMV infection enabled reactivation of CD8+ T cells and viral 
clearance (Ejrnaes, Filippi et al. 2006). Combined treatment of anti-IL10 with 
anti-PD-L1 during the chronic infection phase, enhanced control of the infection 
and restored CD8+ T cell functions (Brooks, Ha et al. 2008). Beneficial effects 
have been also described for the administration of IL-2 during anti-PD-L1 
treatment of chronic LCMV infection. The synergistic effects lead to an increase 
of antigen-specific CD8+ T cells and a reduction of the viral load (West, Jin et al. 
2013).  
In general, an early start of treatment of chronic infections and cancer to restore 
T cell responses correlates with better therapy outcome. Again, pointing 
towards a progressive loss of effector functions and development of exhaustion. 
Additionally, targeting the reactivatable memory-like TCF-1+ CD8+ T cell pool 
could further improve therapy outcome. The frequency of TCF-1+ cells already 
serves as a valuable biomarker for therapy success in melanoma patients 
(Sade-Feldman, Yizhak et al. 2018). Nevertheless, T cell exhaustion is a fine-
tuned state in which immunopathology is repressed. By the reinvigoration of 
exhausted CD8+ T cells with checkpoint immunotherapy, the risk of inducing 
productive inflammatory responses which harm the host increases. Indeed, 
during combined blockade of PD-1 and CTLA-4 severe immune-related adverse 
events such as colitis have been reported (Montfort, Colacios et al. 2019). 
Prophylactic treatment with TNF inhibitors not only showed success in mouse 
models but could also prevent immune-related enterocolitis in cancer patients 
treated with immune checkpoint inhibitors (Badran, Cohen et al. 2019, Perez-
Ruiz, Minute et al. 2019). 
Conclusively, immunotherapy with checkpoint inhibitors shows an enormous 
success and revolutionized cancer treatment. However, T cell exhaustion is 
regulated by a complex network of elements. A better understanding of soluble 
 Introduction 
35 
and cellular interaction partners which drive T cell exhaustion and are essential 
to restore the response will greatly improve the development of new 
therapeutically approaches. 
 
1.7 Thesis aims  
 
Chronic viral infections and cancer exploit a state of hyporesponsiveness of 
reactive T cells that developed to protect the host from severe 
immunopathology. In this process, T cells adopt an exhausted phenotype and 
are functionally impaired which prevents them from clearing the infection or 
eradicating tumour cells (Hashimoto, Kamphorst et al. 2018). However, 
checkpoint inhibitor-based immunotherapies enable reactivation of exhausted T 
cells and are an enormous success for the treatment of various cancer types. 
The scientific field that addresses the underlying mechanism of PD-1/PD-L1 
blockade and explores its efficacy in various experimental settings and human 
conditions has received much attention and is rapidly evolving. Experimental 
studies deciphered a subset of exhausted CD8+ T cells representing a memory-
like cell population that responds to therapy with checkpoint inhibitors (Im, 
Hashimoto et al. 2016, Utzschneider, Charmoy et al. 2016). Nevertheless, the 
exact underlying mechanisms of CD8+ T cell reinvigoration are still not 
completely elucidated. Therefore, it is of great interest to better understand 
factors that impact on T cell exhaustion as well as checkpoint immunotherapy. 
In this study, we aimed to illuminate critical cellular interaction partners, which 
influence the reinvigoration of exhausted CD8+ T cells during anti-PD-L1 
treatment. Specifically, the role of DC and certain subsets of these antigen-
presenting cells was investigated in this context. Furthermore, we endeavoured 
to resolve signalling pathways that are involved in the cellular communication 
and how these impact on the activation and differentiation of exhausted CD8+ T 
cells during anti-PD-L1 treatment. Focusing on the group of memory-like 
exhausted CD8+ T cells, we asked the question if these cells represent a 
heterogenous population and aimed to examine the interplay with DC subsets 
in secondary lymphoid organs.  
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Overall, the aim of this study was to elucidate which DC subsets influence 
subsets of exhausted CD8+ T cells during anti-PD-L1 treatment on a 
transcriptional and functional level as well as in the context of their splenic 
localization. 
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Mice 
 
Mice were bred and maintained under specific pathogen-free conditions and in 
accordance to institutional animal guidelines in the animal facility (House of 
Experimental Therapy, HET) of the University of Bonn (Germany), the animal 
house facility of the Department of Microbiology and Immunology at the 
University of Melbourne, Peter Doherty Institute (Australia) and the animal 
facility of the Institute of Systems Immunology I, University of Würzburg 
(Germany). All animal experiments were approved by the animal ethics 
committees of the associated universities. C57BL/6J (B6) wildtype strains 
(H-2Kb) were purchased from Janvier (Le Genest-Saint-Isle, France). All mice 
are on the genetic background of C57BL/6J and were used at 8-12 weeks of 
age.  
 
Mouse strain Publication and description 
 
C57BL/6J C57BL/6J non-transgenic mice were used as wildtype 
controls (WT). 
 
CD11c.DOG  B6.Cg-Tg(Itgax-DTR/OVA/EGFP)1Gjh/Crl.  
Mice of this strain express the model antigen ovalbumin 
fragment containing sequences encoding amino acids 
140-386 and the human DTR under control of the CD11c 
promotor. 
(Hochweller, Striegler et al. 2008) 
 
CD45.1 P14 CD45 is a pan leukocyte marker with two allelic variants. 
While C57BL/6J WT mice express CD45.2, CD45.1 mice 
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express CD45.1. In addition, these mice have a transgenic 
TCR that recognizes the LCMV glycoprotein gp33-43 
(gp33) epitope (KAVYNFATCGI) in the context of MHC I. 
 (Shen, Saga et al. 1985, Pircher, Burki et al. 1989) 
 
OT-I Mice of this strain have a transgenic TCR that recognizes 
the OVA257-264 peptide (SIINFEKL) in the context of 
MHC I. 
(Hogquist, Jameson et al. 1994) 
 
P14 Mice of this strain have a transgenic TCR that recognizes 
the LCMV glycoprotein gp33-43 (gp33) epitope 
(KAVYNFATCGI) in the context of MHC I. 
 (Pircher, Burki et al. 1989) 
 
tdTomato Mice of this strain express the fluorescent protein tdTomato 
under the ubiquitin promotor. 
 (Kastenmuller, Brandes et al. 2013) 
 
XCR1+/DTRVenus Mice of this strain express the human DTR and the 
fluorescent protein Venus under the control of the Xcr1 
promotor. Heterozygous mice still express XCR1 whereas 
homozygous mice are XCR1-deficient. 
(Yamazaki, Sugiyama et al. 2013) 
 
XCR1+/Venus Mice of this strain express the fluorescent protein Venus 
under the control of the Xcr1 promotor. Heterozygous 
animals still express XCR1 whereas homozygous animals 
are XCR1-deficient. 
(Yamazaki, Sugiyama et al. 2013) 
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2.1.2 Viruses and cells 
 
The original stocks of lymphocytic choriomeningitis virus strain clone 13 (LCMV 
Cl13) were kindly provided by the laboratories of Dietmar Zehn (Division of 
Animal Physiology and Immunology, School of Life Sciences Weihenstephan, 
Technical University of Munich, Germany) and Hans Christian Probst (Institute 
for Immunology, University Medical Center Mainz, Germany). 
The MC57G fibrosarcoma cell line, L929 murine fibroblast cell line and the VL-4 
(rat aLCMV-NP) hybridoma cell line were also provided by the laboratory of 
Hans Christian Probst and subsequently kept in culture. 
 
2.1.3 Equipment 
 
Table 2.1: Equipment 
Device Name and Company 
Autoclave Belimed, Cologne, Germany 
Balances CP224S-0CE and CP2201, Sartorius, 
Göttingen, Germany 
Bead mill homogenizer Bead Ruptor Elite; OMNI International, 
Kennesaw, GA, USA 
Cell sorter Influx, Becton-Dickinson, Franklin 
Lakes, NJ, USA 
Aria II, Becton-Dickinson, Franklin 
Lakes, NJ, USA 
Centrifuge Multifuge 3 S-R Heraeus, Hanau, 
Germany 
Sprout mini centrifuge, Biozym, 
Hessisch Oldendorf, Germany 
Mikro 200R centrifuge, Hettich, 
Tuttlingen, Germany 
Cryostat CM 3050S, Leica, Hamburg, Germany 
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Flow cytometer FACSCantoTM II, LSRFortessaTM, 
FACSCelestaTM, Becton-Dickinson, 
Franklin Lakes, NJ, USA 
Freezer -20°C Bosch, Munich, Germany 
Freezer -80°C Heraeus, Hanau, Germany 
Ice machine Icematic Scotsman®; Frimont 
Bettolinc, Pogliano, Italy 
Incubator HeraCell, Heraeus, Hanau, Germany 
Infrared lamp HP3616, Philips, Hamburg, Germany 
Lasers Tunable Chameleon laser, Coherent, 
Santa Clara, CA, USA 
MACS cell separator QuadroMACS, Miltenyi Biotec, 
Bergisch-Gladbach, Germany 
Microscopes Olympus CKX31, Olympus, 
Düsseldorf, Germany 
Primovert, Zeiss, Jena, Germany 
LSM 780, Zeiss, Jena, Germany 
LSM 710, Zeiss, Jena, Germany 
SP8, Leica, Wetzlar, Germany 
Mouse cages Tecniplast Smartflow, 
Hohenpeißenberg, Germany 
Neubauer chamber Assistent, Karl Hecht GmbH, 
Sondheim, Germany 
Pipette boy Integra Biosciences; Biebertal, 
Germany 
Pipets Research plus (10, 20, 200, 1000), 
Eppendorf, Hamburg, Germany 
Preparation instruments Bochem, Weilburg; Hammacher, 
Solingen; 
F.S.T., Heidelberg, Germany 
Refrigerator 4°C Bosch, Munich, Germany 
Sieves, steel Mechanical Workshop, University 
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Hospital Bonn, Germany 
Water bath TW8, Julabo, Seelbach, Germany 
Workbench (sterile) HeraSafe, Heraeus, Hanau, Germany 
Vortex Mixer neolab, Heidelberg, Germany 
 
2.1.4 Consumables and reagents 
 
Table 2.2: Consumables 
Consumables Name and Company 
Cell culture flask (T25, T75, T150) Greiner bio-one, 
Frickenhausen, Germany 
Cell strainer BD Bioscience, USA 
Cover slips controlled thickness 0.17 ± 0.01 mm, 
CE, Assistent, Karl Hecht GmbH, 
Sondheim, Germany 
Cryomolds Tissue-Tek®, Sakura, Alphen aan den 
Rijn, Netherlands 
Cryo tubes Cryopure 1.6ml, Sarstedt, Nümbrecht, 
Germany 
FACS tubes Sarstedt, Nümbrecht, Germany 
FALCON tubes 15 ml, Greiner bio-one, Solingen, 
Germany  
50 ml, Sarstedt, Nümbrecht, Germany 
Glass pipets Greiner, Nürtingen, Germany 
Injection needles 27G, 25G, 20G; BD Microlance, 
Becton, Dickinson and Company, 
Franklin Lakes, NJ, USA 
Microscopy slides Superfrost Plus, VWR, Darmstadt, 
Germany 
Microtome blades Feather, Osaka, Japan 
Nylon gauze Labomedic, Bonn, Germany 
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Pasteur pipettes 150 mm and 230 mm; Roth, Karlsruhe, 
Germany 
Petri dishes 10 cm; Greiner bio-one, Solingen, 
Germany 
pH value indicator stripes stripes pH fix 4.5-10.0; Macherey-
Nagel; Düren, Germany 
Pipet tips sterile pipette tips 0.2 ml/0.01 ml, 
VWR, Darmstadt, Germany  
Ultratip 1 ml, Greiner bio-one, 
Frickenhausen, Germany  
TipOne 0.2 ml, STARlab, Hamburg 
Pipette Tip 0.01 ml neutral, Sarstedt, 
Nümbrecht, Germany 
Reaction tubes microtubes (0.5 ml, 1.5 ml, 2 ml), 
Sarstedt, Nümbrecht, Germany 
Sterile filter AcroVac Filter Unit PES 0.2 μm Supor, 
Pall Life Sciences, Dreieich, Germany 
Syringes 2 ml/5 ml BD Discardit II, Becton-
Dickinson, Heidelberg, Germany 
Tissue culture plates TPP Tissue culture testplates (96, 24, 
6 wells), Trasadingen, Switzerland 
 
Table 2.3: Chemicals and reagents 
Chemicals and Reagents Name and Company 
Bovine serum albumin (BSA) Roth, Karlsruhe, Germany 
Brefeldin A Sigma Aldrich, Munich, Germany 
Cell Trace Violet (CTV) Life Technologies, Carlsbad, CA, 
USA 
Collagenase (type 3) Roche Diagnostics, Mannheim, 
Germany 
Worthington, Lakewood, NJ, USA 
 Materials & Methods 
43 
Dimethylsulfoxid (DMSO) Roth, Karlsruhe, Germany 
Diphtheria toxin (DTX) Calbiochem, San Diego, CA, USA 
Disodium phosphate (Na2HPO4) AppliChem, Darmstadt, Germany 
DNAse I recombinant, Grade I, Roche, 
Mannheim, Germany 
Embedding medium Tissue-Tek® O.C.T.TM Compound, 
Sakura, Alphen aan den Rijn, 
Netherlands 
Ethanol 70% (v/v) Otto Fischar, Saarbrücken, Germany 
Ethylene diamine tetraacetic acid 
(EDTA) 
0.5M pH8.0, Applichem, Damstadt, 
Germany 
Fcg block Privigen, CSL Behring, Marburg, 
Germany 
Fetal bovine serum (FBS/FCS) Good Filtrated Bovine Serum, PAN 
Biotech, Aidenbach, Germany 
Fluoromount-G ebioscience, San Diego, CA, USA 
Formaldehyde Roth, Karlsruhe, Germany 
Gelatine from cold waterfish skin 
(GCWFS)  
SigmaAldrich, Munich, Germany 
Hank’s balanced salt solution with 
indicator (HBSS) 
Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA 
Heparin sodium (25000 IU) Ratiopharm, Ulm, Germany 
HEPES Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA 
Hydrochloric acid (HCl) Roth, Karlsruhe, Germany 
Hydrophobic Barrier (PAP) Pen ImmEdgeTM Pen (H-4000), Vector 
Laboratories, Burlingame, CA, USA 
Isoflurane AbbVie, Wiesbaden, Germany 
L-Lysine Sigma Aldrich, Munich, Germany 
NaCl solution (0.9%) Braun, Melsungen, Germany 
Normal mouse serum (NMS) Life Technologies, Carlsbad, CA, 
USA 
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Optiprep  Sigma Aldrich, Munich, Germany 
Paraformaldehyde (PFA) AppliChem, Darmstadt, Germany 
Penicillin/Streptomycin/Glutamine Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA 
Phosphate-buffered saline (PBS) Biochrom AG, Berlin, Germany 
RPMI 1640 medium Invitrogen, Darmstadt, Germany 
Sodium dihydrogen 
phosphate (NaH2PO4) 
Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH) Roth, Karlsruhe, Germany 
Sucrose Sigma Aldrich, Munich, Germany 
Tris base AppliChem, Darmstadt, Germany 
Triton X-100 Promega, Madison, WI, USA 
Trypan Blue (0.4 %) Lonza, Cologne, Germany 
Trypsin-EDTA (0.05 %) Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA 
β-Mercaptoethanol (C2H6OS) Sigma Aldrich, St. Louis, MO, USA 
 
2.1.5 Antibodies 
 
Table 2.4: Antibodies used for in vivo blockade of interactions 
Antigen Clone Company 
CD4 GK1.5 BioXcell, West Lebanon, 
NH, USA 
CD70 FR70 BioXcell, West Lebanon, 
NH, USA 
IL-15 AIO.3 BioXcell, West Lebanon, 
NH, USA 
PD-L1 10F.9G2 BioXcell, West Lebanon, 
NH, USA 
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Table 2.5: Antibodies used for flow cytometry and immunofluorescence 
Application: flow cytometry (F), immunofluorescence (IF) 
Antigen Application, 
Clone 
Conjugate Company 
B220 IF, RA3-6B2 AF700 BioLegend 
CD3e F, 145-2C11 BUV 395 BD Biosciences 
CD4 F, RM4-5 BV786, PE-Cy7 BD Biosciences  
CD8a F, 53-6.7 
F, 53-6.7 
BV786 
PB, PE 
BioLegend 
BD Biosciences  
CD11b F, M1/70 BV711 BioLegend 
CD11c F, N418 PE-Cy7 eBioscience 
CD19 F, 1D3 
F, 6D5 
APC-Cy7 
BV605 
BD Biosciences 
BioLegend 
CD44 F, IM7 FITC, BV510 BD Biosciences  
CD45.1 F, A20 
F, A20 
PE-Cy7 
FITC 
eBioscience 
BD Biosciences 
CD62L F, MEL-14 PE-Cy7 eBioscience 
CD169 IF, 3D6.112 primary BioRad 
CD244 F, ebio244F4 FITC LifeTechnologies 
CXCR5 F, 2G8 biotinylated BD Biosciences 
CXCR6 F, SA051D1 PE BioLegend 
CX3CR1 F, SA01F11 BV786 BioLegend 
F4/80 F, BM8 
IF, BM8 
APC 
BV421 
eBioscience 
BioLegend 
GzmB F, GB11 PE Invitrogen 
Ki-67 F, B56 BV510 BD Biosciences 
MHCII F, M5/114.15.2 AF700 eBioscience 
PD-1 F, RMP1-30 
F, 29F.1A12 
APC 
PE 
eBioscience 
BioLegend 
Tcf7 F, C63D69 PB Cell signalling 
Tim-3 F, RMT3-23 PE-Cy7 BioLegend 
Va2 F, B20.1 PE-Cy7 BD Biosciences 
 Materials & Methods 
46 
XCR1 F, ZET PE BioLegend 
Secondary antibodies F, IF AF-conjugated Invitrogen 
MHC I Tetramer gp33 
H-2D(b) KAVYNFATC 
F PB, APC NIH Tetramer 
Core Facility 
 
2.1.6 Buffers, media and solutions 
 
Prior to use, all stock solutions and buffers were sterile filtered or autoclaved 
and kept under sterile conditions afterwards. 
 
Buffer, medium or solution Composition 
 
Erythrocyte lysis buffer   1.5 M NH4Cl 
(10x ACK)    100 mM KHCO3 
10 mM EDTA-Na2 
in distilled water (pH value 7.2) 
 
Blocking buffer   1 % (v/v) FCS 
1% (m/v) GCWFS 
0.3 % (v/v) Triton-X 100 
in 0.1 M Tris 
1 % NMS added directly before use 
 
Cell medium    8 % heat-inactivated FCS 
50 μM β-Mercaptoethanol 
4 mM L-Glutamin 
100 U/ml Penicillin 
100 μg/ml Streptomycin 
in RPMI 1640 medium 
 
Digestion medium   7 mg/ml type 3 collagenase 
     1 mg/ml DNAse I (grade 2) 
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in KDS-RPMI 2 % 
aliquots kept at -20 °C 
 
FACS buffer    2 % (v/v) FCS 
0.02 % (v/v) NaN3 
in 1x PBS 
 
Fixation buffer (PLP)  2.12 mg NaIO4 
3.75 ml P-buffer 
3.75 ml L-Lysine 
2.5 ml 4% PFA  
(pH value 7.4, adjusted with 10 M NaOH) 
preparation directly before use 
 
HEPES/NaCl   2.2 g NaCl (0.88 % w/v) 
     0.596 g HEPES (10mM) 
     1.25 g BSA (0.5 %) 
     2.5 ml 0.1 M EDTA (pH 8) 
     in 250 ml water 
 
KDS-RPMI 2%   2 % heat-inactivated FCS 
     50 μM β-Mercaptoethanol 
2 mM L-Glutamin 
100 U/ml Penicillin 
100 μg/ml Streptomycin 
     in KDS-RPMI medium 
 
L-Lysin solution   0.2 M L-Lysine 
in P-buffer 
 
Na2HPO4 solution   35.6 g Na2HPO4 (M = 177.99 g/mol) 
in 1 l ddH2O 
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NaH2PO4 solution   31.2 g NaH2PO4 (M = 156.01 g/mol) 
in 1 l ddH2O 
 
PBS     137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
in ddH2O 
 
P-buffer    40.5 % (v/v) 0.1 M Na2HPO4 
9.5 % (v/v) NaH2PO4 
in ddH2O (pH value 7.4) 
 
PFA solution    4 % (w/v) PFA in 1x PBS 
gradually heated (pH value 7.4) 
 
Sucrose solution   30 % (w/v) Sucrose in P-buffer 
 
T cell enrichment buffer  0.5 % (v/v) BSA 
2 mM EDTA 
in 1x PBS 
 
Tris buffer    1 M Tris base in distilled water 
(pH value 7.5, adjusted with 10 M HCl) 
 
Triton-X 100 buffer   0.5% Triton-X 100 in 1x PBS 
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2.1.7 Kits 
 
Table 2.6: Kits 
Name Company 
CD8a T cell isolation kit, mouse Miltenyi Biotec, Bergisch Gladbach, Germany 
Cytofix/Cytoperm BD Biosciences, Heidelberg, Germany 
CellTracer Violet Cell 
Proliferation Kit 
Invitrogen, Darmstadt, Germany 
Foxp3 / Transcription Factor 
Staining Buffer Set 
Invitrogen, Darmstadt, Germany 
LIVE/DEAD Fixable Near-IR 
Dead Cell Stain Kit 
Invitrogen, Darmstadt, Germany 
 
2.1.8 Software 
 
Table 2.7: Software 
Software Company 
BD FACS Diva 8.0.1 BD Biosciences, Heidelberg, Germany 
EndNote X9 Thompson Reuters, Frankfurt a. Main, 
Germany 
FlowJo V10.0.7 Tree star, Ashland, OR, USA 
GraphPad Prism6 GraphPad Software, La Jolla, CA, 
USA  
Imaris 8.2.1  Bitplane, Zurich, Switzerland 
LasX Life Science Leica, Wetzlar, Germany 
Microsoft Office 2018 Microsoft, Redmond, WA, USA 
RStudio RStudio Inc., Boston, MA, USA 
ZEN black and blue  Zeiss, Jena, Germany 
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2.2 Methods 
 
2.2.1 Virus and cell culture 
 
LCMV Clone 13 (Cl13) was produced in a L929 murine fibroblast cell line. Virus 
titer of freshly produced stocks as well as virus titer of spleens of infected mice 
were measured with a limiting dilution assay. For this assay, MC57G 
fibrosarcoma cells were used. 
 
2.2.1.1 Cell culture 
 
L929 murine fibroblasts and MC57G fibrosarcoma cells 
 
L929 murine fibroblasts and MC57G fibrosarcoma cells were kept at -80 °C in 
FCS with 10 % DMSO with one vial containing 1x106 cells. Cells were briefly 
thawed in a water bath at 37 °C and immediately put on ice afterwards. The cell 
medium for L929 cells contains DMEM with 10 % FCS and 1 % P/S. Cell 
medium for MC57G cells contains DMEM with 10 % FCS, 1 % sodium pyruvate 
and 1 % P/S. After thawing, cells were resuspended in 30 ml cold cell medium 
and centrifuged for 5 min at 1600 rpm. After washing with 30 ml cold medium, 
cells were collected in 15 ml warm medium and transferred to a 75 cm2 cell 
culture flask. Cells were cultured for two days at 37 °C, 5 % CO2. Every third 
day, cells were splitted by aspirating the medium, washing the cells with 10 ml 
warm PBS and adding 1 ml Trypsin/EDTA. To dissociate the cell layer, cells 
were incubated for 4 min at 37 °C. By gently hitting the flask and rinsing with 9 
ml warm cell medium, cells were detached from the flask. To split the cells 1:10, 
1.5 ml of the cell suspension was left in the flask and 13.5 ml of fresh cell 
medium were added. 
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VL-4 hybridoma cells 
 
For the culture of VL-4 hybridoma cells and production of anti-LCMV NP 
antibodies, cells were thawed as described above. The cell medium consists of 
IMDM with 10 % FCS, 1 % Glutamin, 1 % pyruvate and 1 % P/S. Cells were 
collected in a 50 ml tube, centrifuged and the pellet resuspended in 30 ml cell 
medium. Cells were transferred to a 75cm2 flask. After two to three days of 
culture at 37 °C and 5 % CO2, the supernatant containing anti-LCMV NP 
antibodies, was collected and stored in the fridge for the LCMV limiting dilution 
assay (Chapter 0). Cells were frozen at -80 °C in FCS containing 10 % DMSO 
at a cell concentration of 1x106 cells per vial. 
 
2.2.1.2 Generation of LCMV stocks 
 
For the generation of LCMV Cl13 stocks, L929 cells were seeded at 3x106 cells 
per 150cm2 flask in DMEM 5 % FCS. Cells were kept in the incubator at 37 °C, 
5 % CO2 overnight. The following day, the cell medium was aspirated and 3x104 
IU of LCMV Cl13 were added in a volume of 3 ml. For the infection of the cells, 
flasks were kept at room temperature (RT) for 30 min and gently rocked several 
times to prevent the cells from drying out. The supernatant was aspirated and 
15 ml of fresh cell medium were added. Cells were kept at 37 °C, 5 % CO2 for 
48 h. After this incubation, the virus containing medium was harvested in 1 ml 
aliquots and immediately stored at -80 °C. 15 ml of fresh cell medium was 
added and virus-containing medium harvested again after 72 h post infection. 
Virus titer of newly prepared stocks was measured with a limiting dilution assay 
(Chapter 0). 
 
2.2.1.3 LCMV limiting dilution assay 
 
For the titration of viral stocks and the measurement of viral load in the spleen, 
a limiting dilution assay was performed. For this, MC57G cells were prepared at 
a concentration of 4x106 cells/ml in DMEM with 10 % FCS, 1 % sodium 
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pyruvate and 1 % P/S. 50 μl of the cell suspension were added into each well of 
a 96 well flat bottom plate. Immediately after, serial virus dilutions from 2x10-2 to 
2x10-6 were added in a total volume of 50 μl per well and mixed gently with the 
cells. For each dilution, eight replicates were prepared. Medium that did not 
contain virus served as a negative control. The mixture of cells and virus was 
incubated at 37 °C, 5 % CO2 for 72 h. After 48 h, 70 μl medium were carefully 
exchanged without touching the cell layer. Before staining, cells were washed 
twice with PBS and permeabilized and fixed using the BD Cytofix/Cytoperm kit. 
Therefor, 50 μl of the fixation/permeabilization solution were added to each well 
and cells were incubated for 30 min on ice. After washing twice with BD 
Perm/Wash buffer (1x), 50 μl of PBS with 10 % FCS were added to each well to 
block non-specific binding sites for 60 min at RT. Cells were washed again with 
BD Perm/Wash buffer and 50 μl of 1:20 VL-4 hybridoma cell line supernatant 
were added to each well for 60 min at RT. The VL-4 hybridoma cell supernatant 
contains antibodies which are specific for the LCMV nucleoprotein (NP). 
Thereby, infected cells can be detected. For visualisation of infected cells, these 
were washed twice with BD Perm/Wash buffer and a secondary fluorescently-
labelled anti-rat AF488 antibody was added at a 1:500 concentration in a total 
volume of 50 μl to the cells. After incubation for 60 min at RT in the dark, cells 
were washed again with BD Perm/Wash buffer. Using an epifluorescent 
microscope wells that contain infected cells were counted and the virus titer was 
calculated. 
 
2.2.2 Treatment of mice 
 
Virus, cells and reagents were diluted in sterile PBS prior to experimental 
injections. For intraperitoneal (i.p.) injection, a total volume of 100-500 μl were 
injected into the peritoneal cavity of the mice. Intravenous (i.v.) injections were 
performed by injecting a total volume of 100-200 μl into the tail vein. To dilate 
the veins, mice were exposed to a heat lamp before an injection. 
 
 Materials & Methods 
53 
2.2.2.1 Infection with LCMV 
 
Highly purified LCMV Cl13 was used for this study. Prior to usage, it was diluted 
in sterile PBS. Mice were warmed up in a clean cage using a heat lamp and 
challenged with an infectious dose of 2x106 IU i.v. After injection, mice were 
transferred back into their original cages and monitored closely. To induce a 
chronic infection, mice were treated with anti-CD4 depleting antibody two days 
prior and on the day of infection (Chapter 0). 
 
2.2.2.2 Submandibular bleeding 
 
Submandibular bleeding was performed for the collection and analysis of blood 
lymphocytes. Therefor, mice were restrained with a neck scruff hold. A 23 G 
needle or 4/5mm lancet was used to gently puncture the anterior facial vein 
(submandibular). The required blood volume (less than 1 % of body weight) was 
collected by holding a tube underneath the puncture site. Mice were transferred 
back into their cage and monitored the following day. 
 
2.2.2.3 Treatment with blocking and depletion antibodies 
 
In vivo blocking (anti-CD70, anti-IL-15, anti-PD-L1) and depletion antibodies 
(anti-CD4) were diluted in sterile PBS prior to injection.  
For immunotherapy of chronically infected mice, PD-L1 signalling was blocked 
using anti-PD-L1 mAb (aPD-L1, 10F.9G2). 200 µg aPD-L1 were injected i.p. in 
a total volume of 200 µl every three days. A maximum of five consecutive 
treatments were given to the mice. 
To block the CD70-CD27 signalling pathway, 300 µg anti-CD70 mAb (aCD70, 
FR70) were i.p. injected in a total volume of 200 µl every three days. A 
maximum of three consecutive treatments were given to the mice. 
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To block the IL-15/IL-15Ra signalling pathway, 200 µg anti-IL-15 mAb (aIL-15, 
AIO.3) were i.p. injected in a total volume of 200 µl every three days. A 
maximum of three consecutive treatments were given to the mice. 
For the depletion of CD4+ cells two days before and on the day of LCMV Cl13 
infection, mice received i.p. injections of 300 µg anti-CD4 mAb (aCD4, GK1.5) 
in a total volume of 500 µl. CD4+ cells opsonized by this antibody are 
recognized and depleted by macrophages. 
 
2.2.2.4 Depletion of cells with DTX 
 
CD11c.DOG and XCR1+/DTRVenus transgenic mice and their WT littermates were 
used for cell depletion experiments. These two transgenic mouse strains 
express a diphtheria toxin receptor (DTR) under the CD11c or XCR1 promotor. 
By treating these mice with diphtheria toxin (DTX), CD11c+ cells and XCR1+ DC 
can be depleted, respectively. WT mice do not express the DTR and are 
thereby protected from the effects of DTX. Prior to injection, DTX was diluted in 
sterile PBS. Injections were performed i.p. with a total volume of 200 µl. 
For the depletion of CD11c+ cells, CD11c.DOG mice received 250 ng DTX i.p. 
every second day with five treatments in total unless indicated otherwise. 
To deplete XCR1+ DC, XCR1+/DTRVenus mice received one i.p. injection of 500 ng 
DTX followed by four i.p. injections of 250 ng DTX every second day unless 
indicated otherwise. 
 
2.2.3 Isolation of cells 
 
2.2.3.1 Isolation of lymphocytes from the blood 
 
To isolate lymphocytes from blood, 100 µl heparin (1:100) were transferred to a 
tube and blood was collected by submandibular bleeding (Chapter 0). 200 µl of 
the sample were transferred into one well of a 96 well round bottom plate and 
centrifuged for 2 min at 1600 rpm. The supernatant was discarded and 200 µl 
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ACK lysis buffer were added for 4 min at RT to lyse erythrocytes. After another 
centrifugation step, cells were washed with 100 µl PBS. Afterwards, cells were 
used for flow cytometry staining (Chapter 0). 
 
2.2.3.2 Isolation of lymphocytes from organs 
 
For the isolation of lymphocytes from organs, spleens and lymph nodes were 
harvested into PBS on ice. Immediately afterwards, organs were homogenized 
through a metal sieve strainer into a 50 ml falcon tube. The cell strainer was 
rinsed twice with 10 ml PBS. The cell suspension was centrifuged at 1600 rpm 
for 7 min at 4 °C. After centrifugation, the supernatant was discarded and the 
cell pellet resuspended in 2 ml ACK buffer and incubated for 4 min at RT to lyse 
erythrocytes. To stop lysis, PBS was added and the cell suspension was filtered 
using nylon gauze. After centrifugation (1600 rpm, 7 min, 4 °C), the cell pellet 
was resuspended in 5 ml cell medium. 
 
2.2.3.3 Enrichment of T cells  
 
To enrich CD4+ and CD8+ T cells from mouse spleen and lymph nodes, single 
cell suspensions were prepared as described (Chapter 0). The EasySepTM 
mouse CD8+ and CD4+ T cell isolation kits were used for negative selection of T 
cells. Cells were resuspended in T cell enrichment buffer (PBS containing 0.5 % 
BSA, 2 mM EDTA). Isolation was performed according to manufacturer’s 
instructions. To exclude pre-activated T cells, a biotinylated anti-CD44 antibody 
(1:10,000) was added to the antibody cocktail. 
 
2.2.3.4 Isolation and enrichment of dendritic dells 
 
For the isolation of dendritic cells (DC), spleens were isolated and collected in 6 
ml KDS-RPMI 2 % each. Spleens were transferred to a petri dish and vigorously 
dissociated with a scalpel. The emulsified tissue was transferred back into the 
tube with KDS-RPMI 2 % medium. 1 ml of digestion medium 
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(collagenase/DNase) was added and the suspension pipetted up and down for 
20 min with a pasteur pipette. 700 µl 0.1 M EDTA were added and pipetted for 5 
min. Afterwards, the cell suspension was filtered through a 40 µm mesh and the 
sample collected by centrifugation at 1500 rpm for 5 min at 4 °C.  
To isolate DC from this cell suspension, an OptiprepTM density gradient 
centrifugation was performed. All reagents were used at RT. A 17 % Optiprep 
solution was prepared with HBSS (5.66 ml Optiprep solution + 14.33 ml HBSS 
with indicator) and a 12 % Optiprep solution was prepared with HEPES/NaCl 
buffer (4.04 ml Optiprep + 15.96 ml HEPES/NaCl). The cell pellet was 
resuspended in 3 ml of the 17 % Optiprep solution and transferred to a 15 ml 
tube. This was carefully overlayed with 3 ml of the 12 % Optiprep solution and 
finally, another overlay was performed with 3 ml HBSS. By centrifugation with 
minimal acceleration and without brake for 15 min at 600 x g at 20 °C, cells can 
be separated by their density. DC can be found in the first layer of cells. The 
second layer contains lymphocytes and erythrocytes. 
To further isolate different DC populations, cells were stained with DC marker 
(Chapter 0) and sorted using a BD Influx cell sorter. Isolated CD11b+ and 
XCR1+ DC were used for analysis by flow cytometry (Chapter 0) and ex vivo 
antigen presentation assay (Chapter 0). 
 
2.2.3.5 Determination of cell numbers 
 
To determine cell numbers of cultured and isolated cells, cell suspensions were 
diluted 1:10 with trypan blue solution to stain dead cells. 10 µl of the cell 
suspension were added to a Neubauer counting chamber and unstained viable 
cells in four large squares were counted. Cell numbers were calculated using 
the following formula: cellsml = 	 (cell	count4 .x	10	(dilution	factor)x	10,000	(chamber	factor) 
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2.2.4 Cell labelling 
 
Cell Trace Violet labelling 
 
To monitor proliferation, cells were labelled using the Cell Trace Violet (CTV) 
Cell Proliferation kit. With every cell division the dye is diluted. Therefore, cells 
will show different CTV intensities depending on how often they divided which 
can be measured by flow cytometry. For the labelling, cells were diluted to 
1x106 cells/ml in PBS. 1 µl CTV was added to each ml of the cell suspension 
and mixed thoroughly. Cells were incubated in a water bath for 20 min at 37 °C 
and gently mixed in between. Thereafter, cell medium (five times the volume of 
the cell suspension) was added and cells were incubated in the water bath for 
another 5 min. Subsequently, cells were centrifuged at 1600 rpm for 7 min, 
resuspended in cell medium to a final concentration of 5x105 cells/ml and used 
for the ex vivo antigen presentation assay (Chapter 0). 
 
2.2.5 Adoptive T cell transfer 
 
Isolated, enriched and labelled cells (Chapter 0 and 0) were transferred into 
recipient mice at cell concentrations varying from 1x106 to 2.5x106 (stated for 
each experiment). For this, cells were resuspended in sterile PBS and injected 
into the tail vein of mice in a total volume of 200 µl. 
 
2.2.6 Ex vivo antigen presentation assay 
 
Antigen presenting cells (APC), are able to present antigen via major 
histocompatibility complexes (MHC) to T cells. T cells are able to recognize the 
presented antigen with their T cell receptor (TCR) and together with the help of 
other signals are able to proliferate. To investigate the potential of antigen 
presentation by DC (and other APC), DC were co-cultured with T cells from 
transgenic mice expressing a specific TCR. These T cells will only proliferate if 
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the APC presents antigen. Thereby, the proliferation of the T cells can be used 
as a readout for antigen presentation. 
In detail, APC (mainly DC and different subpopulations) were isolated and 
enriched from spleens (Chapter 0). 1:2 dilutions starting from 5x104 DC per well 
to 3.125x103 DC per well were prepared in a total volume of 100 µl/well in a V-
bottom 96 well plate. 
For the co-culture with transgenic cells, LCMV-specific CD8+ T cells from P14 
transgenic mice (spleen and lymph nodes) were isolated (Chapter 0) and 
enriched (Chapter 0). P14 cells were labelled with CTV (Chapter 0) and 5x104 
cells were added to each well containing different concentrations of DC. 
Samples were prepared in duplicates. As a negative control, CTV-labelled P14 
cells were co-cultured with naive DC. P14 cells with gp33 peptide (1:1000) as 
well as P14 cells co-cultured with gp33 peptide-pulsed DC (Chapter 0) served 
as positive controls. Cells were gently mixed and incubated for 65 h at 37 °C, 5 
% CO2. Afterwards, cells were stained with different surface markers to detect 
the proliferation and activation of P14 cells by flow cytometry (Chapter 0). 
 
2.2.7 Preparation of gp33 peptide-pulsed and OVA-loaded DC 
 
DC were isolated and enriched as described above (Chapter 0).  
To peptide-pulse DC with gp33 peptide, 5x105 cells were resuspended in 1 ml 
PBS and 1 μl gp33 peptide was added. Cells and peptide were mixed 
thoroughly and incubated in a water bath for 30 min at 37 °C. Thereafter, cells 
were washed three times with cell medium and used as a positive control for the 
ex vivo antigen presentation assay (Chapter 0). 
For the preparation of ovalbumin (OVA)-loaded DC, 10 mg OVA were dissolved 
in 1 ml HBSS and mixed thoroughly. DC isolated from one spleen were 
resuspended in 1 ml OVA solution and incubated in the water bath for 10 min at 
37 °C. After the incubation, cells were washed three times with cell medium. 
OVA-loaded DC were co-cultured with OT-I cells for the ex vivo antigen 
presentation assay (Chapter 0). 
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2.2.8 Flow Cytometry 
 
2.2.8.1 Cell surface staining 
 
Single cell suspensions were prepared as described above (Chapter 0). 2x106 
cells were transferred to one well of a 96 well plate. After centrifugation at 1600 
rpm for 2 min, the cell pellet was resuspended and stained in 50 μl of a staining 
solution consisting of FACS buffer, Fc block (1:66) and antibodies (Chapter 0) 
for 30 min at 4 °C in the dark. Subsequently, cells were washed twice, collected 
in 150 µl FACS buffer and transferred to FACS tubes containing 150 µl FACS 
buffer. Samples were acquired immediately using an LSRFortessaTM, 
FACSCantoTM II or FACSCelestaTM with FACSDivaTM software. FlowJoTM 
software was used for the analysis. 
 
2.2.8.2 Tetramer staining 
 
To stain LCMV-specific CD8+ T cells, a H-2Db gp33 tetramer was used. For 
optimal staining, the tetramer was added 1:100 to the surface stain cocktail and 
staining was performed for 1 h at RT in the dark. Cells were washed twice with 
FACS buffer and either directly used for acquisition or for subsequent 
intracellular staining (Chapter 0). 
 
2.2.8.3 Intracellular cytokine and transcription factor staining 
 
Intracellular staining was performed post staining of surface markers and 
tetramer staining as described above (Chapters 0 and 0). For intracellular 
cytokine and chemokine staining, cells were fixed and permeabilized using the 
BD Cytofix/Cytoperm kit which enables the permeabilization of the cell 
membrane. For this, cells were resuspended in 100 µl fixation/permeabilization 
solution and incubated for 20 min at 4 °C in the dark. For the staining of 
transcription factors, not only the cell membrane but also the nuclear membrane 
needs to be permeabilized. To achieve this, the Foxp3 staining kit was used. 
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Cells were resuspended and incubated in 100 µl fixation/permeabilization 
solution for 20 min at 4 °C in the dark. After fixation and permeabilization, cells 
were washed twice with BD Perm/Wash buffer and stained 
intracellularly/intranuclearly in 50 μl of staining solution consisting of 
Perm/Wash buffer and antibodies (Chapter 0) for 30 min at 4 °C in the dark. 
After washing twice, cells were kept in Perm/Wash buffer until acquisition at an 
LSRFortessaTM, FACSCantoTM II or FACSCelestaTM with FACSDivaTM software. 
FlowJoTM software was used for the analysis. 
 
2.2.9 Confocal microscopy 
 
2.2.9.1 Fixation and embedding of spleen samples 
 
To analyze the localization of certain immune cells in the spleen of chronically 
infected and differently treated animals, confocal microscopy was performed. 
For this, spleens were isolated and immediately fixed in 500 µl of freshly 
prepared PLP buffer for 12 h at 4 °C. Samples were washed twice with 500 µl 
P-buffer and afterwards dehydrated in 500 µl 30 % (v/v) sucrose at 4 °C 
overnight. Finally, samples were embedded in Tissue-Tek and stored at -80 °C 
for cryo cutting and subsequent immunofluorescence staining. 
 
2.2.9.2 Immunofluorescence staining 
 
Serial 30 µm sections were cut on a CM3050S cryostat and adhered to 
Superfrost Plus object slides. Frozen sections were rehydrated with 0.1 M Tris 
buffer for 10 min at RT, followed by permeabilization and blocking with blocking 
buffer containing 1 % normalized mouse serum (NMS) for at least 30 min at RT. 
Staining with fluorescently labelled antibodies was performed in blocking buffer 
(with 1 % NMS) at 4 °C overnight. Afterwards, sections were washed with 0.1 M 
Tris buffer and mounted with Fluoromount-G. Serial spleen sections were 
visually inspected using epifluorescent light microscopy. Several representative 
sections from different spleen areas were acquired using a Zeiss LSM 710 
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confocal microscope with ZEN acquisition control software or a Leica SP8 
confocal microscope with LasX software for detailed analysis. 
 
2.2.10 Single-cell RNA sequencing and analysis 
 
Single-cell RNA sequencing was performed with the help of the Helmholtz 
Institute for RNA-based Infection Research in Würzburg, the Core Unit Systems 
Medicine of the University of Würzburg and the Helmholtz Centre for Infection 
Research in Braunschweig. 
Splenic lymphocytes were isolated and stained as described in 2.2.3.2 and 
2.2.8.1. Cells were sorted using a FACS Aria II cell sorter. Sorted cells were 
counted and droplet-based sequencing performed using the 10x Genomics kit. 
The counted reads were analysed using the Seurat R toolkit (version 3.0). Cells 
with a percentage above 5 % of mitochondrial genes were excluded. Further 
on, cells with less than 200 or more than 2000 genes were removed as outliers. 
A log transformation was performed on the counts and variable genes were 
selected based on average expression and dispersion. For dimensional 
reduction, principal component analysis was performed using variable genes. 
Cluster were calculated with statistical relevant principle components and 
plotted with UMAP. Based on the expression of the known macrophage marker 
Lyz2, one cluster containing 86 cells was excluded from downstream analysis. 
Clustering, UMAP plotting and significant differentially expressed genes were 
recalculated after removal of this cluster. 
 
2.2.11 Statistical Analysis 
 
Raw data sets were analysed using Microsoft Excel and GraphPad Prism 6 
software. Prior to statistical analysis, Gaussian (normal) distribution of data sets 
was tested with D’Agostino-Pearson omnibus normality test and Shapiro-Wilk 
normality test. Student’s t-test (two-tailed) and Mann-Whitney test were used for 
the statistical analysis of differences between two groups with normal and non-
normal distribution, respectively. To determine statistical differences between 
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more than two groups, a repeated-measurements one-way ANOVA was used 
with the Dunnett post-test for parametric data sets and the Kruskal-Wallis test 
for non-parametric data sets. Stars indicate significances (* p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001). Error bars indicate the standard error of the mean (SEM). 
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3. Dendritic cells play an essential role for anti-PD-L1 therapy 
 
3.1 Introduction 
 
During chronic infections as seen with HIV, HCV and HBV or the establishment 
of cancer, the immune system is unable to clear the infection or eradicate 
malignant cells. Under such conditions, T cells typically adapt an exhausted 
phenotype that is associated with the permanent presence of antigen (Pauken 
and Wherry 2015). An important hallmark of CD8+ T cell exhaustion is the 
expression of inhibitory receptors, which are upregulated due to ongoing TCR 
signalling (Blackburn, Shin et al. 2009). This inhibitory signalling causes a 
strong impairment of proliferation and cytokine production (Wherry and Kurachi 
2015). A great improvement for cancer therapy and treatment of chronic 
infections has been the development of blocking antibodies that prevent 
inhibitory signalling by binding directly to the inhibitory receptor or its ligand. 
Thereby, exhausted T cells can be reinvigorated and regain proliferative 
capacity and effector functions (Barber, Wherry et al. 2006). The effect of so-
called immunotherapy was especially promising when treating with antibodies 
that block PD-1 (Programmed cell death protein 1) signalling. 
PD-1 is a surface protein belonging to the CD28/CTLA-4 family and plays an 
important role in the regulation of T cell responses (Sharpe, Wherry et al. 2007). 
Upon binding of its ligand PD-L1, PD-1 signalling leads to the inhibition of TCR 
and costimulatory receptor signalling (Sharpe, Wherry et al. 2007). During acute 
infections, this regulatory signalling inhibits effector functions, such as 
granzyme B production, and overall impedes fast viral clearance (Ahn, Araki et 
al. 2018). Early during chronic infections, PD-1 signalling plays an important 
role in preventing immunopathology (Ahn, Araki et al. 2018). However, it also 
leads to the exhaustion of T cells and therefore the persistence of pathogens as 
described above (Blackburn, Shin et al. 2009). In recent years, many studies 
have focused on exhaustion and immunotherapy in the context of chronic 
infections and cancer. It is well established that only a subset of exhausted 
CD8+ T cells can be reinvigorated (Barber, Wherry et al. 2006). These cells 
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display a memory-like phenotype and can be distinguished from terminally 
exhausted CD8+ T cells by the expression of the transcription factor TCF-1 
(Utzschneider, Charmoy et al. 2016). In addition, there are also studies which 
revealed that blocking more than one inhibitory receptor can have a cumulative 
effect (McLane, Abdel-Hakeem et al. 2019). Nevertheless, the beneficial effects 
of immunotherapy are still limited to certain cancer types and PD-1 blockade 
can provoke various and partly severe side effects (Sharma and Allison 2015, 
Wu, Gu et al. 2019). 
Therefore, we aimed to investigate immunotherapy during chronic viral infection 
in more detail. To this end, we made use of the chronic strain of lymphocytic 
choriomeningitis virus clone 13 (LCMV Cl13). This widely used and well 
characterized infection model played an instrumental role for the understanding 
of T cell exhaustion (Zehn and Wherry 2015). Furthermore, it has been the first 
model with which successful immunotherapy using anti-PD-1 antibodies has 
been described (Barber, Wherry et al. 2006). We first examined the kinetics of 
immunotherapy with blocking the ligand of PD-1, PD-L1, by varying the duration 
of treatment. In addition, the role of dendritic cells (DC) during immunotherapy 
was investigated. DC are important antigen-presenting cells (APC) and are 
highly efficient in activating naïve T cells (Villadangos and Schnorrer 2007, 
Segura and Villadangos 2009). The aim of this work was to clarify if DC are 
essential for successful immunotherapy. We further aimed at elucidation 
whether different DC subsets have non-redundant function and if antigen 
presentation is critical in this context. Deciphering these open questions could 
help to better understand the effects of PD-L1 blockade and therefore improve 
therapy outcome or may help top limit adverse effects.  
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3.2 Results 
 
3.2.1 Kinetics of PD-L1 blockade during chronic LCMV infection 
 
To examine the effects of PD-L1 blockade during chronic infection, the LCMV 
(Cl13) infection model was used. An i.v. infection with 2x106 IU of the chronic 
LCMV strain clone 13 (Cl13) in combination with the depletion of CD4+ cells, 
leads to a persistent infection (Blackburn, Shin et al. 2009). The immune system 
is not able to clear the infection and the antigen-specific CD8+ T cells become 
exhausted (Moskophidis, Lechner et al. 1993, Gallimore, Glithero et al. 1998, 
Zajac, Blattman et al. 1998). To reactivate the exhausted CD8+ T cells during 
chronic LCMV infection, mice were treated with 200 µg anti-PD-L1 antibody i.p. 
(Clone 10F.9G2). This monoclonal antibody binds to PD-L1 and thereby blocks 
the interaction with the inhibitory receptor PD-1 on exhausted CD8+ T cells. To 
date, the response kinetics of anti-PD-L1 therapy are not fully understood. To 
investigate the response in more detail, C57BL/6J (WT B6) mice received one, 
three or five injections of anti-PD-L1. Isolation and analysis of the spleen by flow 
cytometry was performed 24 h after anti-PD-L1 treatment. In addition, the 
therapeutic effect was directly tracked by paired analysis of blood samples 
taken before and after the treatment (Figure 3.1A). 
LCMV-specific CD8+ T cells from chronically infected mice display a distinct 
phenotype compared to memory LCMV-specific CD8+ T cells generated during 
an acute infection (Wherry, Ha et al. 2007). These exhausted CD8+ T cells can 
be easily distinguished by their expression of PD-1. Whereas memory LCMV-
specific cells are negative for PD-1, exhausted CD8+ T cells express PD-1 
among other co-inhibitory receptors (Blackburn, Shin et al. 2009). For this work, 
LCMV-specific CD8+ T cells were stained with PD-1 and gp33 tetramer. PD-1 is 
upregulated on CD8+ T cells after antigen encounter as it is directly connected 
to TCR signalling (Oestreich, Yoon et al. 2008). Thereby, antigen-experienced 
cells can be defined as PD-1+. The pool of PD-1+ CD8+ T cells encompasses 
cells specific for different epitopes of LCMV. The immunodominant LCMV 
epitope in C57BL/6 mice is the glycoprotein 33-41 (gp33) (Murali-Krishna, 
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Altman et al. 1998). Analysis of these cells was performed using a gp33 
peptide-MHC tetramer. The effect of PD-L1 blockade was investigated by 
comparing the frequencies of LCMV-specific CD8+ T cells (PD-1+ and gp33+PD-
1+) in the blood prior to and after the treatment. In control mice, which received 
PBS as well as in mice treated once with anti-PD-L1, the frequency of the cells 
did not change (Figure 3.1B). By contrast, mice that received three injections of 
anti-PD-L1 harbored significantly more antigen-experienced (PD-1+) and gp33 
tetramer+ cells after the treatment. A similar strong expansion of LCMV-specific 
CD8+ T cells was observed in mice that received five anti-PD-L1 injections 
(Figure 3.1B).  
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Figure 3.1: Mouse model of chronic LCMV infection and PD-L1 blockade. 
(A) Adult male mice (8-12 weeks old) received 300 µg anti-CD4 (GK1.5) i.p. on 
d-2 and d0 of infection to deplete CD4+ cells. Mice were i.v. infected with 2x106 
IU LCMV Cl13 on d0. Blood was taken prior to the start of anti-PD-L1 treatment 
(d44). On d45, mice received 200 µg anti-PD-L1 blocking antibody (10F.9G2) 
i.p. once, three or five times every three days. 24 h post anti-PD-L1 
administration, blood and spleen were analysed. (B) Paired frequencies of 
antigen-experienced (PD-1+) and gp33 tetramer+ LCMV-specific CD8+ T cells 
from the blood before and after anti-PD-L1 treatment. Data are representative of 
three independent experiments (n = 5 mice/group). Comparison between 
groups was calculated using a 2-way ANOVA * p ≤ 0.05; ** p < 0.01; *** p < 
0.001. 
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For the analysis of LCMV-specific CD8+ T cells in the spleen of chronically 
infected mice that received PD-L1 blockade, lymphocytes were isolated and 
stained with PD-1 and gp33 tetramer. Representative flow cytometry plots show 
the frequencies of PD-1+ and gp33+ PD-1+ CD8+ T cells (Figure 3.2A). 
Quantitative analysis of the data displayed no change in frequency and 
absolute number of the cells after one injection of anti-PD-L1 (Figure 3.2B). 
However, after three treatments with anti-PD-L1, a two- to three-fold increase of 
PD-1+ and gp33+ in frequency and a five- to ten-fold increase in absolute 
numbers was found. Notably, prolonged treatment did not further augment the 
expansion of LCMV-specific CD8+ T cells. Rather, after five treatments with 
anti-PD-L1 the frequencies and absolute numbers of LCMV-specific cells were 
slightly lower than after three treatments (Figure 3.2B). These data reveal that 
the expansion of exhausted CD8+ T cells during immunotherapy peaks with 
three treatments. Further injections sustained CD8+ T cell activation, yet did not 
further increase the number of antigen-specific CD8+ T cells. 
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Figure 3.2: Splenic LCMV-specific CD8+ T cells proliferate upon PD-L1 
blockade. Chronically infected mice were treated one, three or five times with 
200 µg anti-PD-L1. 24 h post treatment, splenic CD8+ T cells were isolated and 
analysed by flow cytometry. (A) Representative flow cytometry plots of antigen-
experienced (PD-1+) and gp33+ LCMV-specific CD8+ T cells after anti-PD-L1 
treatment. (B) Frequency and absolute number of antigen-experienced (PD-1+) 
and gp33+ LCMV-specific CD8+ T cells after anti-PD-L1 treatment. Data are 
representative of three independent experiments (n = 5 mice/group). Error bars 
indicate the mean ± SEM. For statistical analysis a one-way ANOVA was used. 
* p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
 Results 
72 
To further investigate the proliferation of exhausted cells after anti-PD-L1 
treatment, splenic gp33+ PD-1+ CD8+ T cells were stained for Ki67. Ki67 is a 
protein which is not present during cellular quiescence but is expressed during 
all phases of cell division (Scholzen and Gerdes 2000). Therefore, the presence 
of Ki67 within cells correlates with a state of active cell division. As the previous 
data revealed an increase of LCMV-specific CD8+ T cells, we speculated that 
these cells would also express Ki67 after treatment with anti-PD-L1. 
Representative histograms show the frequency and intensity of Ki67 expression 
(Figure 3.3A). Indeed, quantitative analysis revealed that the pattern of 
expansion of LCMV-specific cells is reflected by Ki67 expression. 24 h after one 
anti-PD-L1 injection, no change in frequency and absolute number of Ki67+ 
gp33+ cells occurred (Figure 3.3B). In comparison to PBS treatment or after one 
injection of anti-PD-L1, after three treatments the frequency of Ki67-expressing 
cells doubled and the absolute number increased up to 10-fold. As described 
above, fewer cells expanded after five compared to three anti-PD-L1 
treatments. This was also reflected in the frequency and absolute number of 
Ki67+ gp33+ cells. Compared to untreated mice, mice which received five anti-
PD-L1 injections did not harbor significantly more Ki67+ cells, again, indicating 
no advance of five over three anti-PD-L1 treatments (Figure 3.3B). 
Additionally, the splenic viral titer was measured and is depicted as infectious 
units per gram spleen. The viral load was significantly decreased in mice that 
received three anti-PD-L1 treatments compared to PBS-treated animals 
(Figure 3.3C).  
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Figure 3.3: PD-L1 blockade-induced proliferation peaks after three 
treatments. Chronically infected mice were treated one, three or five times with 
200 µg anti-PD-L1. 24 h post treatment, splenic CD8+ T cells were isolated and 
analysed by flow cytometry. (A) Representative histograms of gp33+ LCMV-
specific CD8+ T cells after anti-PD-L1 treatment showing frequency of Ki67+ 
proliferating cells. (B) Frequency and absolute number of Ki67+ gp33+ CD8+ 
T cells after anti-PD-L1 treatment. (C) Viral load depicted as infectious units (IU) 
per g spleen of PBS-treated and 3x anti-PD-L1-treated animals. Data are 
representative of three independent experiments (n = 5 mice/group). Error bars 
indicate the mean ± SEM. For statistical analysis a one-way ANOVA was used. 
* p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
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As an additional readout for the reactivation of exhausted CD8+ T cells during 
anti-PD-L1 treatment, the expression of PD-1 can be used, as it directly 
correlates with T cell stimulation (Agata, Kawasaki et al. 1996). Upon TCR 
engagement, PD-1 is rapidly expressed with NFATc1 (nuclear factor of 
activated T cells c1) being one of the driving transcription factors (Oestreich, 
Yoon et al. 2008). During chronic infections, persistent antigen presentation 
supports the high expression of PD-1. Given that anti-PD-L1 treatment 
upregulates TCR signalling, a further increase in PD-1 expression is anticipated 
under this condition. To test this notion, the median fluorescence intensity (MFI) 
of LCMV-specific cells (PD-1+ and gp33+) was measured after anti-PD-L1 
treatment. As shown above, 24 h after a single anti-PD-L1 injection, exhausted 
CD8+ T cells did not change in number or Ki67 expression. However, a 
significant increase of PD-1 expression was detected on antigen-experienced 
CD8+ T cells (PD-1+) (Figure 3.4A). This was also seen when specifically 
analysing gp33+ CD8+ T cells (Figure 3.4B). The increased PD-1 expression 
reveals that cells are already activated by a single anti-PD-L1 injection. PD-1 
expression was further increased after three anti-PD-L1 treatments. However, it 
was significantly decreased after five anti-PD-L1 injections. Here, the PD-1 
expression level of gp33+ cells decreased to similar levels as in untreated 
animals (Figure 3.4A and B). These data are in line with our previous 
interpretation that anti-PD-L1 therapy reaches a plateau after the third injection. 
The T cell response peaks after three injections and surprisingly decreases with 
ongoing treatment. The reason for these findings remains to be elucidated. 
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Figure 3.4: PD-1 expression peaks after three anti-PD-L1 treatments. 
Chronically infected mice were treated one, three or five times with 200 µg 
anti-PD-L1. 24 h post treatment, splenic CD8+ T cells were isolated and 
analysed by flow cytometry. (A) Left: representative histograms show PD-1 
expression of PD-1+ cells after anti-PD-L1 treatment, right: quantitative analysis 
of median fluorescence intensity (MFI) of PD-1+ cells. (B) Left: representative 
histograms show PD-1 expression of gp33+ cells after anti-PD-L1 treatment, 
right: quantitative analysis of PD-1 MFI of gp33+ cells. Data are representative 
of three independent experiments (n = 5 mice/group). Error bars indicate the 
mean ± SEM. For statistical analysis a one-way ANOVA was used. * p ≤ 0.05; 
** p < 0.01; *** p < 0.001.  
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Exhausted CD8+ T cells are described to consist of two main subsets of cells, 
which differ on a transcriptional, metabolic and functional level (Im, Hashimoto 
et al. 2016, Utzschneider, Charmoy et al. 2016, Man, Gabriel et al. 2017). Most 
importantly, only one of the subsets responds to immunotherapy with 
proliferation and consecutive reinvigoration. To differentiate the two subsets by 
flow cytometry as well as for quantitative analysis, Tim3 and TCF-1 were used 
as markers (Figure 3.5A). The Tim3+ subset represents cells, which express 
higher levels of co-inhibitory receptors and are therefore considered to be more 
exhausted and functionally impaired. These cells display a terminally 
differentiated phenotype (Paley, Kroy et al. 2012). In comparison, the TCF-1+ 
subset expresses lower levels of PD-1 and other co-inhibitory receptors and 
harbors memory-like features (Im, Hashimoto et al. 2016). This smaller subset 
of exhausted CD8+ T cells is able to respond to immunotherapy when either PD-
1 or PD-L1 is blocked (Im, Hashimoto et al. 2016, Leong, Chen et al. 2016, 
Utzschneider, Charmoy et al. 2016, Siddiqui, Schaeuble et al. 2019). Memory-
like TCF-1+ cells undergo self-renewal but also give rise to Tim3+ cells with 
heightened effector capacity.  
After one or three treatments with anti-PD-L1, no change in frequency of 
TCF-1+ or Tim3+ gp33+ cells occurred (Figure 3.5B and C, left). However, after 
five injections, a strong shift towards the Tim3+ subset was observed. The 
TCF-1+ cell pool decreased to more than half of its frequency when compared 
to untreated samples whereas the Tim3+ cell pool increased and constituted 
95 % of the LCMV-specific CD8+ T cell population. Importantly, as shown in 
figure 3.2B, the absolute number of gp33+ PD-1+ CD8+ T cells drastically 
increased especially after three treatments. At this point, both subsets, TCF-1+ 
and Tim3+, equally increased in absolute cell numbers (Figure 3.5B and C, 
right). However, after five treatments, the TCF-1+ cell pool was reduced to the 
level of untreated mice, whereas the Tim3+ cells were as many as after three 
injections.  
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Figure 3.5: Distinct subsets of LCMV-specific CD8+ T cells respond 
differentially to PD-L1 blockade. Chronically infected mice were treated one, 
three or five times with 200 µg anti-PD-L1. 24 h post treatment, splenic 
CD8+ T cells were isolated and analysed by flow cytometry. (A) Representative 
flow cytometry plots showing the two subpopulations (TCF-1+ and Tim3+) of 
LCMV-specific CD8+ T cells with and without PD-L1 blockade. (B) Frequency 
and absolute number of TCF-1+ gp33+ CD8+ T cells after anti-PD-L1 treatment. 
(C) Frequency and absolute number of Tim3+ gp33+ CD8+ T cells. Data are 
representative of three independent experiments (n = 5 mice/group). Error bars 
indicate the mean ± SEM. For statistical analysis a one-way ANOVA was used. 
* p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
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In summary, 24 h after a single treatment with 200 µg anti-PD-L1 antibody, 
LCMV-specific CD8+ T cells did not expand in blood and spleen and did not 
differ in phenotype. However, the increased expression of PD-1 that correlates 
with TCR engagement indicates that exhausted CD8 T cells respond to the first 
injection, but have not yet entered cell cycle. In contrast to that, after three 
treatments with anti-PD-L1, a significantly higher number of LCMV-specific cells 
was detected in blood and spleen of chronically infected mice. Additionally, 
mice treated three times harbored an increased number of proliferating 
Ki67+ cells. Interestingly, this increase in cell number was detected for both 
subsets, TCF-1+ and Tim3+ exhausted T cells. However unexpectedly, after five 
anti-PD-L1 injections, the expansion of cells did not further increase. Compared 
to after three injections, there were less PD-1+ and gp33+ cells and fewer of 
them were proliferating (Ki67+). The expression of PD-1 was drastically 
decreased after five treatments. Importantly, after five treatments, a strong shift 
towards the terminally differentiated Tim3+ phenotype occurred. The memory-
like TCF-1+ cells were significantly reduced. The kinetic analysis of anti-PD-L1 
therapy unveiled a limit of cell proliferation, which is reached between three and 
five treatments. In addition to that, the number of TCF-1+ cells first increases 
during immunotherapy but is reduced with ongoing treatment. It is important to 
clarify which factors enable proliferation and which possibly prevent further 
expansion as well as influence the differentiation of the cells during PD-L1 
blockade. As the PD-1 expression level of LCMV-specific CD8+ T cells after five 
anti-PD-L1 treatments falls back to levels detected before treatment, it is very 
likely that TCR engagement and signalling is decreased as well. In principle, 
these results can be explained by both T cell-intrinsic factors as well as 
potential extrinsic factors like changes in antigen presentation, activation of 
suppressive lymphoid or myeloid cell populations, immunomodulatory cytokines 
or changes in localization that alter preferred cellular interaction partners. To 
approach these various possibilities, we first aimed to identify the critical cellular 
players that activate exhausted CD8+ T cells during checkpoint immunotherapy. 
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3.2.2 CD11c+ cells are critical for successful immunotherapy 
 
In 2017, Kamphorst et al. and Hui et al. revealed an important prerequisite for 
proliferation of exhausted CD8+ T cells upon immunotherapy: co-stimulatory 
signalling via the CD28 receptor (Hui, Cheung et al. 2017, Kamphorst, Wieland 
et al. 2017). The ligands for CD28, CD80 and CD86, are primarily expressed by 
antigen-presenting cells (APC) (Lenschow, Walunas et al. 1996). During 
infections the priming and expansion of antigen-specific T cells is highly 
dependent on the presentation of antigen by these cells (Parish and Kaech 
2009). The most professional antigen-presenting cells are dendritic cells (DC) 
(Chopin, Allan et al. 2012). Equipped with various pathogen-sensing receptors 
and superior in up-take, processing and presentation of antigen via MHCI and 
MHCII, DC are most efficient in stimulating naïve T cells. Furthermore, by the 
expression of co-stimulatory molecules, such as CD80 and CD86, DC deliver 
additional signals to induce an optimal T cell response (Larsen, Ritchie et al. 
1992, Inaba, Witmer-Pack et al. 1994). Therefore, we hypothesized that DC 
also play an important role during immunotherapy. Whereas PD-L1 blockade 
prevents inhibitory signalling by PD-1, DC can further stimulate the T cells with 
the presentation of antigen and the delivery of co-stimulatory signals.  
To investigate this hypothesis, we made use of the CD11c.DOG mouse line. 
Unlike CD11c DTR (Jung, Unutmaz et al. 2002) or zDC DTR mice (Meredith, 
Liu et al. 2012), the CD11c.DOG line does not require to perform bone marrow 
chimera for continued depletion without severe side-effects. DC express high 
levels of the transmembrane protein CD11c, also known as Integrin alpha X 
(Belz and Nutt 2012). This mouse line expresses a diphtheria toxin receptor 
(DTR) under the CD11c promotor. Therefore, treatment of these mice with 
diphtheria toxin (DTX), leads to the depletion of CD11c+ cells (Hochweller, 
Striegler et al. 2008). WT mice do not express the DTR and are thereby 
protected from the effects of DTX.  
CD11c.DOG mice were infected with 2x106 IU LCMV Cl13 in combination with 
CD4+ cell depletion. During the chronic infection phase, mice were treated with 
250 ng DTX (five treatments every two day) and 200 µg anti-PD-L1 (four 
 Results 
80 
treatments every three days). To investigate how the absence of CD11c+ cells 
impacts on the response to anti-PD-L1 therapy, a second group that only 
received anti-PD-L1 and no DTX served as a control. 24 h after the last anti-PD-
L1 injection, LCMV-specific CD8+ T cells from blood and spleen were analysed 
by flow cytometry. To directly track the effect in each animal, blood was taken 
before and after the treatment (Figure 3.6A). Representative flow cytometry 
plots show the successful depletion of CD11chi MHCIIhi DC in CD11c.DOG mice 
when DTX was administered (Figure 3.6B).  
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Figure 3.6: Mouse model of CD11c+ cell depletion and PD-L1 blockade 
during chronic LCMV infection. (A) Adult male CD11c.DOG mice received 
300 µg anti-CD4 i.p. on d-2 and d0 of infection. Mice were i.v. infected with 
2x106 IU LCMV Cl13 on d0. Blood was taken prior to treatment (d44). From d45 
onwards, mice received 200 µg anti-PD-L1 blocking antibody i.p., four times 
every three days. To deplete CD11c+ cells, mice received 250 ng DTX i.p. from 
d45 onwards five times every second day. 24 h after the last anti-PD-L1 
injection, blood and spleen were isolated for flow cytometry analysis. (B) 
Representative flow cytometry plots showing the depletion of CD11c+ MHCII+ 
DC in CD11c.DOG mice after treatment with DTX.  
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The comparison of antigen-experienced (PD-1+) and gp33 tetramer+ LCMV-
specific T cells in the blood of mice before and after the treatment, revealed that 
cells did not expand by anti-PD-L1 treatment in mice which were depleted of 
CD11c+ cells (Figure 3.7A). A similar result was obtained when analyzing the 
spleens of these mice. The frequency and absolute number of PD-1+ as well as 
gp33+ CD8+ T cells were significantly decreased in mice that did not harbor 
CD11c+ cells as compared to CD11c+ cell proficient animals (Figure 3.7B). In 
addition, the fraction of CD8+ T cells expressing the proliferation marker Ki67 
was also slightly decreased in DTX-treated mice (Figure 3.7C). 
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Figure 3.7: PD-L1 blockade-induced expansion of CD8+ T cells is 
dependent on CD11c+ cells. (A) Paired frequencies of antigen-experienced 
LCMV-specific (PD-1+) and gp33+ CD8+ T cells in the blood prior to and post 
anti-PD-L1 treatment in the presence and absence of CD11c+ cells (B) 
Frequency and absolute number of splenic PD-1+ and gp33 + CD8+ T cells, as 
well as proliferating Ki67+ gp33+ cells (C), post anti-PD-L1 treatment with and 
without CD11c+ cell depletion. Data were pooled from two independent 
experiments (n = 4 mice/group). Error bars indicate the mean ± SEM. 
Comparison between groups was calculated using the unpaired Student‘s t-test. 
* p ≤ 0.05; ** p < 0.01; *** p < 0.001. 
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Activated CD8+ T cells express CD11c to a certain extent and are therefore 
possibly targeted by DTX treatment (Vinay and Kwon 2010). To check if the 
decreased number of LCMV-specific CD8+ T cells is caused by the depletion of 
such, we adoptively transferred CD8+ T cells from transgenic P14 mice. These 
mice harbor CD8+ T cells, which express a transgenic TCR specific for gp33. 
The cells do not express a DTR and are therefore not depleted upon DTX 
treatment. On the day of infection, CD11c.DOG mice received 2x103 P14 cells 
and were treated as described previously (Figure 3.8A). The response of P14 
cells to PD-L1 blockade in the presence or absence of CD11c+ cells was 
assessed by flow cytometry. Clearly, the representative flow cytometry plots 
(Figure 3.8B) as well as the quantitative analysis (Figure 3.8C) show that P14 
cells expanded to a significantly lower extend in DTX-treated mice. This finding 
fully reflects the effect seen with endogenous CD8+ T cells and confirms that the 
expansion of antigen-specific CD8+ T cells during PD-L1 blockade is dependent 
on CD11c+ cells. 
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Figure 3.8: Impaired expansion of LCMV-specific CD8+ T cells is not 
caused by the depletion of CD11c+ CD8+ T cells. (A) CD11c.DOG mice 
received 2x103 transgenic LCMV-specific P14 cells and were infected with 
LCMV Cl13. During the chronic infection phase mice were treated with anti-PD-
L1 in combination with DTX to deplete CD11c+ cells. (B) Representative flow 
cytometry plots of P14 cells from spleens of mice with and without CD11c+ cells. 
(C) Frequency and absolute number of splenic P14 cells after anti-PD-L1 in 
combination with DTX treatment. Error bars indicate the mean ± SEM. 
Comparison between groups was calculated using the unpaired Student‘s t-test. 
* p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
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As described earlier, the two subsets of memory-like (TCF-1+) and terminally 
exhausted (Tim3+) CD8+ T cells, respond differently to PD-L1 blockade. We 
investigated if the presence or absence of CD11c+ cells has an impact on the 
differentiation of exhausted CD8+ T cells. Here, we found similar frequencies of 
TCF-1+ and Tim3+ cells in both groups (Figure 3.9A). As the absolute number of 
LCMV-specific cells was lower in mice that received DTX, the absolute cell 
numbers of TCF-1+ as well as Tim3+ cells were decreased in these mice to the 
same level as in PBS-treated controls.  
Surprisingly, cells from DTX-treated mice were still able to produce GzmB as an 
important effector molecule (Figure 3.9B). However, measuring the viral titer in 
spleens of anti-PD-L1-treated mice in combination with DTX revealed that these 
mice carried a higher viral load (Figure 3.9C). This points to a situation where 
the cells were not sufficiently reinvigorated to exert their effector functions and 
eliminate infected cells.  
Up to this point, CD11c+ cells were depleted only in combination with 
immunotherapy. The question arises if DC are also critical to control the viral 
load during chronic infection in the absence of immunotherapy. To investigate 
this, CD11c.DOG mice were infected with LCMV Cl13 and CD11c+ cells were 
depleted during the chronic infection phase with DTX (Figure 3.10A). Here, the 
frequency and number of antigen-specific cells (PD-1+ and gp33+) were only 
slightly decreased in DTX-treated mice (Figure 3.10B). In line with the previous 
data, CD11c+ cell depletion itself did not affect the differentiation of LCMV-
specific CD8+ T cells regarding their expression of TCF-1 and Tim3 
(Figure 3.10C). Additionally, splenic viral titers were not significantly changed in 
mice that did not harbor CD11c+ cells. Pointing towards a critical role of 
CD11c+ DC in the context of anti-PD-L1 treatment. 
Collectively, these experiments show the importance of DC for the proliferation 
of exhausted CD8+ T cells upon immunotherapy. The mere blockade of the 
inhibitory PD-1 pathway is not sufficient to reinvigorate these cells. Professional 
antigen presentation as well as the delivery of co-stimulatory signals by DC 
seem to play an essential and maybe previously underestimated role.
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Figure 3.9: Viral load but not differentiation and GzmB production are 
affected by CD11c+ cell depletion during PD-L1 blockade. (A) Frequency 
and absolute number of TCF-1+ and Tim3+ gp33+ CD8+ T cells after anti-PD-L1 
treatment with and without CD11c+ cell depletion. (B) Frequency and absolute 
number of GzmB+ gp33+ cells. (C) Viral load depicted as infectious units (IU) 
per g spleen of anti-PD-L1-treated animals with and without CD11c+ cell 
depletion. Data are pooled from two independent experiments (n = 4 
mice/group). Error bars indicate the mean ± SEM. Comparison between groups 
was calculated using the unpaired Student‘s t-test. * p ≤ 0.05; ** p <0.01; 
*** p < 0.001.
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Figure 3.10: Depletion of CD11c+ cells increases viral titer without 
affecting the proliferation and differentiation of LCMV-specific CD8+ T 
cells. (A) CD11c.DOG mice received 300 µg anti-CD4 i.p. on d-2 and d0 and 
were i.v. infected with 2x106 IU LCMV Cl13 on d0. From d45 onwards, mice 
received 250 ng DTX i.p. every second day. On d54, spleens were isolated and 
analysed. (B) Frequency and absolute number of PD-1+ and gp33+ CD8+ T 
cells. (C) Frequency of TCF-1+ and Tim3+ gp33+ CD8+ T cells with and without 
depletion of CD11c+ cells. (D) Splenic viral load of mice harboring CD11c+ cells 
or not. Error bars indicate the mean ± SEM. Comparison between groups was 
calculated using the unpaired Student‘s t-test. * p ≤ 0.05; ** p < 0.01; 
*** p < 0.001.  
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3.2.3 Decreasing viral antigen presentation by DC during immunotherapy 
 
As shown in the previous chapter, DC play an important role for the 
reinvigoration of exhausted CD8+ T cells during immunotherapy. Subsequent 
questions are how DC support the reactivation of these cells and why PD-L1 
blockade reaches a limit between three and five treatments. For the full 
activation of naive CD8+ T cells, DC play a supreme role as they deliver all of 
the three required signals – antigen presentation, co-stimulatory signals and 
cytokines (van Stipdonk, Lemmens et al. 2001, Chopin, Allan et al. 2012). We 
hypothesized, that in the context of CD11c+ depletion and PD-L1 blockade, 
exhausted CD8+ T cells are not able to proliferate as antigen presentation 
together with co-stimulation is missing. Without proper TCR stimulation and co-
stimulatory signals, the expansion of exhausted T cells cannot take place even 
though the inhibitory effects of PD-1 signalling are blocked. 
To investigate the level of antigen presentation by APC from chronically infected 
mice, we made use of an ex vivo antigen presentation assay. For this, APC 
from spleens of chronically infected mice were isolated by digestion and density 
gradient centrifugation (Figure 3.11A). To investigate which APC subsets 
present antigen, we co-cultured them with transgenic P14 cells that are specific 
for LCMV glycoprotein. Prior to the co-culture with APC, P14 cells were labelled 
with Cell Trace Violet (CTV). This dye enables the analysis of proliferation by 
flow cytometry with dye dilution. Each new generation of divided cells is marked 
by a 50 % decreased dye intensity. APC and P14 cells were co-cultured for 
65 h at 37 °C with 5 % CO2 (Figure 3.11B). During this time, P14 cells divide if 
antigen is presented, TCR is activated and co-stimulatory signals are 
transmitted. As a positive control, isolated splenic APC from d3 post infection 
were used. Flow cytometry analysis shows that antigen presentation by APC 
from chronically infected mice was significantly lower compared to antigen 
presentation by APC from d3 post infection (Figure 3.11C). 
To further elucidate which APC present antigen during the chronic infection 
phase, cells were sorted by FACS into B cells, DC (XCR1+ DC (cDC1) and 
CD11b+ DC (cDC2)) and remaining cells, which are MHCIImid-low and among 
 Results 
91 
others contain macrophages. Again, an ex vivo antigen presentation assay with 
CTV-labelled P14 cells was performed. The assay clearly revealed that during 
chronic infection, DC were the dominant antigen-presenting cells, whereas B 
cells and macrophages were not able to stimulate P14 cells ex vivo. Notably, 
co-culture with cDC2 (CD11b+ DC) lead to a stronger proliferation of P14 cells 
compared to cDC1 (XCR1+ DC) (Figure 3.11D). 
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Figure 3.11: DC present antigen during chronic infection phase. (A) Adult 
male WT B6 mice received 300 µg anti-CD4 i.p. on d-2 and d0 of infection and 
were i.v. infected with 2x106 IU LCMV Cl13 on d0. Spleens were isolated and 
APC enriched by digestion and density gradient centrifugation. (B) In an ex vivo 
co-culture assay 5x104 APC were co-cultured with 5x104 CTV-labelled P14 cells 
for 65 h at 37 °C, 5 % CO2. Proliferation of P14 cells was determined by flow 
cytometry. (C) Representative flow cytometry plots showing P14 cell 
proliferation after co-culture with APC isolated at d3 and d30 post infection. (D) 
Representative flow cytometry plots showing P14 cell proliferation after co-
culture with sorted B cells, CD11b+ DC, XCR1+ DC and non-B/DC cells (mainly 
macrophages) from chronically infected mice (d30).  
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An interesting question that remains is whether antigen presentation by DC 
changes in the context of immunotherapy. In order to address this question, 
chronically infected mice were treated one, three or five times with 200 µg anti-
PD-L1. 24 h post treatment, spleens were isolated (Figure 3.1A). Untreated 
mice served as a control. CD11b+ DC and XCR1+ DC were enriched and used 
for the above described co-culture assay with CTV-labelled P14 cells. In 
general, a 1:1 co-culture of DC and P14 cells induced the strongest proliferation 
(Figure 3.12). The number of divided P14 cells decreased with each serial 1:2 
dilution of DC. As observed before, co-culture with CD11b+ DC provoked a 
higher P14 expansion. CD11b+ and XCR1+ DC from mice treated once with 
anti-PD-L1 did not stimulate the expansion of P14 cells to the same extent as 
DC from untreated mice (Figure 3.12). Unexpectedly, this effect was more 
pronounced when mice were treated three or five times with anti-PD-L1. 
CD11b+ and XCR1+ DC isolated from mice that received three or five injections 
were not able to significantly induce proliferation in P14 cells. Even at the 
highest concentration of DC (1:1 co-culture with P14), P14 cells did not divide 
(Figure 3.12). These findings reveal that the capacity of DC to activate 
exhausted CD8+ T cells declines during the course of immunotherapy. Notably, 
B cells and macrophages were not able to drive the proliferation of P14 cells ex 
vivo in untreated nor anti-PD-L1-treated mice (data not shown). This is in line 
with our in vivo DC depletion experiments shown above, indicating that DC are 
the only APC able to drive antigen-specific CD8+ T cell proliferation during 
immunotherapy of chronically infected mice. 
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Figure 3.12: Antigen presentation by DC from anti-PD-L1-treated mice is 
highly decreased. WT mice received anti-CD4 i.p. on d-2 and d0 and were i.v. 
infected with 2x106 IU LCMV Cl13. On d45 mice received 200 µg anti-PD-L1 i.p. 
one, three or five times every three days. 24 h post anti-PD-L1 application, 
spleens were isolated and CD11b+ and XCR1+ DC sorted by FACS. In an ex 
vivo co-culture assay 5x104 DC (and serial 1:2 dilutions) were co-cultured with 
5x104 CTV-labelled P14 cells for 65 h at 37 °C. Proliferation of P14 cells was 
determined by flow cytometry. Graphs depict the number of divided P14 cells 
after co-culture with DC. Data are representative of three independent 
experiments (n = 5 mice/group). Error bars indicate the mean ± SEM.   
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In order to address whether DC isolated from anti-PD-L1-treated animals have 
an overall impaired capacity to stimulate antigen-specific CD8+ T cells, we 
added exogenous antigen. Specifically, DC were loaded with an unrelated 
protein, the model antigen ovalbumin (OVA), and co-cultured with CD8+ T cells, 
that express a specific transgenic TCR for this antigen (OT-I T cells). In detail, 
DC from mice that received one, three or five anti-PD-L1 injections, were 
enriched and sorted for CD11b+ and XCR1+ DC. These DC were loaded with 
OVA and subsequently co-cultured with OT-I T cells. Only if the DC are able to 
process the full OVA protein and present it via MHCI to OT-I cells, these cells 
will proliferate. OT-I cells were labelled with CTV to track their proliferation by 
flow cytometry. As displayed in representative histograms, CD11b+ and 
XCR1+ DC were clearly able to process and present OVA (Figure 3.13). 
OT-I T cells strongly proliferated during co-culture with DC from anti-PD-L1-
treated mice.  
These data show that DC fully retain their capacity to stimulate antigen-specific 
CD8+ T cells during PD-L1 blockade in chronically infected animals. However, 
these DC do not seem to present viral antigen to a level that is sufficient to drive 
the proliferation of exhausted CD8+ T cells over the course of treatment. These 
results fit well to the proliferation data obtained after several rounds of 
anti-PD-L1 therapy, showing that the positive effects of immunotherapy reach a 
limit over time.  
 
In summary, we conclude that DC are the critical cellular element that underlie 
successful immunotherapy. Additionally, the level of viral antigen presentation 
by DC determines and limits the effect of immunotherapy. Interestingly, both DC 
subsets XCR1+ DC (cDC1) and to a higher level CD11b+ DC (cDC2) presented 
viral antigen and were able to drive CD8+ T cell proliferation ex vivo. Therefore, 
we next aimed to address whether these two distinct DC subsets have a similar 
or differential role during checkpoint immunotherapy in vivo. 
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Figure 3.13: DC from anti-PD-L1-treated mice are able to process and 
present antigen. WT B6 mice were infected with LCMV Cl13. DC from 
untreated mice and mice that received one, three or five anti-PD-L1 injections 
during the chronic infection phase were isolated. Sorted CD11b+ and XCR1+ DC 
were loaded with OVA. In an ex vivo co-culture assay 5x104 OVA-loaded DC 
were co-cultured with 5x104 CTV-labelled OT-I cells for 65 h at 37 °C. 
Proliferation of OT-I cells was determined by flow cytometry. Representative 
histograms depict CTV expression of proliferated OT-I T cells. Data are 
representative of two independent experiments (n = 5 mice/group).  
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3.3 Discussion 
 
In 2006, Barber et. al described the reinvigoration of exhausted CD8+ T cells 
with anti-PD-1/PD-L1 treatment during chronic LCMV infection (Barber, Wherry 
et al. 2006). Only eight years later, pembrolizumab, the first anti-human PD-1 
blocking antibody, was approved for the treatment of metastatic melanoma by 
the US Food and Drug Administration (FDA). To date, there are several 
different checkpoint inhibitors on the market and many more are currently tested 
in clinical trials. The cornerstone of this immunological breakthrough, the 
discovery of inhibitory receptors, has been rewarded with the 2018 Noble Prize 
in Physiology or Medicine for James P. Allison and Tasuku Honjo 
(NobelPrize.org 2019). Despite the enormous success of checkpoint 
immunotherapy, the exact underlying mechanisms are not fully understood, and 
treatment is limited to certain cancer types (Wu 2019). Little is reported on the 
kinetics of anti-PD-L1 treatment and the cellular interaction partners involved in 
CD8+ T cell reinvigoration. 
In this chapter, we investigated the CD8+ T cell response during chronic LCMV 
infection and anti-PD-L1 therapy and found that DC play a critical role for the 
reinvigoration of exhausted CD8+ T cells and control of viral load. During 
chronic viral infections, such as with LCMV and HIV, DC have been described 
to be partly dysfunctional (Ng, Sullivan et al. 2011, Ng, Snell et al. 2013). 
Paralysed DC downregulate MHC I molecules, co-stimulatory molecules (CD40, 
CD80, CD86) and show a decreased production of inflammatory cytokines 
(Sevilla, McGavern et al. 2004). In addition, DC can induce the secretion of 
immunosuppressive cytokines, such as IL-10, which further drive exhaustion of 
T cells during chronic infection (Baca Jones, Filippi et al. 2014). Therefore, T 
cell activation by DC might be strongly impaired as in addition exhausted CD8+ 
T cells express high levels of various inhibitory receptors which block TCR and 
co-stimulatory signalling (Blackburn, Shin et al. 2009). Depletion of DC during 
the chronic infection phase without anti-PD-L1 treatment did not affect CD8+ T 
cell responses or viral load. These data are in line with findings obtained during 
the acute LCMV infection where depletion of DC did not impact the expansion 
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and function of T cells (Hilpert, Sitte et al. 2016). Likely, other APCs are able to 
stimulate and activate T cells. In addition, non-hematopoietic cells have been 
shown to present antigen and drive T cell exhaustion during chronic LCMV 
infection (Mueller and Ahmed 2009). In contrast to this, DC play an important 
role for the reactivation of exhausted CD8+ T cells during checkpoint 
immunotherapy. In line with previous reports, we have shown that DC, XCR1+ 
DC as well as CD11b+ DC, still present antigen during chronic LCMV infection. 
CD11b+ DC are directly infected and can directly present antigen to CD8+ T 
cells (Baca Jones, Filippi et al. 2014). XCR1+ DC might not be infected but are 
able to cross-present antigen and thereby activate CD8+ T cells (Belz, 
Shortman et al. 2005). Notably, in this study we made use of the CD11c.DOG 
mouse line which allows depletion of CD11c+ cells without the need to generate 
mixed bone marrow chimera like other mouse lines which enable depletion of 
DC (Hochweller, Striegler et al. 2008). However, CD11c can be expressed by 
other cells than DC, which are also be depleted in our model. These cells are 
for example red pulp macrophages and marginal zone macrophages, which are 
also antigen-presenting cells, that can activate CD8+ T cells. Therefore, we 
cannot exclude a contribution of these cells for the reactivation of exhausted 
CD8+ T cells during checkpoint immunotherapy. However, there are other 
studies, which support the important role of DC during checkpoint 
immunotherapy. A study by Kamphorst et al. described that co-stimulatory 
CD28 signalling is critical to reinvigorate the CD8+ T cell response with PD-L1 
blockade (Kamphorst, Wieland et al. 2017). The ligands for CD28, CD80 and 
CD86, can be delivered by APCs, especially DC. This already led them to the 
hypothesis that DC participate in the activation of exhausted CD8+ T cells 
(Kamphorst, Wieland et al. 2017). In addition, studies on checkpoint 
immunotherapy in the context of cancer also revealed a role for DC. During anti-
PD-1 therapy, IL-12-producing DC supported the reactivation of exhausted 
CD8+ T cells and reduced of tumour burden (Garris, Arlauckas et al. 2018). 
Interestingly, IFNg, produced by CD8+ T cells upon anti-PD-1 administration, 
induced IL-12 production by DC. These findings hint to a feed-back scenario 
where DC themselves need to be stimulated to then support CD8+ T cells. 
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Another study further supports this notion as TLR4-stimulation during anti-PD-1 
treatment during chronic viral infection highly improved CD8+ T cell responses 
by an increased expression of CD80 and CD86 on DC (Wang, Chung et al. 
2019). Here, the improved co-stimulatory activity of DC resulted in a 
significantly increased expansion and activation of exhausted CD8+ T cells and 
subsequently in a better control of the viral load compared to anti-PD-L1 
treatment alone (Wang, Chung et al. 2019). Our findings combined with other 
studies therefore show the necessity of DC-CD8+ T cell communication for 
successful anti-PD-L1 treatment.  
 
Additionally, we investigated the CD8+ T cell response after treating one, three 
or five times with anti-PD-L1. Notably, most studies investigating anti-PD-1/anti-
PD-L1 therapy during chronic LCMV infection, used a standard treatment of 
200 µg anti-PD-1/anti-PD-L1 i.p. every three days with five injections in total 
(Barber, Wherry et al. 2006, Blackburn, Shin et al. 2009, Im, Hashimoto et al. 
2016, Utzschneider, Charmoy et al. 2016). 24 h after a single injection of 
anti-PD-L1, expansion nor phenotypical changes of antigen-specific CD8+ T 
cells could be detected. During acute viral infections, antigen-specific CD8+ T 
cells are able to divide within 24 h (Murali-Krishna, Altman et al. 1998). Notably, 
during chronic infection, the CD8+ T cells are exhausted and divide less 
efficiently. It is possible that the decreased proliferative capacity has not been 
overcome post a single anti-PD-L1 treatment. We also cannot exclude that the 
dose of antibodies administered with a single injection is sufficient to reach the 
T cell zones of secondary lymphoid organs where reactivatable exhausted 
CD8+ T cells predominantly reside. However, as an increase in the expression 
of PD-1, reflecting an increase in TCR signalling, was detected after a single 
anti-PD-L1 injection, the exhausted cells already displayed a state of increased 
activation. In other words, we do see evidence for an effect of PD-L1 blockade 
already after one injection. However, the strongest effect of PD-L1 blockade 
was observed after three injections. Surprisingly, T cell responses were not 
further elevated with ongoing treatment but rather reached a plateau or declined 
slightly. T cell intrinsic as well as extrinsic factors could be the basis for this 
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observation. One possible reason could be that with increased TCR signalling, 
inhibitory receptors are even further upregulated and dampen the activation of 
the CD8+ T cells. This hypothesis can be supported by various studies 
demonstrating that co-treatment of anti-PD-1/anti-PD-L1 with antibodies 
blocking other inhibitory receptor signalling pathways (CTLA-4, Lag3, Tim3, 
TIGIT) showed a synergistic and increased effect over monotherapy 
(Hashimoto, Kamphorst et al. 2018, McLane, Abdel-Hakeem et al. 2019). 
Additionally, it has been described that the exhausted state of CD8+ T cells is 
imprinted by epigenetic changes. During T cell exhaustion by chronic viral 
infection and cancer, de novo DNA methylation mediated by the DNA 
methyltransferase Dnmt3a has been shown to restrict T cell responses and 
expansion (Ghoneim, Fan et al. 2017). This unique epigenetic signature of 
exhausted CD8+ T cells also limited the expansion of CD8+ T cells upon anti-
PD-1 treatment. The effect could be reversed by the usage of a demethylating 
agent prior to checkpoint immunotherapy (Ghoneim, Fan et al. 2017). 
Furthermore, extrinsic factors like regulatory cells could play a role in 
dampening the CD8+ T cell response upon anti-PD-L1 treatment. Indeed, a role 
for Treg cells during checkpoint immunotherapy has recently been reported 
during treatment of advanced gastric cancer patients with anti-PD-1. Cancer 
progression was detected for a fraction of patients and could be set in context 
with increased numbers of Treg cells (Kamada, Togashi et al. 2019).  
However, simultaneously to the plateau of the CD8+ T cells response, we 
observed a strong decrease of viral antigen presentation by XCR1+ DC and 
CD11b+ DC during the course of anti-PD-L1 treatment. As we found that DC are 
essential for the successful reinvigoration of exhausted CD8+ T cells, we 
hypothesize that this decreased antigen presentation limits activation of 
exhausted CD8+ T cells. As a consequence, a prolonged anti-PD-L1 treatment 
is ineffective at least with regards to CD8+ T cell expansion. This points to an 
overall scenario in which checkpoint immunotherapy is self-limiting. The 
question that remains is why antigen presentation is negatively impacted during 
ongoing anit-PD-L1 treatment. As DC were still able to present ovalbumin 
antigen, an impaired functionality seems highly unlikely. During acute infections 
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and tumour development, APCs which initially activate CD8+ T cells become 
themselves targets of the cytotoxic response and get eliminated (Hermans, 
Ritchie et al. 2000, Ritchie, Hermans et al. 2000, Ludewig, Bonilla et al. 2001). 
This regulatory feedback mechanism is important to limit an overwhelming 
inflammatory response by antigen-specific T cells during acute viral and 
bacterial infections. We hypothesize that during early anti-PD-L1 treatment 
exhausted CD8+ T cells regain their ability to receive TCR signalling as the 
inhibitory PD-1 signalling is blocked. This TCR as well as co-stimulatory 
signalling is delivered by DC. However, the reactivation of CD8+ T cells also 
restores their cytotoxic capacity. As DC can be infected with LCMV Cl13 or 
cross-present antigen (Belz, Shortman et al. 2005, Baca Jones, Filippi et al. 
2014), these antigen-presenting cells are likely targets of reactivated CD8+ T 
cells. DC have a high turnover and are constantly replenished (Liu and 
Nussenzweig 2010). Therefore, DC extracted after three and five treatments 
with anti-PD-L1 seem to be uninfected or at least do not present viral antigen. A 
possible explanation for this finding is that antigen-presenting DC have been 
removed by cytotoxic T cells and been replaced by newly generated DC from 
the bone marrow. In line with these observations is the finding that CD8+ T cells 
expressed significantly lower levels of PD-1 after five anti-PD-L1 treatments 
compared to three injections, again, pointing towards reduced TCR 
engagement. However, measuring the splenic viral titer after three injections of 
anti-PD-L1, showed that the infection is not completely cleared. Therefore, it 
remains unclear where antigen persists and why the newly arriving DC do not 
have efficient access to this antigen. Mueller et al. revealed that the stromal 
network of lymphoid organs, namely fibroblastic reticular cells (FRC), are 
targeted by LCMV Cl13 (Mueller, Matloubian et al. 2007). In a second study, 
they further described that non-hematopoietic cells present antigen during 
chronic infection and that this antigen presentation contributes to exhaustion 
(Mueller, Matloubian et al. 2007). It is possible that the virus persists in these 
non-hematopoietic cells, which developed further mechanisms to protect 
themselves, and therefore the organ architecture, from being attacked by CD8+ 
T cells. If reactivated CD8+ T cells can quickly regain cytotoxic functions and 
 Results 
102 
target DC, they hence target an important cellular interaction partner, which is 
critical for further reinvigoration of the exhausted CD8+ T cells. Further studies 
investigating if DC are indeed eliminated by reactivated CD8+ T cells and where 
exactly antigen persists in the presence of continuous anti-PD-L1 treatment will 
help to understand this complex network of cellular interaction during chronic 
infection and checkpoint immunotherapy. Additionally, it is important to 
understand where exhausted CD8+ T cells and DC in lymphoid tissues interact 
and whether certain DC subsets impact the CD8+ T cell response differentially. 
In other words, we need to elucidate the microanatomy of checkpoint 
immunotherapy and define critical cellular interactions in the tissue context. 
These issues will be addressed in the following chapters.  
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4. Dendritic cell subsets exhibit a differential role for T cell 
proliferation and differentiation during checkpoint therapy 
 
4.1 Introduction 
 
In the previous chapter, I discussed the essential role of DC during checkpoint 
immunotherapy. During the chronic infection phase, viral antigen is presented 
by both XCR1+ DC (cDC1) and CD11b+ DC (cDC2) subsets. We hypothesized 
that viral antigen presentation together with co-stimulatory signals delivered by 
conventional DC (cDC) are essential for the expansion of exhausted CD8+ T 
cells in the context of checkpoint immunotherapy. In animals that were depleted 
of cDC during checkpoint immunotherapy, CD8+ T cells failed to expand despite 
the blockade of inhibitory signalling via the PD-1 pathway. 
Importantly, cDC display a heterogeneous cell population consisting of 
lymphoid tissue-resident and migratory DC. The group of lymphoid tissue-
resident DC can be further divided into XCR1+ DC (cDC1) and CD11b+ DC 
(cDC2). Both subsets differ in their localization and function. XCR1+ DC excel at 
stimulating CD8+ T cells whereas CD11b+ DC preferentially activate CD4+ T 
cells (Dudziak, Kamphorst et al. 2007). In the spleen, most XCR1+ DC reside 
centrally in the T cell zone of the white pulp and fewer in the red pulp. CD11b+ 
DC are located at the bridging channels of the marginal zone (Gerner, 
Kastenmuller et al. 2012, Gatto, Wood et al. 2013). In addition, XCR1+ DC, as 
well as their migratory counterpart of CD103+ DC in peripheral tissues and 
lymph nodes, are specialized in cross-presenting viral antigen (Bevan 1976, 
Gurka, Hartung et al. 2015). Therefore, these DC are able to present viral 
antigen via MHCI to CD8+ T cells without the necessity of being directly 
infected. The exact mechanism of this process is still incompletely understood, 
yet it allows XCR1+ DC to activate antiviral CD8+ T cells without being under the 
control of an intracellular pathogen (Gutierrez-Martinez, Planes et al. 2015). 
Functionally, this DC subset has been shown to be essential to mount an 
adaptive cytolytic CD8+ T cell response and is required to clear infections such 
as HSV-1 and L. monocytogenes (Bedoui, Whitney et al. 2009, Jirmo, Nagel et 
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al. 2009, Alexandre, Ghilas et al. 2016). Optimal T cell responses against 
tumour antigens also depend on cross-presentation executed by XCR1+ DC 
(Sanchez-Paulete, Teijeira et al. 2017). Many studies investigating the role of 
cross-presenting XCR1+ DC during infection were performed with cytolytic 
viruses. Here, infected cells are killed and antigen is released. Under such 
conditions, XCR1+ DC can efficiently take up viral antigen and cross-present it 
via MHCI. Notably, also after acute infection with LCMV Armstrong, a non-
cytolytic virus, cross-presentation by XCR1+ DC was reported (Belz, Shortman 
et al. 2005). Additionally, XCR1+ DC have been shown to present a unique 
cellular platform that mediates CD4+ T cell help to CD8+ T cells. Therefore, 
mature XCR1+ DC are able to deliver necessary co-stimulatory signals which 
support the activation of CD8+ T cells (Eickhoff, Brewitz et al. 2015, Hor, 
Whitney et al. 2015). 
As we revealed an essential role for DC during chronic infection and 
immunotherapy, we aimed to investigate this in more detail by focusing on the 
subset of XCR1+ DC with its well-described non-redundant function in CD8+ T 
cell activation. To this end, we made use of the XCR1 Venus DTR mouse line 
that allows depletion of XCR1+ DC by administration of DTX. By comparing 
these results with the previous findings looking at CD11c+ cell depletion, we can 
decipher the contribution of different DC subsets for the reinvigoration of 
exhausted CD8+ T cells during PD-L1 blockade.  
Additionally, we aimed to determine key signalling molecules delivered by 
XCR1+ DC that could impact the T cell response during immunotherapy. For the 
optimal activation of naïve CD8+ T cells, three signals delivered by APC are of 
great importance: TCR stimulation, co-stimulation and cytokines (van Stipdonk, 
Lemmens et al. 2001). Our data reveal that antigen presentation and hence 
TCR stimulation is of importance during immunotherapy as we observed a 
decrease in CD8+ T cell expansion when antigen presentation by DC was highly 
reduced with ongoing anti-PD-L1 treatment. The importance of co-stimulatory 
signalling during reactivation of exhausted CD8+ T cells was described by 
Kamphorst et. al. (Kamphorst, Wieland et al. 2017). Their study revealed that 
co-stimulation by CD28 is essential during immunotherapy. In addition, there is 
 Results 
105 
evidence that CD4+ T cell help is required to contain chronic infection and to 
support the response to immunotherapy (Aubert, Kamphorst et al. 2011). The 
co-stimulatory signalling axis of CD27-CD70 plays an important role in this 
context: mature DC, which received CD4+ T cell help, upregulate CD70. CD70 
binds to the co-stimulatory receptor CD27, which is expressed by CD8+ T cells. 
In the context of influenza infection, it was shown that CD8+ T cells can thereby 
be optimally primed (Belz, Bedoui et al. 2007). To examine if CD27-CD70 
signalling is also required during checkpoint immunotherapy, we blocked CD70 
with monoclonal antibodies in vivo. 
Moreover, we addressed the role of IL-15 signalling during anti-PD-L1 
blockade. IL-15 is described as an important cytokine being critical for the 
maintenance of memory CD8+ T cells upon acute infections (Schluns and 
Lefrancois 2003, Oh, Perera et al. 2008). IL-15 signalling is primarily mediated 
by transpresentation. In detail, IL-15 binds to the IL-15Ra on the same cell and 
this IL-15:IL-15Rα complex can in turn bind the complex of IL-2Rb and the 
common gamma chain on CD8+ T cells (Dubois, Mariner et al. 2002). Notably, a 
supreme role of IL-15 produced by XCR1+ DC was described during HSV-1 
infection in the context of CD4+ T cell help (Greyer, Whitney et al. 2016). By 
blocking of IL-15 signalling in vivo using anti-IL-15 blocking antibodies, we 
examined the impact of this signalling pathway in the context of chronic LCMV 
infection and PD-L1 blockade. In this chapter, we therefore aimed to elucidate 
differential roles for certain DC subsets and key signalling molecules, which 
further support the T cell response during checkpoint immunotherapy. 
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4.2 Results 
 
4.2.1 XCR1+ DC are required to preserve the TCF-1+ CD8+ T cell 
compartment during immunotherapy 
 
The findings presented in chapter 3 revealed that DC are essential for the 
proliferation of exhausted CD8+ T cells during anti-PD-L1 blockade. As tissue-
resident DC of the spleen encompass two distinct populations, XCR1+ DC 
(cDC1) and CD11b+ DC (cDC2), we aimed to unravel if these subsets differ in 
their ability to support CD8+ T cell reinvigoration. With specific depletion of 
XCR1+ DC, we deciphered the role of this DC subset in more detail to better 
understand its contribution during anti-PD-L1 treatment. 
For this approach, XCR1 DTR mice were used. These mice harbour a DTR 
cassette under the Xcr1 promoter. By the administration of DTX, XCR1+ cells 
can be efficiently depleted. XCR1 DTR mice were treated with anti-CD4 on d-2 
and d0 and infected with 2x106 IU LCMV Cl13. In the chronic infection phase, 
mice were treated with 250 ng DTX (five treatments every two days) and 200 µg 
anti-PD-L1 (four treatments every three days). 24 h after the last anti-PD-L1 
injection, blood and spleen were isolated and analysed by flow cytometry. A 
direct comparison of LCMV-specific CD8+ T cells in the blood before and after 
the treatment was performed (Figure 4.1A). Representative flow cytometry plots 
display the successful depletion of XCR1+ DC in DTX-treated mice (Figure 
4.1B). Notably, the overall frequency of CD11chi MHCII+ DC was not affected. 
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Figure 4.1: Mouse model of XCR1+ DC depletion and PD-L1 blockade 
during chronic LCMV infection. (A) Adult male XCR1 Venus DTR mice 
received 300 µg anti-CD4 i.p. on d-2 and d0 of infection and were i.v. infected 
with 2x106 IU LCMV Cl13 on d0. Blood was taken prior to treatment (d44). From 
d45 onwards, mice received 200 µg anti-PD-L1 blocking antibody i.p. four times 
every three days. To deplete XCR1+ DC, mice received 250 ng DTX i.p. from 
d45 onwards five times every second day. 24 h after the last anti-PD-L1 
injection, blood and spleen were isolated for analysis. (B) Representative flow 
cytometry plots showing the depletion of XCR1+ DC in DTX-treated mice.  
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Comparing the frequency of LCMV-specific CD8+ T cells (PD-1+ and gp33+) in 
the blood before and after treatment revealed that the absence of XCR1+ DC 
did not affect CD8+ T cell expansion (Figure 4.2A). Exhausted CD8+ T cells 
were still able to respond to PD-L1 blockade when XCR1+ DC were absent. 
Likewise, no significant differences regarding LCMV-specific CD8+ T cells could 
be detected in the spleen. Mice that received anti-PD-L1 and mice which were 
treated with anti-PD-L1 and DTX, exhibited similar frequencies and absolute cell 
numbers of LCMV-specific CD8+ T cells (PD-1+ and gp33+) (Figure 4.2B). In 
contrast to mice depleted of all DC during immunotherapy (Chapter 3, figure 
3.7B), the depletion of XCR1+ DC during immunotherapy did not affect the 
expansion of exhausted T cells. Consistent with this finding, no difference in the 
frequency and number of Ki67+ proliferating gp33+ cells were observed (Figure 
4.2C). Compared to PBS-treated mice (Chapter 3, figure 3.3), both groups 
displayed elevated levels of Ki67+ gp33+ CD8+ T cells. Unexpectedly, these 
data point towards a redundant role of XCR1+ DC regarding the expansion of 
exhausted CD8+ T cells during anti-PD-L1 treatment. 
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Figure 4.2: XCR1+ DC do not promote proliferation of exhausted CD8+ T 
cells during PD-L1 blockade. (A) Paired frequencies of LCMV-specific PD-1+ 
and gp33+ CD8+ T cells in the blood prior to and post anti-PD-L1 treatment in 
the presence and absence of XCR1+ DC. (B) Frequency and absolute number 
of splenic PD-1+ and gp33+ CD8+ T cells post anti-PD-L1 treatment with and 
without XCR1+ DC depletion. (C) Frequency and absolute number of 
proliferating Ki67+ gp33+ T cells. Data are pooled from three independent 
experiments (n = 4 mice/group). Error bars indicate the mean ± SEM. 
Comparison between groups was calculated using the unpaired Student‘s t-test. 
* p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
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As previously described, there are two main subsets of exhausted CD8+ T cells. 
The memory-like TCF-1+ cells, which respond to immunotherapy by proliferation 
and functional reinvigoration and the terminally exhausted Tim3+ cells 
(Utzschneider, Charmoy et al. 2016). TCF-1+ cells give rise to Tim3+ cells but 
are also able to self-renew (Im, Hashimoto et al. 2016). During PD-L1 blockade, 
a relative shift from TCF-1+ cells to Tim3+ cells was detected that is based on an 
absolute increase of the latter subset (Chapter 3, figure 3.5). Since T cell 
expansion was dependent on the presence of DC, there was no shift towards 
Tim3+ cells when CD11c+ DC where depleted (Chapter 3, figure 3.9A). In the 
context of XCR1+ DC depletion during anti-PD-L1 treatment, the differentiation 
of gp33+ cells was examined as well. Surprisingly, the frequency of TCF-1+ cells 
was strongly reduced in mice that were depleted of XCR1+ cells (Figure 4.3A). 
Importantly and in contrast to the relative loss of TCF-1+ cells during anti-PD-L1 
therapy alone, additional depletion of XCR1+ DC induced an absolute loss of 
TCF-1+ cells (Figure 4.3B). The absolute numbers of Tim3+ T cells was similar 
between anti-PD-L1-treated mice in absence or presence of XCR1+ DC. This 
argues for a model in which proliferation is driven by XCR1- DC, that is CD11b+ 
DC, while maintenance of stemness or prevention of full differentiation towards 
a Tim3+ phenotype during immunotherapy is regulated by XCR1+ DC. 
Besides the proliferation and differentiation of exhausted CD8+ T cells after PD-
L1 blockade in combination with XCR1+ DC depletion, frequency and absolute 
number of GzmB-producing cells was measured. DTX-treated mice harboured 
the same number of GzmB-producing cells as mice that were treated with anti-
PD-L1 alone (Figure 4.4A). Both groups showed an increase in GzmB+ cells 
compared to completely untreated mice. Comparable to the expansion and 
proliferation of exhausted CD8+ T cells upon PD-L1 blockade, XCR1+ DC are 
not essential for the increase of GzmB+ cells during therapy. 
Next, we addressed whether the absolute loss of TCF1+ CD8+ T cells was 
associated with an altered viral control. To this end, we compared the viral titers 
in mice treated with PD-L1 blockade alone or in combination with XCR1+ DC 
depletion. Indeed, mice that were depleted of XCR1+ DC during PD-L1 
blockade displayed an increased viral load compared to mice that received 
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anti-PD-L1 treatment alone (Figure 4.4B). This indicates that XCR1+ DC not 
only maintain the numbers of the memory-like subpopulation of exhausted 
CD8+ T cells (TCF1+) but are functionally critical for the decrease of viral load 
during immunotherapy. In other words, they are essential for a successful 
immunotherapy although they are not the main drivers of CD8+ T cell 
proliferation. 
Whether these two findings (loss of the TCF1+ cell compartment and reduced 
viral control in the absence of XCR1+ DC) are directly connected, a 
consequence of each other or reflect different roles of XCR1+ DC during 
immunotherapy, remains to be clarified. 
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Figure 4.3: XCR1+ DC maintain memory-like cells during anti-PD-L1 
therapy. XCR1 Venus DTR mice were chronically infected with 2x106 IU LCMV 
Cl13 in combination with CD4+ cell depletion. From d45 onwards, mice were left 
untreated, treated with anti-PD-L1 or anti-PD-L1 in combination with DTX to 
deplete XCR1+ DC. (A) Representative flow cytometry plots of TCF-1+ und 
Tim3+ subpopulations of exhausted gp33+ CD8+ T cells from differentially 
treated mice. (B) Frequency and absolute number of TCF-1+ and Tim3+ gp33+ 
CD8+ T cells after anti-PD-L1 treatment with and without XCR1+ cell depletion. 
Data are pooled from two independent experiments (n = 4 mice/group). Error 
bars indicate the mean ± SEM. Comparison between groups was calculated 
using the unpaired Student‘s t-test. * p ≤ 0.05; ** p < 0.01; *** p < 0.001.
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Figure 4.4: Increased viral load in chronically infected mice depleted of 
XCR1+ DC during immunotherapy despite intact GzmB production. (A) 
Frequency and absolute number of GzmB+ gp33+ CD8+ T cells from anti-PD-L1 
treated mice in the presence or absence of XCR1+ DC. (B) Viral load 
depicted as infectious units (IU) per g spleen of anti-PD-L1 treated animals in 
combination with XCR1+ DC depletion. Data are pooled from three independent 
experiments (n = 3-4 mice/group). Error bars indicate the mean ± SEM. 
Comparison between groups was calculated using the unpaired Student‘s t-test. 
* p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
PBS DTX
105
106
107
108
IU
 / 
g 
sp
le
en
anti-PD-L1
**
PBS DTX
0
20
40
60
80
100
%
 G
zm
B+
 g
p3
3+
anti-PD-L1
ns
PBS DTX
103
104
105
106
# 
G
zm
B+
 g
p3
3+
anti-PD-L1
nsA 
B 
 
 Results 
115 
So far, the role of XCR1+ DC during immunotherapy was investigated. To 
uncover if XCR1+ DC are critical for the maintenance of memory-like cells 
during chronic infection, XCR1+ DC were depleted without simultaneous PD-L1 
blockade. In detail, XCR1 Venus DTR mice received anti-CD4 and were 
infected with 2x106 IU LCMV Cl13. During the chronic infection phase, 250 ng 
DTX were administered five times every second day (Figure 4.5A). 24 h after 
the last DTX injection, spleens were isolated and analysed by flow cytometry. 
We detected a tendency towards less LCMV-specific PD-1+ and gp33+ cells in 
DTX-treated mice compared to untreated animals (Figure 4.5B). However, 
frequency and absolute number of these cells did not change significantly with 
XCR1+ DC depletion. In addition, the depletion of XCR1+ DC did not impact the 
differentiation of exhausted gp33+ CD8+ T cells regarding their expression of 
TCF-1 and Tim3 (Figure 4.5C). This is in contrast to the impact of XCR1+ DC 
depletion during anti-PD-L1 treatment, where a significant shift from the TCF-1+ 
to the Tim3+ cell population was observed. Moreover, XCR1+ DC depletion 
during the chronic infection phase did not significantly impact the viral load in 
the spleen (Figure 4.5D). 
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Figure 4.5: Depletion of XCR1+ DC during chronic LCMV infection. 
(A) XCR1 Venus DTR mice received anti-CD4 and were i.v. infected with 
2x106 IU LCMV Cl13. To deplete XCR1+ DC, mice received 250 ng DTX i.p. 
from d45 onwards five times every second day. 24 h after the last DTX injection, 
spleens were isolated for analysis. (B) Frequency and number of LCMV-specific 
CD8+ T cells (PD-1+ and gp33+) in the presence and absence of XCR1+ DC. (C) 
Frequency of TCF-1+ and Tim3+ gp33+ cells. (D) Splenic viral load of untreated 
and DTX-treated mice. Error bars indicate the mean ± SEM. Comparison 
between groups was calculated using the unpaired Student‘s t-test. * p ≤ 0.05; 
** p < 0.01; *** p < 0.001.  
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4.2.2 XCL1-XCR1 signalling is not required for the reinvigoration of 
exhausted CD8+ T cells 
 
As XCR1+ DC play an important role for the maintenance of memory-like 
TCF-1+ cells during PD-L1 blockade, we aimed to investigate the factors that 
enable the communication between these two cell types. Memory-like 
exhausted CD8+ T cells are functionally and transcriptionally distinct from 
terminally exhausted cells (Im, Hashimoto et al. 2016, Utzschneider, Charmoy 
et al. 2016). One of the genes that is differentially expressed between the two 
exhausted cell types, is XCL1 (Im, Hashimoto et al. 2016). XCL1 is a 
chemokine, which is expressed by NK cells and activated CD8+ T cells (Dorner, 
Dorner et al. 2009). The exclusive receptor for XCL1 is XCR1, which is solely 
expressed by cDC1. Our group revealed that CD8+ T cells attract XCR1+ DC via 
the production of XCL1, thus enabling the orchestration of an ideal cellular 
microenvironment for optimal CD8+ T cell priming (Brewitz, Eickhoff et al. 2017). 
The high expression of XCL1 by TCF-1+ cells and the loss of these cells when 
XCR1+ DC are depleted, points towards an important role of XCL1-XCR1 
signalling during PD-L1 blockade. To investigate this notion, we made use of 
XCR1-/- mice. These mice still harbour cDC1 (XCR1+ DC), but the DC do not 
express the XCR1 receptor. Thereby XCL1-XCR1 signalling is genetically 
abolished in these mice. The mice were chronically infected with LCMV Cl13 
and treated with 200 µg anti-PD-L1 (five times, every second day) during the 
chronic infection phase. WT mice which still expressed XCR1, served as a 
control. Spleens were analysed 24 h after the last anti-PD-L1 injection (Figure 
4.6A). Quantitative analysis of CD8+ T cells from both groups revealed similar 
frequencies and absolute numbers of LCMV-specific cells (PD-1+ and gp33+) 
(Figure 4.6B). Furthermore, the differentiation of exhausted CD8+ T cells was 
not affected by the expression of XCR1 on cDC1. Both groups harboured 
similar frequencies of TCF-1+ and Tim3+ cells (Figure 4.6C). Also, the splenic 
viral load was comparable in both groups (Figure 4.6D). These findings match 
the results obtained with XCL1-/- mice. Using the same experimental setup as 
above, we found that reinvigoration of exhausted CD8+ T cells by anti-PD-L1 
 Results 
118 
treatment was unaltered in the absence of XCL1 (data not shown). These 
results argue that the XCR1-XCL1 signalling axis is not essential in the context 
of chronic LCMV infection and anti-PD-L1 treatment. The question how 
XCR1+ DC maintain memory-like cells during immunotherapy remains to be 
answered.
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Figure 4.6: XCR1 receptor is not essential to maintain TCF-1+ cells during 
PD-L1 blockade. (A) WT and XCR1-/- mice received anti-CD4 and were i.v. 
infected with 2x106 IU LCMV Cl13. During the chronic infection phase mice 
were treated with five injections of 200 µg anti-PD-L1 i.p. 24 h after the last 
injection, spleens were isolated and analysed. (B) Frequency and number of 
LCMV-specific CD8+ T cells (PD-1+ and gp33+) in WT and XCR1-/- mice. (C) 
Frequency of TCF-1+ and Tim3+ gp33+ cells. (D) Splenic viral load of WT and 
XCR1-/- mice. Data are pooled from two independent experiments (n = 3 
mice/group) Error bars indicate the mean ± SEM. Comparison between groups 
was calculated using the unpaired Student‘s t-test. * p ≤ 0.05; ** p < 0.01; *** p 
< 0.001.  
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4.2.3 CD27-CD70 signalling is not critical for checkpoint immunotherapy 
during chronic viral infection 
 
As shown above, DC subsets differently impact the proliferation and 
differentiation of exhausted CD8+ T cells during anti-PD-L1 blockade. During 
the priming phase of CD8+ T cells, CD4+ T helper signals are at least in part 
mediated by CD27-CD70 interactions (Feau, Garcia et al. 2012). These helper 
signals are not directly transmitted to CD8+ T cells but instead indirectly and 
exclusively via XCR1+ DC (Eickhoff, Brewitz et al. 2015, Hor, Whitney et al. 
2015). Therefore, we speculated that this pathway may also be critical during 
checkpoint immunotherapy and may be the basis for the impact of XCR1+ DC 
on CD8+ T cell differentiation that we described above. To examine if co-
stimulatory signalling via the CD27-CD70 pathway influences reactivation of 
exhausted T cells during immunotherapy, we made use of an in vivo anti-CD70 
blocking antibody (clone FR70). This monoclonal antibody binds to CD70 and 
thereby prevents its interaction with CD27. WT mice were chronically infected 
with 2x106 IU LCMV Cl13 in combination with CD4+ cell depletion. During the 
chronic infection phase, mice received 300 µg anti-CD70 i.p. on d45, d48 and 
d51. The control group received PBS. In addition, both groups were treated with 
200 µg anti-PD-L1 on d46, d49 and d52. 24h after the last anti-PD-L1 injection, 
spleens were isolated and analysed (Figure 4.7A). Blocking of CD70 signalling 
during immunotherapy had no impact on the expansion of exhausted CD8+ T 
cells. Both groups showed similar frequencies and absolute numbers of cells 
(PD-1+ and gp33+) (Figure 4.7B). Moreover, CD70 signalling did not affect 
differentiation of exhausted CD8+ T cells during PD-L1 blockade. The frequency 
of TCF-1+ and Tim3+ gp33+ CD8+ T cells was comparable when CD70 signalling 
was blocked (Figure 4.7C). In summary, blocking of CD70 had no impact on the 
frequency, number and phenotype of CD8+ T cells during immunotherapy. In 
line with these results, the splenic viral load was comparable in mice receiving 
anti-PD-L1 treatment with and without CD70 blockade (Figure 4.7D). Combining 
these results, we show that co-stimulatory signalling by the CD27-CD70 axis is 
not critical for successful immunotherapy during chronic LCMV infection.
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Figure 4.7: CD70 signalling is not critical during immunotherapy. (A) B6 
WT mice received anti-CD4 and were i.v. infected with 2x106 IU LCMV Cl13. 
During the chronic infection phase, mice were treated with three i.p. injections of 
300 µg anti-CD70 and three injections of 200 µg anti-PD-L1. 24 h after the last 
injection, spleens were isolated and analysed. (B) Frequency and number of 
LCMV-specific CD8+ T cells (PD-1+ and gp33+). (C) Frequency of TCF-1+ and 
Tim3+ gp33+ cells. (D) Splenic viral load depicted as IU / g spleen. Data present 
one experiment (n = 4 mice/group). Error bars indicate the mean ± SEM. 
Comparison between groups was calculated using the unpaired Student‘s t-test. 
* p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
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4.2.4 IL-15 supports control of viral load during immunotherapy 
 
IL-15 is described as an important cytokine, that promotes survival of T, B and 
NK cells and is shown to regulate the differentiation of memory T cells 
(Fehniger and Caligiuri 2001, Kokaji, Hockley et al. 2008). Given the prominent 
function of XCR1+ DC to mediate IL-15 signalling (Greyer, Whitney et al. 2016), 
we speculated that IL-15 may be the molecular link between XCR1+ DC and the 
maintenance of the memory-like TCF1+ CD8+ T cell population. To examine 
whether IL-15 plays an important role for the reactivation of exhausted CD8+ T 
cells during immunotherapy, an anti-IL-15 blocking antibody (clone AIO.3) was 
administered during anti-PD-L1 therapy of chronically infected mice. In detail, 
B6 WT mice were infected with 2x106 IU LCMV Cl13 in combination with CD4+ 
T cell depletion. During the chronic infection phase, mice received 200 µg anti-
IL-15 i.p. on d45, d48 and d51 and 200 µg anti-PD-L1 i.p. on d46, d49 and d52. 
The control group received anti-PD-L1 treatment alone. 24 h after the final anti-
PD-L1 injection, spleens were isolated and analysed (Figure 4.8A). The 
frequency of antigen-experienced CD8+ T cells (PD-1+) was significantly 
increased in mice in which IL-15 signalling was blocked (Figure 4.8B). However, 
this effect was less profound within the gp33+-specific CD8+ T cell pool. 
Importantly, the absolute cell number of LCMV-specific CD8+ T cells did not 
differ when mice were treated with anti-IL-15 during immunotherapy (Figure 
4.8B). Among gp33+ CD8+ T cells, the frequency of TCF-1+ and Tim3+ slightly 
shifted to the TCF-1+ cell population in mice treated with anti-IL-15 and anti-PD-
L1 (Figure 4.8C). In addition, anti-IL-15-treated mice exhibited a higher splenic 
viral load compared to mice that received only anti-PD-L1 (Figure 4.8D). 
Combining these results, the effects seen with IL-15 blockade do not 
recapitulate the results obtained in the context of XCR1+ DC depletion. IL-15 
signalling seems to play a complex role during immunotherapy with several 
cellular sources being involved and multiple cell populations (CD8+ T cells and 
NK cells) receiving this signal. The absolute expansion of CD8+ T cells seems 
to be unaltered by IL-15 blockade, yet functionally the blockade leads to an 
impaired control of chronic LCMV infection. 
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Figure 4.8: IL-15 signalling improves control of viral load during 
immunotherapy. (A) B6 WT mice received anti-CD4 and were i.v. infected with 
2x106 IU LCMV Cl13. During the chronic infection phase, mice were treated 
with three i.p. injections of 200 µg anti-IL-15 and three injections of 200 µg 
anti-PD-L1. 24 h after the last injection, spleens were isolated and analysed. (B) 
Frequency and number of LCMV-specific CD8+ T cells (PD-1+ and gp33+). (C) 
Frequency of TCF-1+ and Tim3+ gp33+ cells. (D) Splenic viral load depicted as 
IU / g spleen. Data present one experiment (n ≥ 4 mice/group). Error bars 
indicate the mean ± SEM. Comparison between groups was calculated using 
the unpaired Student‘s t-test. * p ≤ 0.05; ** p < 0.01; *** p < 0.001.  
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Collectively, these data reveal a supreme role of XCR1+ DC for the 
maintenance of memory-like CD8+ T cells during immunotherapy. The decrease 
of the TCF-1+ cell pool during ongoing anti-PD-L1 treatment described in 
chapter 3, is pronounced in mice depleted of XCR1+ DC during PD-L1 
blockade, suggesting a role for these DC to support CD8+ T cells in regaining 
their effector function. However, we did not observe this effect during the 
chronic infection phase when mice did not receive anti-PD-L1 treatment.  
In an effort to identify the underlying molecular mechanism we investigated 
three likely pathways: XCR1-XCL1, CD27-CD70 and IL-15R-IL-15 interactions. 
Signalling via the XCR1-XCL1 axis is not essential for the expansion of 
exhausted CD8+ T cells during immunotherapy. Despite XCL1 being highly 
expressed by memory-like TCF-1+ cells and a loss of this cell fraction observed 
when XCR1+ DC were absent, no differences were detected when cDC1 did not 
express the XCR1 receptor. For the investigation of how XCR1+ DC and 
exhausted TCF-1+ cells could communicate we focused on co-stimulatory 
signalling via the CD27-CD70 axis and IL-15 signalling. Our results revealed 
that CD70 signalling is redundant during anti-PD-L1 treatment. However, IL-15 
signalling supports control of the viral load and could therefore be part of the 
communication between DC and exhausted CD8+ T cells. Nevertheless, 
blocking of IL-15 did not fully reflect the effects we observed when DC were 
depleted, hinting towards a more complex network of effector molecules and 
signalling pathways that are essential for CD8+ T cell reactivation. Possibly, the 
localization and microenvironment are important prerequisites for the cells to be 
reinvigorated. Deciphering where DC and exhausted CD8+ T cells interact, 
could help to better understand factors that are critical for successful checkpoint 
immunotherapy. 
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4.3 Discussion 
 
In the previous chapter, we investigated the role of DC for CD8+ T cell 
reinvigoration during chronic viral infection and found that they play an essential 
role during checkpoint immunotherapy. So far, we examined the T cell response 
in the absence of all conventional DC. However, our data reveal a differential 
role for DC subsets during immunotherapy. XCR1+ DC maintain the memory-
like cell population and thereby impact the differentiation of exhausted CD8+ T 
cells. After depletion of XCR1+ DC, the remaining XCR1- DC (mainly CD11b+ 
DC) were sufficient to stimulate exhausted CD8+ T cell proliferation. As 
mentioned, TCF-1+ cells give rise to Tim3+ cells but importantly also undergo 
self-renewal. This self-renewal is critical as this subset of exhausted CD8+ T 
cells is the one that responds to immunotherapy (Im, Hashimoto et al. 2016). 
Taking this into account, XCR1+ DC could play an essential role for prolonged 
PD-L1 blockade by maintaining the reactivatable TCF-1+ cell pool. One of the 
first studies describing the memory-like subset of exhausted CD8+ T cells by the 
expression of CXCR5, already hypothesized a role for XCR1+ DC as RNA 
transcript levels of XCL1 (the ligand for XCR1) were strongly increased in the 
memory-like subset compared to the terminally exhausted one (Im, Hashimoto 
et al. 2016). Additionally, a study by Argilaguet et al. revealed a role for XCR1+ 
DC in maintaining the memory-like cell TCF-1+ population during an earlier 
phase of chronic LCMV infection without checkpoint immunotherapy 
(Argilaguet, Pedragosa et al. 2019). Importantly, XCR1+ DC have also been 
investigated in various tumour models in the context of anti-PD-1 therapy. 
Tumour engrafted Batf3-deficient mice, which lack XCR1+ DC, were not able to 
respond to anti-PD-1 or anti-PD-L1 treatment (Salmon, Idoyaga et al. 2016, 
Sanchez-Paulete, Cueto et al. 2016). Supporting these findings, the presence 
of XCR1+ DC in the tumour microenvironment correlated with the efficacy of 
anti-PD-1 treatment (Broz, Binnewies et al. 2014, Barry, Hsu et al. 2018, 
Bottcher, Bonavita et al. 2018). Furthermore, transfer of XCR1+ DC loaded with 
tumour antigen synergized with checkpoint immunotherapy (Wculek, Amores-
Iniesta et al. 2019).  
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The question that is unresolved is how XCR1+ DC maintain the TCF-1+ cell 
population. There are different possibilities: XCR1+ DC could directly interact 
with TCF-1+ cells, for example by the XCR1-XCL1 axis or deliver important co-
stimulatory molecules or cytokines. Furthermore, XCR1+ DC could also 
indirectly support the TCF-1+ cells by retaining them within an optimal 
environment for these cells. This environment would promote interactions with 
other cells, their surface receptors and ligands as well as their secreted 
molecules. In fact, we are likely dealing with a highly complex system in which 
the combination of multiple intrinsic and extrinsic pathways contributes to the 
overall outcome. We investigated three likely candidates based on their 
essential role for optimal priming of CD8+ T cells during acute infections: XCR1-
XCL1, CD27-CD70 and IL-15Ra-IL-15 signalling. None of these signalling 
pathways played an essential role and blocking of these did not recapitulate the 
results obtained with the depletion of XCR1+ DC.  
However, to examine the role of XCR1 signalling we used XCR1-deficient mice, 
which were chronically infected and analysed during the chronic infection phase 
compared to their XCR1-competent littermates. Notably, we cannot rule out that 
compensatory mechanisms for XCR1-XCL1 signalling developed in these mice. 
Therefore, a better approach would be to enable the development of the chronic 
infection in the presence of XCR1 signalling and abrogate this only during the 
chronic infection phase. Additionally, a comparison of XCL1-proficient vs. XCL1-
deficient CD8+ T cells in the same host during checkpoint immunotherapy would 
be most informative to address a possible function of this cytokine. 
We also investigated if co-stimulatory signalling of CD27 enabled by binding of 
its ligand CD70 impacted the CD8+ T cell response during chronic LCMV 
infection. This was not the case during anti-PD-L1 treatment. These negative 
results need to be cautiously interpreted, however, we applied an antibody 
clone that proved to be efficient in other experimental settings at a similar dose 
and application route (Penaloza-MacMaster, Ur Rasheed et al. 2011). 
Interestingly, other studies even described a rather inhibitory role of the CD27-
CD70 axis during chronic LCMV infection. MacMaster et al. blocked this 
signalling during the onset of chronic infection with anti-CD70 blocking 
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antibodies, which led to an increase in the absolute number of antigen-specific 
CD8+ T cells (Penaloza-MacMaster, Ur Rasheed et al. 2011). In line with these 
observations are results obtained with anti-CD27 blockade during the early 
phase of LCMV Cl13 infection, which reduced the viral load (Matter, Odermatt 
et al. 2006). By contrast, CD70-deficient mice were impaired in their ability to 
resolve an acute LCMV infection. However, ultimately the generation of memory 
CD8+ T cells was not impacted (Munitic, Kuka et al. 2013). These findings 
support the notion that CD27-CD70 signalling is critical during the primary 
response of a viral infection but less so for memory responses. During chronic 
infections, this co-stimulatory signalling could even drive exhaustion. This is in 
contrast to other co-stimulatory signalling pathways such as CD28-CD80/CD86, 
which are essential for the reinvigoration of exhausted CD8+ T cells by 
checkpoint immunotherapy. Notably, CD28 signalling has been put in context 
with cell cycle entry whereas CD27 signalling has been functionally connected 
with effector and memory differentiation and survival (Denoeud and Moser 
2011). 
In addition to possible co-stimulatory signalling pathways instructed by XCR1+ 
DC, we investigated the role of the common gamma chain cytokine IL-15 in the 
context of anti-PD-L1 treatment. Blocking of IL-15 did not reflect the results 
obtained with XCR1+ DC depletion. However, as we observed a slight increase 
in the frequency of antigen-specific cells when blocking IL-15, it is possible that 
IL-15 signalling can contribute to exhaustion. This, however, is somewhat in 
conflict with the increased viral load post IL-15 blockade during anti-PD-L1 
treatment. Importantly, terminally exhausted CD8+ T cells have been described 
to be less responsive to common gamma chain cytokines as some of the 
receptors are downregulated (Fuller, Hildeman et al. 2005, Lang, Recher et al. 
2005), while IL-2Rb is maintained (Beltra, Bourbonnais et al. 2016). Signalling 
via IL-2 and IL-15 has been described to drive terminal exhaustion rather than 
to maintain CD8+ T cell function during chronic infection (Beltra, Bourbonnais et 
al. 2016). In vitro, IL-15 has been shown to induce the expression of PD-L1 on 
various immune cells (Kinter, Godbout et al. 2008). However, recombinant IL-15 
or IL-15 superagonists and fusion complexes with IL-15Ra administered in 
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combination with anti-PD-1 treatment of various murine and human cancers 
showed synergistic effects and lowered tumour burden (Kim, Kwilas et al. 2016, 
Mathios, Park et al. 2016, Wrangle, Velcheti et al. 2018, Knudson, Hicks et al. 
2019). Notably, the beneficial effects of IL-15 administration were not only 
based on CD8+ T cell functions but also on increased numbers of NK cells and 
improved function. NK cells display a very complex role during acute and 
chronic LCMV infection and this might not reflect their role during cancer. For 
example, it has been described that NK cells shape the adaptive immune 
response during acute LCMV infection by targeting CD8+ T cells and thereby to 
some extent prevent immunopathology (Pallmer, Barnstorf et al. 2019). Similar 
findings were made in the context of chronic viral infections with LCMV. Here, 
the depletion of NK cells improved CD8+ T cell responses, prevented severe T 
cell exhaustion and led to an improved control of the infection (Cook and 
Whitmire 2013). By contrast, the depletion of NK cells in cancer models, highly 
increased tumour burden (Knudson, Hicks et al. 2019). Therefore, the 
interpretation of the results obtained by IL-15 blockade during anti-PD-L1 
treatment is complicated as there are various cellular recipients which 
contribute differently to viral clearance. Additionally, it has been shown that 
missing IL-15 signalling can be compensated by other common gamma chain 
cytokines, such as IL7, to maintain the memory T cell response (DeGottardi, 
Okoye et al. 2016). 
In order to identify key molecules that are essential for the communication 
between XCR1+ DC and memory-like TCF-1+ cells, an unbiased approach 
seems to be most straight forward. In particular, we anticipate that the analysis 
of scRNAseq data from TCF-1+ cells after anti-PD-L1 treatment in the presence 
or absence of XCR1+ DC may be highly informative in this regard. In the next 
chapter we first concentrated on deciphering the tissue context in which DC and 
exhausted CD8+ T cells meet and communicate and how checkpoint 
immunotherapy influences these interactions.  
 Results 
129 
5. Localization of XCR1+ DC and memory-like cell populations 
    during chronic infection and checkpoint immunotherapy 
 
5.1 Introduction 
 
Findings of the former two chapters revealed that DC play an essential role 
during immunotherapy. Importantly, the two main resident subsets of 
conventional DC, XCR1+ DC and CD11b+ DC, exhibited complementary 
functions during anti-PD-L1 blockade. XCR1+ DC impacted on the 
differentiation of exhausted CD8+ T cells by maintaining the memory-like cell 
population during immunotherapy. When depleting XCR1+ DC during treatment, 
the remaining XCR1- DC (mainly CD11b+ DC) were sufficient in supporting the 
proliferation of CD8+ T cells. 
The question that remains is which signals XCR1+ DC and CD11b+ DC deliver 
and how these differ. In chapter 3, we could show that both DC subsets present 
viral antigen and likely deliver costimulatory signals via CD28 as naïve P14 
proliferated upon co-culture with XCR1+ DC and CD11b+ DC from chronically 
infected animals. There are different possibilities of how XCR1+ DC and CD11b+ 
DC could impact the proliferation and differentiation of exhausted CD8+ T cells. 
First, they could directly provide distinct additional signals. Second, they could 
indirectly impact on CD8+ T cells by interacting with them within different 
microenvironments. In this case external signals in the vicinity of XCR1+ DC or 
CD11b+ DC affect the CD8+ T cells. Third, it could be that XCR1+ DC and 
CD11b+ DC deliver similar signals but communicate with different subsets of 
memory-like TCF-1+ cells, hinting towards heterogeneity within this cell 
population. Notably, these different options are not mutually exclusive. Based 
on the notion that differential impact of XCR1+ DC vs. CD11b+ DC on CD8+ T 
cells is caused by additional signals provided by XCR1+ DC, we have directly 
tested two obvious pathways. In the previous chapter, we have shown that 
CD27-CD70 signalling is not essential during PD-L1 blockade. However, IL-15 
signalling improved the control of viral load during immunotherapy. 
Nevertheless, blocking of the IL-15 signalling axis did not fully reflect results 
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obtained with the depletion of XCR1+DC during anti-PD-L1 treatment. This 
argues that IL-15 signalling provided by XCR1+ DC may contribute but is not the 
critical pathway underlying the maintenance of the memory-like TCF-1+ 
compartment. Therefore, we hypothesized that additional signalling molecules 
are involved in the communication between DC and T cells during chronic 
infection and checkpoint immunotherapy. To better understand this complex 
interaction network including intrinsic and extrinsic (environmental) signals, we 
aimed to investigate the localization of XCR1+ DC and CD8+ T cells in the 
context of chronic viral infection and anti-PD-L1 treatment. During steady state, 
XCR1+ DC are mainly located in the T cell zones of the white pulp in the spleen 
(Bachem, Hartung et al. 2012). Additionally, Im et al. described a predominant 
localization of memory-like TCF-1+ in the same location (Im, Hashimoto et al. 
2016). By contrast, terminally exhausted Tim3+ are described to be located in 
the red pulp. Using XCR1 reporter mice, we investigated the localisation of 
XCR1+ DC in the spleen during chronic LCMV infection and checkpoint 
immunotherapy. Furthermore, we aimed to elucidate the localization of viral 
antigen-presenting cells in the spleen and if this changes during the course of 
anti-PD-L1 treatment and in the absence of XCR1+ DC. In addition, we 
investigated memory-like TCF-1+ cells by single-cell RNA sequencing to 
address whether these cells represent a homogenous population or can be 
divided into further subpopulations which differ in their expression of 
localization-associated molecules. These insights will help to better understand 
the dynamics of communication between DC and memory-like CD8+ T cells in 
the tissue context and thereby decipher essential factors which impact the 
success of checkpoint immunotherapy. 
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5.2 Results 
 
5.2.1 Impact of chronic LCMV infection and checkpoint immunotherapy 
on localization of XCR1+ DC and in vivo antigen presentation 
 
The XCL1-XCR1 axis plays an important role in the context of CD8+ T cell 
priming during acute viral infections (Brewitz, Eickhoff et al. 2017). Surprisingly, 
we were unable to find a crucial role for this signalling pathway in the context of 
checkpoint immunotherapy during chronic LCMV infection (Chapter 4.2.2). 
Nevertheless, XCR1+ DC are critical cellular interaction partners that maintain 
the memory-like TCF-1+ cell pool of exhausted CD8+ T cells during anti-PD-L1 
treatment (Chapter 4.2.1). To address this interaction in more detail, we first 
aimed to elucidate the localization of XCR1+ DC during the course of chronic 
LCMV infection and anti PD L1 therapy. To this end, we analysed XCR1 Venus 
reporter mice. These mice express the fluorescent protein Venus under the 
Xcr1 promoter. Confocal microscopy of spleens from uninfected mice revealed 
that XCR1+ DC are mainly located in the T cell zones of the white pulp of the 
spleen (Figure 5.1A). Fewer cells were located in the red pulp. Mueller et al. 
described that the splenic architecture is permanently altered during chronic 
LCMV infection (Mueller, Matloubian et al. 2007). In line with this, we observed 
less intact T cell zones in the spleens of chronically infected mice. Additionally, 
localization of XCR1+ DC was strongly affected. Besides the typical localization 
of this DC subset in the T cell zones of the white pulp, many XCR1+ DC were 
also detected in the red pulp of the spleen (Figure 5.1B).  
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Figure 5.1: Chronic LCMV infection impacts localization of XCR1+ DC in 
the spleen. (A) IF images of the spleen of naive XCR1Venus/+ mice. B cells were 
stained with anti-B220 (blue) and XCR1+ DC are depicted in yellow. (B) 
XCR1Venus/+ mice received anti-CD4 and were i.v. infected with 2x106 IU LCMV 
Cl13. IF images of the spleen analysed during the chronic infection phase. Data 
are representative of two independent experiments (n = 3 mice/group).  
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Interestingly, the localization of XCR1+ DC was further changed by anti-PD-L1 
treatment. After three injections of 200 µg anti-PD-L1 during the chronic 
infection phase, XCR1+ DC were still found in the T cell zone and the red pulp. 
However, we observed an augmented accumulation of these DC in the marginal 
zone (MZ) of the spleen, when compared to PBS-treated animals (Figure 5.2B 
and 5.3). The marginal zone is an area, which is located between the white pulp 
and the red pulp of the spleen indicated in Figure 5.2A. Additionally to the 
localization of XCR1+ DC, the MZ was affected by anti-PD-L1 treatment as well. 
The expression of CD169, used for the identification of marginal zone 
macrophages, was decreased in the spleens of animals, which received 
immunotherapy (Figure 5.3). It remains currently unclear whether the 
accumulation of XCR1+ DC in the MZ is based on an additional recruitment of 
preDC from the blood or reflects a reorganization of the existing splenic network 
or a combination of both. 
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Figure 5.2: Localization of XCR1+ DC is influenced by anti-PD-L1 treatment 
during chronic LCMV infection. (A) IF image depicting the red pulp (RP) and 
the marginal zone (MZ) of the spleen during steady state. (B) Chronically 
infected XCR1Venus/+ mice received three anti-PD-L1 treatments (200 µg i.p.). IF 
images show localization of XCR1+ DC in the spleen of PBS-treated animals 
and animals which received anti-PD-L1. B cells were stained with anti-B220 
(blue) and XCR1+ DC are depicted in yellow. Data are representative of one 
experiment (n = 3 mice/group).  
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Figure 5.3: Anti-PD-L1 treatment affects marginal zone and localization of 
XCR1+ DC in the spleen. Chronically infected XCR1Venus/+ mice received PBS 
(left) or three anti-PD-L1 treatments (200 µg i.p.) (right). IF images show 
localization of XCR1+ DC (yellow) in the white pulp and marginal zone. Marginal 
zone is depicted in green and red pulp in grey. Data are representative of one 
experiment (n = 3 mice/group).  
I 
F4/80 (RP) 
XCR1+ DC 
CD169 (MZ) 
F4/80 (RP) 
XCR1+ DC 
F4/80 (RP) 
CD169 (MZ) 
PBS anti-PD-L1 
 Results 
136 
As the localization of XCR1+ DC is affected by checkpoint immunotherapy, we 
aimed to examine where antigen is presented during anti-PD-L1 treatment in 
the presence and absence of XCR1+ DC. In order to visualize the localisation of 
cells that present viral antigen in the context of MHC I, we transferred naive 
LCMV-specific P14 CD8+ T cells. Naive T cells actively migrate and search the 
tissue for the presence of antigen-presenting cells. Once they have engaged 
peptide-MHC I complexes they arrest and upregulate the early activation 
marker CD69, which hinders cells from egress from the lymphoid tissue. We 
further combined this approach with the XCR1 Venus DTR mouse line, which 
allows depletion of XCR1+ DC. Specifically, mice were chronically infected with 
LCMV Cl13 in combination with CD4 depletion. During the chronic infection 
phase, mice received three injections of anti-PD-L1 in combination with DTX to 
deplete XCR1+ DC. As a readout of antigen presentation, 2.5x106 naïve P14 
cells, which express the fluorescent protein tdTomato, were transferred post 
treatment and spleens isolated for analysis by confocal microscopy 12 h post 
transfer. In anti-PD-L1-treated animals, which still harboured XCR1+ DC, P14 
cells were detected in the central areas of the T cell zone as well as the MZ and 
fewer in the red pulp of the spleen (Figure 5.4A). By contrast, in the absence of 
XCR1+ DC and in the context of anti-PD-L1 treatment, few P14 cells localized to 
the T cell zone and most of them were detected in the MZ and red pulp (Figure 
5.4B). This argues that XCR1+ DC could be the predominant DC population that 
presents antigen within the T zone, while other DC and possibly MZM (marginal 
zone macrophages) preferentially do so in the MZ and the red pulp. However, 
as we observed a strong decrease of antigen presentation by XCR1+ DC during 
anti-PD-L1 treatment ex vivo (Chapter 3), we speculate that XCR1+ DC provide 
certain retention signals that lead to the accumulation of P14 cells in the T cell 
zones. Having identified three areas of the spleen (white pulp, marginal zone 
and red pulp), in which viral antigen presentation takes place as well as 
possible retention signals are delivered, we next wanted to address whether 
TCF1+ CD8+ T cells comprise a heterogeneous population and if so whether 
subsets thereof could be distinguished based on chemokine or adhesion 
molecules that indicate a preferential localization in the spleen.  
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Figure 5.4: Splenic sublocalization of naïve P14 cells is dependent on the 
presence of XCR1+ DC during immunotherapy. 2.5x106 naïve P14 cells 
(tdTomato) were transferred into chronically infected XCR1 Venus DTR after 
treatment. IF images show localization of P14 cells (red) 12 h post transfer in 
the spleens of mice which received (A) anti-PD-L1 treatment alone or (B) in 
combination with DTX. B cells are depicted in blue and T cell zones are 
encircled. Data are representative of one experiment (n = 3 mice/group).  
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5.2.2 Single-cell RNA sequencing deciphers subpopulations of memory-
like exhausted CD8+ T cells  
 
Memory-like TCF-1+ CD8+ T cells have been described to be primarily localized 
in the white pulp. By contrast, terminally exhausted Tim3+ CD8+ T cells mostly 
reside in the red pulp of the spleen (Im, Hashimoto et al. 2016). Studies 
identifying these two subsets investigated the expression of various intracellular 
and surface markers. While these studies focused on differences between 
these two subsets, they also provided first hints at a potential heterogeneity 
within the memory-like TCF-1+ compartment. Some of the expressed receptors 
are known to regulate the localization of lymphocytes within tissues. For 
example, the expression of the chemokine receptors CXCR5, CCR7, CXCR3 
and the adhesion molecule CD62L have been described for a fraction of TCF-1+ 
cells (Im, Hashimoto et al. 2016). To investigate the heterogeneity of the 
memory-like TCF-1+ cell pool in more detail and in order to put this into context 
of their localization in secondary lymphoid organs, we performed single-cell 
RNA sequencing (scRNAseq) of splenic Tim3- PD-1+ CD8+ T cells from 
chronically infected mice. Analysis of these data revealed nine distinct clusters 
within the Tim3- cells displayed in a UMAP projection shown in Figure 5.5A. 
These clusters could be distinguished by a variety of differentially expressed 
genes. Importantly, clusters 1 and 3 were more distinct from the other clusters 
and could be identified by the expression of the 2B4 (CD244) and the absence 
of Tcf7 (TCF-1) (Figure 5.5B). As we aimed to focus on the heterogeneity of the 
TCF-1+ subset, we further on excluded clusters 1 and 3 from the analysis.  
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Figure 5.5: Single-cell RNA sequencing analysis of splenic Tim3- PD-1+ 
CD8+ T cells from chronically infected mice. Mice were infected with 2x106 
IU LCMV Cl13 in combination with CD4 depletion. On day 30 post infection, 
spleen was isolated and Tim3- PD-1+ CD8+ T cells sorted for scRNAseq 
analysis. (A) UMAP projection of nine distinct colour-coded clusters of Tim3-
cells determined by Seurat v.3. (B) UMAP projection of CD244 and Tcf7 
transcript levels in distinct clusters. Colour scale: 0 (grey) to 3 (blue). Each dot 
corresponds to one individual cell.   
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Analysing the TCF-1+ cells, eight distinct clusters could be revealed. These are 
displayed in a UMAP projection in Figure 5.6A. The clusters could be 
distinguished by a variety of differentially expressed genes. A heatmap of the 
top ten differentially expressed genes for each cluster is shown in Figure 5.6B. 
The top ten expressed genes are additionally listed in Table 5.1. This gene 
expression profile provides insights on the function and possible tissue 
localization of the different memory-like TCF-1+ subpopulations as well as 
possible signals the cells receive and cellular contacts they could have. For 
example, cluster 0 displays cells which express Xcl1. XCL1 is the ligand for 
XCR1, which could indicate communication of this cell cluster with XCR1+ DC. 
In addition, Cxcr5 is expressed, which hints towards a possible localization 
close to B cell follicles (Leong, Chen et al. 2016). Also, Slamf6, which on protein 
level regulates T cell activation (Dragovich, Adam et al. 2019). Other clusters 
display a role in effector functions by the expression of Gzma and Gzmb 
(cluster 1 and 7). Cells within cluster 2 express Sell, which codes for the 
adhesion molecule CD62L that is required for circulation within secondary 
lymphoid organs as well as Il7r (CD127), an important survival cytokine. Both 
are described as important markers for memory cells. Cluster 4 harbors cells 
which upregulated genes for different interferon-induced proteins. This could 
indicate increased responsiveness or exposure of this cluster to IFNa/b and 
IFNg signals. Additional in-depth analysis of the different subsets of memory-like 
TCF-1+ cells will enhance our understanding of its various functions. Further on, 
we concentrated on the expression of certain chemokine receptors and 
adhesion molecules which enable a better understanding of the possible 
localization of the different TCF-1+ subpopulations.  
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Figure 5.6: Single-cell RNA sequencing analysis of Tcf7-expressing cells 
(A) UMAP projection of eight distinct colour-coded clusters of Tcf7-expressing 
cells determined by Seurat v.3. Each dot corresponds to one individual cell. (B) 
Heatmap displaying the top 10 genes expressed in each cluster. The columns 
correspond to the cells in each cluster, the rows correspond to the genes. The 
colour scale is based on a z-score distribution from −2 (purple) to 2 (yellow). 
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Table 5.1: Top ten differentially expressed genes for each cluster of 
memory-like TCF-1+ cells from chronically infected mice. Mice were 
infected with 2x106 IU LCMV Cl13 in combination with CD4 depletion. On day 
30 post infection, spleen was isolated and Tim3- PD-1+ CD8+ T cells sorted for 
scRNAseq analysis. Tcf7- expressing clusters were analysed and listed are the 
top ten differentially expressed genes for each cluster sorted by the log-fold 
change (avg logFC) in gene expression.  
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Interestingly, the expression of the chemokine receptors CXCR6, CXCR5, 
CX3CR1 and the adhesion molecule CD62L significantly distinguished the 
clusters of TCF-1+ cells within the data set (Figure 5.7). In addition, analysis of 
the scRNAseq data also revealed Mki67 (Ki67) expression specifically in cluster 
5 (Figure 5.7). Cxcr6 expression was found in nearly all of the TCF-1+ cell 
cluster but was most dominantly expressed in cluster 1 and 5, in which Cx3cr1 
and Mki67 expression were enriched as well. In contrast, Cxcr5-expressing 
cells were found in cluster 0, but the expression of this chemokine receptor was 
highly decreased in the clusters expressing Cxcr6, Cx3cr1 and Mki67. Cluster 2 
harbors cells, which show an increased expression of Sell (CD62L). To validate 
if the high transcript levels of these molecules are reflected by protein 
expression on the surface of cells, we analysed for their presence on Tim3- 
PD-1+ CD8+ T cells from chronically infected mice by flow cytometry. Indeed, 
surface expression of CXCR6, CXCR5, CX3CR1 and CD62L reflected the 
results obtained with scRNAseq and confirmed the existence of different 
subpopulations of memory-like TCF 1+ CD8+ T cells (Figure 5.8). We observed 
distinct clusters of TCF-1+ cells with these markers with an overlap between 
CXCR6+ and CX3CR1+ cells. Notably, in comparison to the small cluster of 
Mki67-expressing cells revealed with scRNAseq, a higher proportion of Ki67+ 
cells were detected with flow cytometry with some of these being CXCR6+ and 
CX3CR1+ (Figure 5.8). Based on the critical role of chemokine receptors and 
adhesion molecules that define these subsets, we hypothesize that these 
TCF-1+ CD8+ T cells subsets are found in distinct areas of the spleen. 
In summary, confocal microscopy and scRNAseq data of this chapter show that 
chronic LMCV infection and immunotherapy with anti-PD-L1 impact on the 
localization of XCR1+ DC and that memory-like TCF-1+ cells display a 
heterogenous group with subpopulations expressing distinct localization-
associated molecules. These new findings provide an important step forward in 
better resolving where exactly these subsets are localized and which DC 
subsets reside in the same area to impact on proliferation and differentiation 
during chronic infection and checkpoint immunotherapy.  
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Figure 5.7: Subpopulations of TCF-1+ cells express distinct transcription 
levels of chemokine receptors and adhesion molecules. UMAP projections 
of Cxcr6, Cxcr5, Cx3cr1, Sell and Miki67 transcript levels in distinct clusters of 
the Tcf7-expressing clusters. Each dot corresponds to one individual cell. 
Colour scale: 0 (grey) to 3 (blue).  
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Figure 5.8: TCF-1+ subpopulations can be distinguished by the expression 
of distinct chemokine receptors and adhesion molecules. Mice were 
infected with 2x106 IU LCMV Cl13 in combination with CD4 depletion. On day 
30 post infection, spleen was isolated and Tim3- PD-1+ CD8+ T cells stained for 
flow cytometry analysis. Representative flow cytometry plots showing the 
expression of the chemokine receptors CXCR6, CX3CR1 and CXCR5, the 
adhesion molecule CD62L and the proliferation marker Ki67 Data are 
representative of two independent experiments (n = 1-3 mice/group).  
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5.3 Discussion 
 
Examining the localization of certain cells can greatly improve our 
understanding of cellular communication pathways. This not only provides 
important clues about whether cells need to co-exist in similar locations as a 
prerequisite of cell-cell interaction, but also deciphers the impact of the local 
microenvironment the cells reside in. In this chapter, we aimed to elucidate the 
impact of chronic LCMV infection and checkpoint immunotherapy on the 
localization of XCR1+ DC and memory-like TCF-1+ cells. Different DC subsets 
could influence the memory-like population owing to either distinct signals 
delivered directly or by altering the local microenvironment and thereby the 
conditions in which the T cells respond to infection and therapy. Moreover, 
different subgroups within the memory-like TCF-1+ cell pool could reside in 
different areas and therefore differ in their cellular interaction with other immune 
cells. In addition, the distinct microenvironments these different subsets reside 
in could affect their activation and differentiation. 
Chronic LCMV infection disrupts the splenic architecture. In contrast to acute 
LCMV infection, this is likely caused by increased infection and resulting 
functional impairments of stromal cells, namely fibroblastic reticular cells (FRC) 
(Mueller, Matloubian et al. 2007). The white pulp of the spleen, which includes 
the T cell zone and the B cell follicles, is smaller and disorganized, which is 
partly mediated by NK and CD8+ T cells (Mbanwi, Wang et al. 2017). XCR1+ 
DC predominantly reside in the T cell zone of the white pulp and fewer of them 
are found in the red pulp (Steinman, Pack et al. 1997). However, we found here 
that more of these DC located to the red pulp of the spleen during chronic 
LCMV infection. The alterations of splenic architecture described above likely 
underlie this change in localization. It is also possible that XCR1+ DC directly 
migrate to the red pulp, where many infected cells, such as red pulp 
macrophages reside. Interestingly, Argilaguet et al. described that the number 
of XCR1+ DC decreases during the first five days after infection with a chronic 
LCMV strain (Argilaguet, Pedragosa et al. 2019) This this is rapidly followed by 
an influx as indicated by increased numbers of XCR1+ DC with a peak around 
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d9 post infection. Thereafter, a decrease of this DC subsets was described to a 
level comparable to prior to infection (Argilaguet, Pedragosa et al. 2019). These 
newly incoming XCR1+ DC likely migrate to different areas than under steady 
state conditions as a consequence of the disrupted architecture and the 
inflammatory environment during chronic viral infection. Notably, checkpoint 
immunotherapy additionally impacts their localization. We have observed that 
XCR1+ DC accumulate in the marginal zone of the spleen. This area represents 
the interface between white pulp and red pulp. At the same time, we detected a 
loss of CD169 staining within the MZ. Whether this reflects a downregulation of 
this protein, a loss of MZM or even a more profound alteration of the MZ needs 
to be further investigated. To date, little is known about the effect of anti-PD-L1 
treatment on the splenic architecture of the spleen. Marginal zone macrophages 
are infected with LCMV Cl13 (Mueller, Matloubian et al. 2007). Therefore, these 
cells could be direct targets of the reinvigorated cytotoxic T cell response by 
anti-PD-L1 treatment. This scenario would hint at an induction of 
immunopathology by checkpoint immunotherapy. One could speculate that 
reactivated CD8+ T cells produce the chemokine XCL1, which could in turn 
recruit intrasplenic XCR1+ DC to the marginal zone. However, the direct cause 
of the change in localization of XCR1+ DC upon anti-PD-L1 treatment remains 
to be investigated. 
Nevertheless, we still observed XCR1+ DC in the T cell zones of the white pulp 
with and without checkpoint immunotherapy. Here, they appeared to be 
essential for the localization of transferred naïve P14 cells to the T cell zone of 
the spleen, as only few them could be detected in this area in the absence of 
XCR1+ DC. XCR1+ DC could be the main cell type responsible for LCMV-
antigen presentation in the T cell zone. Conversely, ex vivo DC-P14 co-culture 
experiments presented in chapter 3 revealed that antigen presentation over the 
course of anti-PD-L1 treatment is strongly decreased. We cannot exclude a bias 
in the isolation process of DC from PBS- and anti-PD-L1-treated mice. 
However, XCR1+ DC could also lead to the retention of naïve P14 cells by 
antigen-independent signals. As the memory-like TCF-1+ cells have also been 
described to predominantly localize to the T cell zones, direct XCR1+ DC and T 
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cell interactions could be of great importance for the reinvigoration and self-
renewal of these cells. In chapter 2, we described that this memory-like T cell 
subset is reduced upon the depletion of XCR1+ DC during anti-PD-L1 
treatment. Therefore, XCR1+ DC could deliver retention signals to these T cells 
and thereby keep them in the white pulp. It is possible that T cells receive less 
inflammatory, differentiation-driving signals in this area of the spleen compared 
to the red pulp. A possible pathway of how XCR1+ DC could lead to the 
retention of TCF-1+ cells in the white pulp is via the adhesion molecule class I-
restricted T cell-associated molecule (CRTAM). During infection, activated CD8+ 
T cells have been shown to be retained by binding of CRTAM to its ligand 
nectin-like molecule-2 (Necl2), which is expressed by XCR1+ DC (Takeuchi, 
Itoh et al. 2009). Interestingly, this notion is supported by our scRNAseq data, 
which reveal the expression of Crtam especially in cells that are part of the 
clusters of Cxcr5- and Sell-expressing (CD62L) cells (data not shown). It will be 
of great interest to elucidate the signals which drive self-renewal of the TCF-1+ 
cell compartment and which signals drive the differentiation into the terminally 
exhausted Tim3+ subset of exhausted CD8+ T cells. 
In this chapter we further revealed that the TCF-1+ compartment comprises of a 
heterogenous group of cells, which likely reside in different areas of the spleen. 
The latter conclusion is based on differences in their expression of certain 
chemokine receptors and adhesion molecules. The gene expression profile of 
the various clusters of TCF-1+ cells may reflect that they all reside in different 
microenvironments and therefore are exposed to different signals. For example, 
CXCR6+ TCF-1+ cells are more likely to reside in the marginal zone or red pulp 
as CXCR6 signalling plays a role for the egress of CD8+ T cells from the T cell 
zones and guides their migration to the red pulp (Matloubian, David et al. 2000). 
CXCR6 is also expressed by the terminally exhausted Tim3+ subset (Wu, Ji et 
al. 2016). It can be speculated that the CXCR6+ TCF-1+ cells will ultimately 
differentiate into Tim3+ cells that reside in the red pulp (Im, Hashimoto et al. 
2016). In contrast to this subset of TCF-1+ cells, the CD62L+ and CXCR5+ cells 
appear more likely to reside in the T cell zones of the spleen. As mentioned 
above, the expression of Crtam could guide retention. Additionally, Sell 
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expression (CD62L) overlaps with the expression of Ccr7 (CCR7) (data not 
shown). This chemokine receptor enables migration of CD8+ T cells and DC to 
the T cell zones upon secretion of its ligands CCL19 and CCL21 (Link, Vogt et 
al. 2007). Notably, the generation of memory cells has been described to be 
absent during chronic viral infection (Wherry, Barber et al. 2004, Shin and 
Wherry 2007). However, by the expression of Sell (CD62L), Ccr7 (CCR7) and 
Il7r (CD127), these cells display key features of central memory T cells 
(Sallusto, Geginat et al. 2004). Also residing in the T cell zones but maybe more 
towards the B cell follicles could be the CXCR5+ TCF-1+ cells. These cells have 
also been described as T follicular cytotoxic cells (TFC) and have been shown to 
contain chronic viral infection (He, Hou et al. 2016, Leong, Chen et al. 2016). 
Another cluster of cells expressed the fractalkine receptor CX3CR1. Upon acute 
infection, the expression levels of CX3CR1 allow to distinguish three different 
memory subsets (Gerlach, Moseman et al. 2016). Classical central memory T 
cells (TCM) express low levels of CX3CR1 while effector memory T cells (TEM) 
express high levels. A third subset of memory cells expresses intermediate 
levels of CX3CR1 and has high capacity to undergo self-renewal, give rise to 
TCM cells and additionally is found to migrate through peripheral tissues 
(Gerlach, Moseman et al. 2016). Interestingly, tumour-infiltrating CD8+ T cells 
can also be distinguished by the expression of CX3CR1. Here, CX3CR1hi CD8+ 
T cells display terminally differentiated cells and only the CX3CR1int and 
CX3CR1low cells proliferated upon checkpoint immunotherapy (Yamauchi 2018). 
Notably, results displayed in this chapter showed that some of the CX3CR1+ 
cells expressed the proliferation marker Ki67. This argues for a low but constant 
proliferation of the exhausted CD8+ T cells. It can be speculated that these cells 
are also the first responders that proliferate in the context of checkpoint 
immunotherapy. 
The identification of distinct memory-like TCF-1+ subsets enables better in-
depth analysis of the mechanisms driving self-renewal and differentiation into 
terminally exhausted CD8+ T cells. In addition, this can be investigated in the 
context of DC-T cell communication and checkpoint immunotherapy. Therefore, 
we aim to compare the transcription profile of memory-like TCF-1+ cells from 
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chronically infected untreated mice with those from anti-PD-L1-treated animals. 
This will reveal if a distinct subset of TCF-1+ cells responds to checkpoint 
immunotherapy. Additionally, this can be examined in the presence or absence 
of XCR1+ DC to understand the impact of these cells for the reinvigoration of 
exhausted CD8+ T cells. 
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6. General discussion 
 
Intact CD8+ T cell responses are critical for the control of viral infections. 
However, during chronic viral infections such as with HIV, HCV and HBV as well 
as during cancer, CD8+ T cells progressively lose their effector functions. During 
this state of T cell exhaustion, a complex network of intrinsic and extrinsic 
factors inhibits T cell activation and proliferation to prevent immunopathology. 
This regulatory mechanism prevents from self-harm but at the same supports 
persistence as the infection cannot be cleared. The inhibitory receptor PD-1 and 
its ligand PD-L1 play a crucial role in this context. Infection of PD-1-deficient or 
PD-L1-deficient mice with a chronic LCMV strain causes lethal 
immunopathology (Barber, Wherry et al. 2006, Frebel, Nindl et al. 2012). In 
contrast, blocking this signalling pathway during an established chronic 
infection, can partly reverse T cell exhaustion without causing fatal 
immunopathology (Barber, Wherry et al. 2006). The CD8+ T cells can be 
reinvigorated but still display an exhausted phenotype due to additional 
inhibitory receptors as well as transcriptional and epigenetic changes (Wherry 
and Kurachi 2015). Checkpoint immunotherapy is an enormous success for the 
treatment of various cancer types and the administration of checkpoint inhibitors 
has rapidly become a routine clinical application. Research of the past years 
has revealed a subset of exhausted CD8+ T cells which can respond to 
checkpoint immunotherapy and many studies investigate how treatment can be 
improved. Nevertheless, the underlying mechanisms of the development of T 
cell exhaustion, the balance between terminal exhaustion and control of the 
infection as well as of the process of reactivation with anti-PD-1/anti-PD-L1 
treatment remain incompletely understood.  
 
In this study, we aimed at elucidating cellular interaction partners of exhausted 
CD8+ T cells and found that DC are essential for the reinvigoration of such by 
anti-PD-L1 treatment. However, our data also hint towards a self-limiting 
scenario in which DC are targeted by the regained cytotoxic functions of the 
exhausted CD8+ T cells. Moreover, we found that this was the case for the two 
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subsets of XCR1+ DC and CD11b+ DC. Additionally, this study reveals that 
these DC subsets display complementary roles. In the absence of XCR1+ DC 
during checkpoint immunotherapy, exhausted CD8+ T cells are still able to 
proliferate. These findings reveal that the remaining predominantly CD11b+ DC, 
are sufficient to deliver critical expansion signals. Nevertheless, we found a 
supreme role of XCR1+ DC for the maintenance of the memory-like TCF-1+ cell 
pool during anti-PD-L1 treatment. As we showed that these memory-like TCF-1+ 
cells display a heterogenous group of cells which could reside in distinct areas 
within the secondary lymphoid tissues, these subsets likely have different 
cellular interaction partners including DC subsets and receive diverse signals.  
 
Checkpoint immunotherapy with combinatorial approaches targeting DC to 
improve therapy outcome are of great interest in the cancer field. There are 
various DC-targeting approaches such as the administration of adjuvants which 
boost the endogenous DC compartment. For example, treatments with 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and FMS-like 
tyrosine kinase 3 ligand (Flt3L) are used to enhance and support DC 
development and maturation (Saito, Takayama et al. 2008, Yan, Shen et al. 
2017). Additionally, TLR agonists are administered, which have been shown to 
activate dysfunctional DC during cancer treatment (Wculek, Cueto et al. 2019). 
In addition to these mediators of DC activation, delivery of tumour-associated 
antigens (TAAs), which can be cross-presented by DC, leads to improved 
control of tumour burden (Finn 2017). Both, adjuvants and antigens, can also 
be directly delivered by coupling to DC-specific antibodies (Bonifaz, Bonnyay et 
al. 2004, Sancho, Mourao-Sa et al. 2008). In addition, different DC vaccination 
approaches have been investigated and are used for cancer treatment. Here, in 
vitro generated or autologous DC are ex vivo treated and adoptively transferred 
into the patient. So far, for human cancer therapy mostly blood monocyte-
derived DC have been used (Garg, Coulie et al. 2017, Saxena and Bhardwaj 
2017). However, in a recent study by Wculek et al. XCR1+ DC loaded with 
tumour antigen were used for this approach (Wculek, Amores-Iniesta et al. 
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2019). This treatment synergized with anti-PD-1 treatment in a murine tumour 
model.  
 
There are several aspects of this study which can be used for further 
investigation of processes underlying checkpoint immunotherapy as well as the 
design of novel DC-targeting treatment approaches: 
 
6.1 Cytotoxic targeting of DC by reactivated CD8+ T cells during 
immunotherapy 
 
During acute infections and tumour development, DC which activate CD8+ T 
cells have been described to also be targets of the cytotoxic response by these 
cells (Hermans, Ritchie et al. 2000, Ritchie, Hermans et al. 2000, Ludewig, 
Bonilla et al. 2001). Our results point towards a similar scenario during 
checkpoint immunotherapy. We hypothesize that CD8+ T cell reactivation limits 
itself by killing of DC. So far, it remains unclear how DC are targeted and 
unraveling the exact underlying mechanism will help to develop strategies to 
circumvent it. The cytotoxic CD8+ T cell response during LCMV infection has 
been shown to be dependent on perforin (Kagi, Ledermann et al. 1994, Walsh, 
Matloubian et al. 1994, Nansen, Jensen et al. 1999). Interestingly, early studies 
reported that perforin regulates the expansion of antigen-specific CD4+ and 
CD8+ T cells (Matloubian, Suresh et al. 1999). In the context of checkpoint 
immunotherapy, killing of DC by reactivated CD8+ T cells could be perforin-
mediated as well. However, constant blocking of the perforin pathway will also 
prevent killing of other infected cells and hence preclude control of the viral 
load. Therefore, transient inhibition of perforin-mediated killing during anti-PD-
L1 treatment could improve therapy outcome. In the context of DC vaccination 
approaches for the treatment of cancer, improving the survival of transferred DC 
could also promote improved CD8+ T cell expansion and activation. Some 
immune cells, such as CD8+ T cells and NK cells have evolved mechanisms to 
be intrinsically protected from the perforin-mediated cytotoxicity. Structural 
changes of the membrane including phospholipid modifications can protect 
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these cells from perforin-mediated killing (Lopez, Brennan et al. 2012). Transfer 
of in vitro generated DC, which are protected from this killing mechanism, in 
combination with checkpoint immunotherapy could be an approach to improve 
cancer therapy. 
 
6.2 XCR1+ DC preserve memory-like TCF-1+ cells during 
immunotherapy 
 
Elucidating how XCR1+ DC maintain the pool of exhausted CD8+ T cells which 
respond to checkpoint immunotherapy, could be used to improve treatment 
strategies as well. In murine tumour models, transfer of XCR1+ DC synergized 
with anti-PD-1 treatment (Wculek, Amores-Iniesta et al. 2019). Utilizing this DC 
subset to improve therapy in the context of chronic viral infections could show 
similar results. Memory-like TCF-1+ cells represent the subset of exhausted 
CD8+ T cells that can be reactivated by anti-PD-1/PD-L1 treatment (Im, 
Hashimoto et al. 2016, Utzschneider, Charmoy et al. 2016). We hypothesize 
that the expansion of this cell compartment would lead to an improved therapy 
outcome as more cells can be reactivated by checkpoint inhibitors. This could 
be achieved with enhancing critical signals transmitted by XCR1+ DC 
simultaneous to immunotherapy. In this regard, also staggered or alternating 
treatment regimens could be investigated. Increasing the pool of memory-like 
cells prior to checkpoint immunotherapy might help to further expand the 
cytotoxic CD8+ T cell pool in order to fight infected or tumour cells.  
 
6.3 Heterogeneity within the memory-like TCF-1+ cell compartment 
 
We found that the pool of memory-like TCF-1+ cells includes distinct subsets 
which likely reside in different areas of lymphoid organs and therefore exist in 
different microenvironments in which they receive various signals by distinct 
cellular interaction partners. It will be of great interest to explore which of these 
subsets respond to checkpoint immunotherapy and how. Are these subsets 
functionally or developmentally connected? If so, this would point to a scenario 
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where exhausted CD8+ T cells undergo various differentiation steps from a 
small progenitor memory-like cell pool to the terminally exhausted cells. In 
melanoma patients, the frequency of TCF-1+ cells serves as a valuable 
biomarker for the success of checkpoint immunotherapy (Sade-Feldman, 
Yizhak et al. 2018). In case only a subset of the TCF-1+ cell pool responds to 
anti-PD-1/anti-PD-L1 treatment, the presence and frequency of this subset 
could be used as an even more precise biomarker. In addition, combination 
therapies using anti-PD-1/anti-PD-L1 together with blocking antibodies targeting 
other inhibitory receptors show synergistic effects with improved therapy 
outcome (Kaufmann, Kavanagh et al. 2007, Blackburn, Shin et al. 2009). Which 
cells are directly targeted by these combinatorial treatment approaches remains 
unclear. However, designing new or improving combination therapies by 
targeting one or more subgroups of memory-like TCF-1+ cells could further 
increase treatment efficacy. 
 
Taken together, this study revealed an essential but complex role for dendritic 
cells during checkpoint immunotherapy. The presented findings provide new 
insights into the multifaceted parameters which impact the reinvigoration of 
exhausted CD8+ T cells and underline the importance of different DC subsets in 
this context. In particular, this involves CD8+ T cell heterogeneity, functional 
specialization of DC subsets and spatiotemporal aspects of their interaction. 
The mouse model of chronic LCMV infection greatly helped to understand 
various immunological mechanisms in the past decades and it will be of great 
interest to translate the findings of this study to other chronic infections as well 
as cancer in humans. Delineating the exact molecular mechanisms will provide 
the framework for the design of novel and more effective immunotherapeutic 
treatments in the future. 
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